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SUMM ARY
A key step in metastasis is the interaction and penetration of the vascular 
endothelium by cancer cells. Tight Junctions (TJ) are located between the cancer 
epithelial cells themselves functioning in an adhesive manner, and between the 
endothelial cells. They represent a critical barrier which the cancer cells must overcome 
in order to penetrate and initiate metastasis. The Claudin family are TJ proteins 
expressed in both endothelial and epithelial cells. They participate in the formation of 
tissue barriers between different tissue compartments by regulating the efflux of 
molecules through TJ complexes.
This thesis examined the level of expression and distribution of Claudin-5 in 
human breast cancer tissues and analysed them against clinical parameters. The effect of 
knockdown and forced expression of Claudin-5 in the MDA-MB-231 aggressive breast 
cancer cell line and in the HECV human endothelial cell line was also examined. Results 
revealed that Claudin-5 is aberrantly expressed in human breast cancer and has a link to 
the clinical outcome of the patient. Patients who died from breast cancer had higher 
levels of Claudin-5 compared with patients who remained disease-free. Furthermore, 
patients whose tumours expressed high levels of Claudin-5 had shorter survival than 
those with low levels.
Investigating in vitro the effect of altering levels of expression of Claudin-5 in 
M DA-M B-231and HECV cells revealed that the role of Claudin-5 was not primarily in 
keeping the cell barrier tight suggesting little function in the TJ of these cells, in fact a 
link was identified between Claudin-5 and cell motility. Furthermore, a possible link 
between Claudin-5 and N-W ASP, and Claudin-5 and ROCK was demonstrated when 
interactions between these proteins were seen in both cell lines. Moreover, cell motility 
was assessed following treatment with N-W ASP inhibitor, Arp2/3 inhibitor and ROCK 
inhibitor. Results show that the knockdown of Claudin-5 in HECV cells masked their 
response to N-W ASP inhibitor, Arp2/3 inhibitor and ROCK inhibitor. A parallel 
response was observed in the knockdown of Claudin-5 in MDA-MB-231 after treatment 
with N-W ASP inhibitor and Arp2/3 inhibitor; however treatment with ROCK inhibitor 
did not reveal any differences in motility in this particular cell line.
This study portrays a very new and interesting role for Claudin-5 in cell motility 
involving the N-W ASP and ROCK signalling cascade indicating a possible role for 
Claudin-5 in the metastasis and progression of human breast cancer.
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Chapter 1 
Introduction
1
1.1 Breast cancer
1.1.1 Breast cancer incidence and risk factors
Breast cancer is by far the most frequent cancer in women; more than a 
million women are diagnosed with breast cancer every year. More than half the cases 
are in industrialized countries, with about 426,900 new cases o f  breast cancer 
occurring each year in Europe (in 2006 there were 45,822 new cases diagnosed in the 
UK: 45,508 woman and 314 men) and an estimated 182,460 in the USA (Figure
1.1 A) (Office for National Statistics, 2006).
It is widely recognised that the high incidence of breast cancer in the more 
affluent world areas, with the highest age-standardised incidence in North America, 
is due to the presence of screening programs that detect early invasive cancers, some 
of which would otherwise have been diagnosed later or, in the worst case, not at all. 
Although there is a high incidence of breast cancer, the relatively good prognosis 
means that it is the most prevalent cancer in the world today; there are an estimated
4.4 million people alive who have had breast cancer diagnosed within the past 5 
years (compared with just 1.4 million survivors from lung cancer). Between 1989 
and 2007 in the UK, the breast cancer mortality rate fell by 41% in women aged 40- 
49 years; by 41% in women aged 50-64; by 38% in women aged 65-69; by 35% in 
women aged 15-39; and by 20% in women over 70 (Figure 1.1B) (Office for 
National Statistics, 2006).
There has been however, a general increase in incidence rates of about 0.5% 
annually worldwide. At this pace of growth, there would be around 1.4 million new
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cases in 2010. The incidence of breast cancer shows considerable geographic cancer 
variation. In China, there are annual increases in incidence of 3% to 4%, and in other 
parts of Asia increases are also very similar, whilst in the UK the number of cases 
has increased by 14% over the last ten years (Parkin et al., 2005).
Genetic factors, including ‘high risk’ breast cancer susceptibility genes 
BRCA1 and BRCA2, genes encoding growth factors and receptors, intracellular 
signalling molecules, cell cycle regulators, apoptosis regulators and adhesion 
molecules may account for up to 10% of breast cancer incidence in developed 
countries, but their occurrence in the population is too low to explain the differences 
in risk worldwide. Therefore, the vast majority must be a consequence o f  different 
environmental exposures. This is evident from studies of migrants from Japan to 
Hawaii showing that the incidence of breast cancer in migrants assumes the rate in 
the host country within the first generation, indicating the magnitude of the influence 
of the environmental surroundings (Kolonel et al., 2004).
A large number of risk factors have been suggested as playing a role in the 
development of breast cancer. These include age, reproductive factors (first 
pregnancy, breastfeeding), lifestyle (physical activity, diet, alcohol intake and 
smoking), oral contraceptives and hormone replacement therapy (McPherson et al., 
2000).
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Figure 1.1: (A) Number o f  new cases diagnosed and age specific incidence in the UK 
(Source: Office for National Statistics, 2006). (B) A decrease in breast cancer 
mortality in all age groups between the late 1980s and 2007 (Source: Office for 
National Statistics, 2006).
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Breast cancers are derived from epithelial cells that are found in the terminal 
duct lobular unit. Cancer cells that remain within the basement membrane and are 
confined to the ductal epithelium and acini are classified as in situ  or non-invasive. 
An invasive breast cancer is one in which there is spread of cancer cells outside the 
basement membrane of the ducts and lobules into the surroundings adjacent normal 
tissue.
Although a broad range of pathological subtypes of invasive breast cancer 
have been identified the most commonly used classification of invasive breast 
cancers divides them into ductal and lobular types. Invasive ductal carcinoma 
represents the largest group, being almost 80% of the invasive cancers. Invasive 
lobular cancers make up a majority of the remaining 20% (Weigelt et al., 2005).
When an invasive breast cancer is diagnosed, the tumour is staged to assess 
the cancer and provide information to the clinician and the patient. The Tumour 
Node Metastases (TNM) system is a worldwide staging system depending on clinical 
measurements and clinical assessment of lymph node status. The criteria for the 
cancer staging were defined by the Union for International Cancer Control (UICC) 
more than 50 years ago (Berndt and Titze, 1969). The parameters used for the TNM  
include size of tumour (T) followed by a number from 0 to 4; spread to the axilary 
lymph node (N) followed by a number from 0 to 3; and its spread to distant sites (M) 
followed by a 0 or 1. Once the T, N, and M categories have been determined, this 
information is combined in a process called stage grouping (Table 1.1). With modern 
advances in breast cancer diagnosis, UICC have reviewed the system to introduce 
changes that will improve TNM  classification (Gospodarowicz et al., 2004).
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Stage T (tum our size) N (node status) M (m etastasis)
0 Pre- cancerous
I T - l N-0 M-0
T-l N -l
II T-2 N-0 or N -l M-0
T-3 N-0
T-Any N -l
II I T-3 N-0 or N -l M-0
T-4 N-0
IV T-Any size N-Any status M -l
Table 1.1: TNM  staging system for breast cancer. Where T, N and M means: 
T=tumour size: T - l=  0-2cm, T-2=2-5cm, T-3= >5cm; T-4= ulcerated or attached. N= 
node status: N-0= clear or negative nodes, N - l=  cancerous or positive nodes. 
M=metastasis: M-0= no metastasis, M -l=  metastasis.
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1.1.2 Breast cancer m etastasis
Metastasis is the presence of disease at distant sites due to the spread of 
cancer cells which results in overwhelming mortality in patients with cancer. It is a 
complex, multi-staged process determined by a large number of different factors and 
involving a number of sequential steps and events which must be completed for the 
cancer cell to successfully metastasise and form a secondary tumour in a distant 
organ, the so called metastatic cascade.
The most widely accepted model for metastasis is the “seed and soil” 
hypothesis postulated by Stephen Paget in 1889. He suggested that malignant tumour 
cells are shed from the primary tumour and disseminated in the entire body though 
they will only metastasise when the seed (disseminated tumour cells) and soil 
(secondary organ) are compatible. Ever since, the knowledge in this area has 
expanded significantly. However, the mechanisms underlying the whole process are 
still unclear and currently the available therapies are mainly palliative.
The metastatic cascade is thought to consist of the following steps: invasion, 
intravasation and extravasation (Figure 1.2). Invasion occurs when tumour cells gain 
the ability to dissociate from the primary tumour and penetrate the surrounding 
tissues through degradation of the basement membrane and the extracellular matrix, 
leading to intravasation as the detached cells enter the circulatory or lymphatic 
system. Once the tumour cell arrives at a possible point of extravasation, it interacts 
and attaches at the new site to penetrate the endothelium and the basement membrane 
to produce a secondary tumour, this is called extravasation.
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In order to activate the metastastatic cascade, cancer cells must acquire a 
motile phenotype. Cell motility is orchestrated by a variety of complicated signal 
pathways, most of which are just starting to be unravelled. Understanding cell 
motility not only requires knowledge of the signal pathways regulating actin 
polymerisation, but also details concerning their dynamics.
Cell motility and migration occur in response to chemokines or growth factor 
signals. In response to these stimuli, changes in the cytoskeleton, in the cell-cell 
adhesion structures, in the cell-substrate adhesion and in the extracellular matrix 
(ECM) take place resulting in a motile cell capable of gaining access to the systemic 
circulation and ultimately metastasis. Cell migration is initiated by the development 
of cellular extensions such as filopodia and lamellipodia that define the front of the 
migrating cells driven by actin polymerisation and filament elongation (Ridley et al., 
1992). The activation of Rho, R ac l and Cdc42, all members of the small GTPases 
familiy, has been reported to result in the formation of actin stress fibres, membrane 
ruffles, lamellipodia and filopodia respectively in in vitro studies (Hall, 1998). It has 
been shown that Cdc42 interacts with Wiskott-Aldrich syndrome protein (W ASP) 
and N-W ASP (a homologue of W ASP) resulting in an active conformation of the 
Arp2/3 complex (Actin related protein) responsible for inducing the assembly of 
branching networks of actin filaments to push the cell membrane forward (Cory and 
Ridley, 2002).
Rho GTPases and their most common effector, ROCK, are important 
regulators of cellular processes including cell motility. Furthermore, Rho-RO CK 
interactions have been demonstrated to be involved in tumour invasion and
metastasis by increasing cell motility in breast cancer cells through the regulation of 
actin cytoskeletal reorganisation and the formation of focal adhesions (Nishimura et 
a l 2003) (Figure 1.3).
Extensive interactions between tumour cells and surrounding tissues during 
their dissemination complicate the analysis of signalling events during this cascade. 
Due to its complex nature, the understanding of the cellular and molecular factors is 
limited. The most important questions arising are focused to define the genetic and 
epigenetic changes conferring such behaviours on these cells (Yang et al., 2006).
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Figure 1.2: Major steps in the metastatic cascade.
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Figure 1.3: Schematic representation o f  early stages o f  cell migration. The figure 
highlights the sequence o f  individual steps including disruption o f  the Tight and 
Adherens Junction as well as the activation o f  motility-related signalling pathways 
involved in the reorganization o f  the actin cytoskeleton such as ROCK and N-WASP.
11
The most common sites of distant metastasis from breast cancer are bone, 
liver and lung (Carty et al., 1995).
Approximately 70% of patients with breast cancer have bone metastases. 
They are associated with poor prognosis and the available treatment options are very 
limited. Bone metastases usually present with severe pain and these symptoms are 
usually seen in the femur and pelvic region. There are complex and multiple steps in 
the process of bone metastasis which are influenced by various cytokines, growth 
factors and cellular signals. There are two types of breast cancer bone metastasis: 
Osteolytic lesions are the most common form and cause destruction of the bone; 
Osteoblastic lesion that are less common and cause new bone formation. Most 
patients have components of both bone resorption and bone formation (Akhtari et al., 
2008).
The liver is the second most common site to be colonised during breast 
cancer metastasis. About 40-50% of women with metastatic breast cancer have 
metastasis to the liver during the course of the disease. Hepatic disease related to 
breast cancer can be consequential to the metastatic spread of the tumour to the liver, 
or as a result of regular treatment with chemotherapeutic agents or endocrine therapy. 
Both cases are associated with a poor prognosis among patients (Diamond et al., 
2009).
Pulmonary metastases are also common features in patients with breast 
cancer. As cancer cells arrive at the pulmonary capillaries, they became physically 
trapped and restricted by the narrowing blood vessels in the lung. Several studies 
have shown that the adhesion and extravasation of cancer cells in the lung is
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mediated by specific surface adhesion molecules on the cancer cells and the 
endothelium like the chemokine receptors CXCR4 and CCR7 (Lu and Kang, 2007).
The diverse nature of breast cancer metastasis makes not only finding a cure 
for the disease complicated, but also assessing risk factors for metastasis. Improving 
the understanding of the molecular mechanisms of the metastatic cascade will also 
provide quality in management of the disease.
Since Tight Junctions (TJs) are located between the cancer epithelial cells, 
themselves functioning in an adhesive manner, and between the endothelial cells, as 
a barrier through which molecules and inflammatory cells can travel, they represent a 
critical barrier which the cancer cells must overcome in order to penetrate and initiate 
metastasis. If any microorganism or cancer cell can gain access to the systemic 
circulation, there exists a wealth of nutrients and an ideal environment for many to 
proliferate. Therefore, TJ integrity is a key step in the metastatic cascade (Martin et 
al., 2004b).
1.2 Tight Junction m olecular structure
As the proverb states: “Good fences make good neighbours” , this humble and 
intelligent statement is not just applicable to the property market; it is indeed a reality 
seen in nature, in all species, in evolution and in development.
A single cell in the ocean can exchange nutrients and waste products 
constantly. However, when a single cell is part of a multicellular organism this
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changes; moving from an easy movement of substances to a complicated and 
extremely organized exchange system with the external environment.
A defining characteristic of multicellular organisms is the capability of 
forming TJ that seal the intercellular space between neighbouring cells and transform 
the layer of individual cells into an effective permeability barrier. Barriers not only 
separate fluids, but they also perform thermodynamic work by reabsorbing solutes 
from compartment A to B, or secreting others from B to A, thus establishing 
gradients across themselves.
TJs are highly regulated areas of adhesion between epithelial and endothelial 
cells. They are the most apical component of the lateral plasma membrane and they 
are connected to the actin cytoskeleton. They create a regulated paracellular barrier 
to the movement of ions, solutes and immune cells between the cells and signalling 
pathways that communicate cell position, limit growth and apoptosis.
The morphology of TJ has been intensively analysed using transmission 
electron microscopy, where the TJ appear as a sequence of very close points as 
fusions of the plasma membrane of both cells, and by freeze fracture electron 
microscopy where these contacts are shown as rows of intra-membrane strands and 
complementary grooves that encircle cells (Staehelin, 1973).
Physiological studies of the past decades have demonstrated that the TJ 
barrier is not absolute, and permeability to small and macro-molecules varies 
amongst different tissues. Moreover, barrier assembly and permeability 
characteristics are influenced by different cellular signalling mechanisms.
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TJs have been proposed to have two equally exclusive functions: 1. A fence 
function by forming an apical/basolateral intra-membrane diffusion barrier which 
prevents the mixing of membrane proteins; and 2. A gate function by controlling the 
breadth and selectivity of diffusion along the paracellular pathway (Cereijido et al., 
2008). These functions will be explained more fully in section 1.3.
The number of TJ strands is an important factor in determining the barrier 
properties of the TJ. There is not a linear relationship between the complexity of the 
TJ strand network and their measured electrical resistance (trans 
epithelial/endothelial resistance, or TER), in other words, the number of TJ strands 
does not correlate with the tightness of the barrier, in fact the relationship is an 
exponential one (Claude, 1978). Such results led to the prediction that TJ must 
contain aqueous pores lined by proteins. Subsequently, it was reported that the 
strands do indeed contain aqueous pores and that the pores oscillate between open 
and closed states (Tsukita et al., 2001). Therefore, it has been accepted that the 
tightness of the TJ is remarkably dynamic and finely regulated in individual cells.
Although the details of how intracellular signals may influence these proteins 
are not understood, many signalling messengers, including prostaglandins, cAMP, 
and protein kinase C, have been seen to regulate the actin cytoskeleton in epithelial 
cells (Anderson and Van Itallie, 1995).
Several types of proteins have been identified as components of TJ (Table 
1.2), depending on their distribution within the junction (Figure 1.4):
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1. Transm em brane proteins such as the M ARVEL/TA M P proteins 
(Occludin, Tricellulin and M ARVEL D3), the Claudin superfamily and 
Junctional Adhesion Molecules (JAMs). These proteins span the cell 
membrane and are anchored into position by links to the cytoplasmic/plaque 
proteins.
2. Cytoplasm ic plaque such as the Zonula Occludens family, ZO-1,- 
2,-3, AF6, MUPP-1, MAGI-1,-2,-3, Cingulin, Angiomotin family and 
Symplekin. These proteins link TJ to the actin-cytoskeleton and the adherens 
junction to the regulatory proteins.
3. A ssociated/regulatory proteins such as the Rho subfamily 
proteins, Rab-13, Rab-3B, heterotrimeric G proteins like Gai-2 and GaO etc.
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Figure 1.4: Molecular structure o f  TJ.
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T ransm em brane Cytoplasm ic plaque Associated/regulatory
protein proteins
Occludin Zonula Occludens (ZO- Rho-GTPases, Rab-13,
Tricellulin
1) Rab-3B, Gai-2, GaO,
M ARVEL D3
ZO-2
c-src, c-yes, ZO NA B, 
19B1, Ponsin, Par-3,
Claudin 1-24
ZO-3
Par-6, Afadin, a-
Junctional Adhesion
AF6 catenin, Pals, PATJ,
Molecules (JAM 1-4) MUPP-1
JEAP, Pilt, PTEN, 
ZAK, Scrib, ITCH,
MAGI-1,-2,-3 W NK4, Vinculin
Cingulin
Angiomotin family
Symplekin
Table 1.2: Proteins involved in TJ structure, function and regulation.
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1.2.1 Transm em brane proteins
TJs contain two principal types of transmembrane components: tetraspan and 
single-span transmembrane proteins. The tetraspan proteins are the TA M P family 
(Occludin, Tricellulin and MARV3D) and the Claudin family (1-24), all of  which 
share the same membrane topology, with their N- and C-termini domains within the 
cytoplasm and two extracellular loops implicated in establishing contact with 
homotypic molecules located in the TJ region of the neighbouring cell. The single­
span transmembrane proteins are the Junctional Adhesion Molecules (JAM1-4 and 
JAM-like) that belong to the immunoglobulin superfamily and mediate homotypic 
cell-cell adhesion.
All these proteins share a common feature, the presence of a PD Z domain. 
This feature is key for the establishment of protein-protein interaction in the Tight 
Junction. PDZ domains contain 80-90 amino acid residues and are named after the 
proteins in which they were initially identified: PSD-95, Dig, and ZO-1 (Daniels et 
al., 1998). These mediate intermolecular homotypic interactions between PDZ 
domains, like the ones established between ZO -land  ZO-2 and also ZO-1 and ZO-3, 
as well as heterotypic interactions by association to specific motifs found at the 
carboxyl terminal ends of several proteins including Claudins, JAM s and ZO-2 and 
ZO-3.
1.2.1.1 O ccludin
Occludin, the first-discovered and probably most abundant tetraspan TJ 
protein is an approximately 60 kDa tetraspan membrane protein (Furuse et al., 1993),
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depending on phosphorylation status. There are two different isoforms that result 
from alternative mRNA splicing, but there is no clear difference in their tissue 
distribution and functions (Muresan et al., 2000). Its localisation in the Tight 
Junction is regulated by phosphorylation in both epithelial and endothelial cells, 
whereas the non-phosphorylated Occludin is localised to both the basolateral 
membrane and in cytoplasmic vesicles.
Although both domains interact with components of the cytosolic plaque, 
they have been shown to have different functionality. The N- terminal domain 
regulates neutrophil transmigration (Oshima et al., 2003), whereas the C-terminal 
domain interacts with various intracellular proteins of the TJ including ZO-1,-2 and -
3. This interaction is essential for the localisation of Occludin at the TJ (Furuse et al., 
1994).
Mice genetically altered to express reduced levels of Occludin have 
previously been generated in a study by Saitou et al. These mice showed the 
presence of normal TJ in the intestinal epithelium (Saitou et al., 2000). This data 
suggested that Occludin may play a role in the regulation of TJ rather than in the 
assembly of the structure itself and may also suggest that Occludin is not the only 
key protein in the making of TJ.
In addition, over-expression in several cancer cells results in increased 
sensitivity to apoptotic factors via modulation of the expression of genes involved in 
apoptotic pathways like mitogen activated protein kinase (MAPK), and thus 
contributes to reduce tumour progression and metastasis. These findings support the 
idea of a regulatory role for Occludin rather than a simple structural one,
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demonstrating that Occludin acts as a signal transmitter in the TJ (Osanai et al., 
2006).
1.2.1.2 Tricellulin
Tricellulin is a tretraspan transmembrane protein localised in tricellular TJs, 
the meeting points of three cells, but it is also seen in bicellular TJ. It is down- 
regulated by the zinc-finger transcription factor Snail. The suppression of Tricellulin 
expression by RNA interference impairs the barrier function of the TJ, suggesting 
that Tricellulin might have a pivotal function for junction assembly and barrier 
function (Ikenouchi et al., 2005).
Four isoforms of human Tricellulin have been described by Riazuddin et al., 
In addition, the same study revealed that Tricellulin-a (TRIC-a) mutations lead to 
non-syndromic deafness (Riazuddin et al., 2006).
1.2.1.3 C laudins
The Claudin superfamily consists of at least 24 tretraspan protein members all 
believed to be expressed in a tissue-specific manner. Claudins are capable of forming 
TJ strands and thus are thought to be the backbone of the TJ (Furuse and Tsukita, 
2006). This will be discussed in full in section 1.5.3.
1.2.1.4 Junctional Adhesion M olecules (JAMs)
Junctional Adhesion Molecules (JAMs) are single-span transmembrane 
proteins that are associated with TJ. They belong to the immunoglobulin (Ig) 
superfamily and consist of two extracellular Ig-like domains, a single transmembrane
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domain and a C-terminal cytoplasmic domain. Four JAMs, JA M -l(JA M -A ), -2 
(VEJAM/JAM-B), -3 (JAM-C) and -4 ,  have been described (Bazzoni, 2003). V- 
set/VSISI/GPA34 is also a member of the family (Scanlan et al., 2006). JAM s 
regulate adhesion between leukocytes and endothelial cells, as well as the 
paracellular transmigration of leukocytes across the endothelium (Weber et al., 2007).
1.2.2 Cytoplasm ic plaque proteins
A very important feature of TJs is that they include a cytoplasmic plaque, 
which forms a link between the junctional membrane and the cytoskeleton. The 
cytoplasmic plaque also recruits a variety of signalling components that includes 
kinases and phosphatases as well as proteins that are involved in signalling in and 
from the nucleus. The cytoplasmic plaque contain two principal types of proteins: 
M AG UK proteins that contain a PDZ domain like ZO proteins, M AGI and MUPP-1, 
and those non-PDZ proteins like Cingulin, Angiomotin family proteins, small 
GTPases and Symplekin (Guillemot et al., 2008). Of all these proteins mentioned 
above, the ZO proteins are the most studied in the TJ cytoplasmic plaque.
1.2.2.1 ZO proteins
ZO-1, ZO-2 and ZO-3 are members of the M AG UK (membrane associated 
guanylate kinase homologs) family. The M AG UK family is characterised by their 
PDZ domain, in particular ZO proteins have three, an SH3 domain and a guanylate 
kinase homologous domain. They are at the core of a network of protein interactions. 
The first PDZ domain of ZO-1, ZO-2 and ZO-3 binds directly to the C-terminal 
domain of Claudins. In fact, a study by Umeda et al., demonstrated that the
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interaction between the first PDZ domains of ZO-1 and ZO-2 and Claudins plays a 
crucial role in the assembly of the TJs (Umeda et al., 2006).
1.2.3 A ssociated/regulatory proteins
A large number of associated proteins like small GTP-binding proteins of the 
Rho subfamily have been involved in the control of Actin organization. Protein 
tyrosine kinases like c-src and c-yes, are also represented in this group of proteins 
acting as regulators of junction assembly and actin dynamics. Other small GTP- 
binding proteins like, Rab-13 and Rab-3B, have been seen to be involved in vesicle 
targeting rather than in cytoskeletal activity (Mitic and Anderson, 1998). Cingulin is 
not directly required for TJ formation and cell polarity but it has been proposed to 
regulate RhoA signalling, through its interaction with the RhoA activator GEF-H1 
(Citi et al., 2009).
Other members of the TJ associated proteins are: ZONAB, 19B1, Ponsin,
Rab 3B, PKC, Par-3, Par-6, Afadin, a-Catenin, Pals, PATJ, JEAP, Pilt, PTEN, ZAK, 
Scrib, ITCH, WNK4 and Vinculin (Martin and Jiang, 2009).
1.3 Tight Junctions functions
Until the early nineties, TJs were mainly seen as paracellular seals. The 
subsequent vast amount of studies that have been done on TJ has changed our view 
in such a way that TJ are now considered as being active participants in the 
regulation of cell proliferation, gene transcription and cellular differentiation. In
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other words, TJs are not static structures that simply seal two neighbouring cells; 
they are implicated in a variety of events that occur in the cell.
This section will summarize the most important roles that TJs have been 
associated with so far.
1.3.1 T ight Junction as gate and fence
One of the major functions of TJs is the construction of a diffusion barrier by 
tight control of the paracellular pathways, so called the gate function, and to create a 
physical barrier preventing the movement within the cytoplasm of lipids and proteins, 
the fence function (Figurel.5). The paracellular diffusion gate represents a semi- 
permeable barrier that limits diffusion depending on the charge and the size of the 
solute. The ion and size selectivity differs among tissues and it is regulated by 
different physiological and pathological stimuli.
Occludin and the Claudins are the main TJ proteins responsible for the 
paracellular permeability. Several studies have pointed at Claudins as being the 
major determinant of the permeability properties. For example, mutant mice lacking 
Claudin-1 die after birth due to water loss through the skin (Furuse and Tsukita,
2006). On the contrary, the fence function requires the cooperation and coordination 
between integral membrane proteins, TJ scaffolding proteins and signalling 
molecules (Umeda et al., 2006).
In epithelial and endothelial cells, “polarity” refers to an asymmetric 
allocation of macromolecules such as, proteins, lipids and carbohydrates, within the 
cell conferring a subdivision in the plasma membrane creating two well
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differentiated areas: the apical and the basolateral domains. TJs between 
neighbouring cells allow the separation of apical and basolateral membranes, a 
necessary state for normal cell functions (Tsukita et al., 2001).
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T ight Junction
Apical m em brane
B aso latera l m em brane
P a ra ce llu la r  T ran sce llu lar
Figure 1.5: TJs serve to separate the apical and basolateral domains, thus 
acting as a gate and fence.
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1.3.2 Tight Junction as a regulator o f adhesion and migration
The epithelium constitutes one of the primary physical barriers that protects 
the organism against infectious agents in the environment. In response to injury, the 
broken epithelial barrier needs to reseal quickly as the altered structure can be a gate 
for pathogens and viruses. These agents cause fluid and electrolyte secretion, or 
activate the inflammatory response (Guttman and Finlay, 2009). W ounding is usually 
followed by healing, but for this to be accomplished; epithelial cells need to migrate 
into the wound space. During this process cells must detach from the basement 
membrane due to disruption of the actin cytoskeleton, and extend their body through 
polarized protrusion extensions in the direction of the movement which results in TJ 
disruption. As explained above, TJs play a fundamental role in cell polarisation. The 
apical-basolateral polarity is disrupted in this process and protein complexes are 
redistributed in the cell. The Par3-Par6-aPKC, PAJT-PLAS-CRB, and Scrib-Dlg-Lgl 
complex are crucial for the polarity of the cell and for directional movement. Those 
complexes relocate within the cell after wounding, leaving proteins associated with 
TJ structure towards the migration borders (Shin et al., 2007). A  recent study in 
Madin-Darby canine kidney (MDCK) epithelial cell, showed that Occludin 
accumulates on the migration edge membrane suggesting that it might intercede in 
the recruitment of Par3-aPKC/PATJ during healing (Du et al., 2010).
1.3.3 Tight Junctions as regulators o f cell-surface polarity, proliferation and 
differentiation
Cell proliferation and polarisation are tightly regulated processes which are 
essential for the development of differentiated tissues. As mentioned in section 1.3.1,
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TJs are necessary for cell polarisation, however several studies have also linked these 
structures to cell proliferation and differentiation, all of which are fundamental steps 
in cancer progression.
The recruitment of leukocytes is an important part of wound healing and the 
angiogenesis processes. It is a complicated mechanism involving leukocyte 
activation, selectin-mediated rolling, integrin-mediated adhesion and diapedeis. 
Leukocytes need to leave the vasculature passing through the barrier that endothelial 
cells form. To achieve this transmigration, interactions between leukocytes and the 
endothelial cells needs to occur. Several studies have implicated JAM -1,-2 and - 3  in 
leukocyte trafficking during inflammation and angiogenesis. In particular, JAM-1 
was seen to participate in the process by undergoing homophilic binding interactions, 
as well as heterophilic interactions to the |32-integrin LFA. JAM -2 has been 
suggested to interact with p 1 -integrin VLA-4 in T-cells. JAM-3 has been shown as a 
receptor for Mac-1, a member o f  the (32-integrin family, contributing to leukocyte 
Transendothelial transmigration (Keiper et al., 2005). Taking into account all this 
evidence, it is clear that JAMs, as members of the TJ structure, participate in 
leukocyte migration.
Recent evidence has pointed to TJs as being regulators of cell proliferation, 
gene expression, differentiation and morphogenesis. One interesting study by 
Katsuno et al., showed the critical role that ZO-1 may play in tissue organisation and 
remodelling. ZO-1 knockdown mice died at the embryonic stage of 10.5 days, with 
embryonic and extraembryonic imperfections, such as impaired angiogenesis in the 
yolk sac or disorganized notochord areas (Katsuno et al., 2008). To complement
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these results, ZO-2 has been seen to form a complex with c-myc and HDAC1 which 
appears to be able to down-regulate the transcription of cyclin D l ,  a pivotal regulator 
of cell cycle (Huerta et al., 2007).
High cell density increases expression of Cingulin in M DCK cells and this 
has been linked to lower levels of active Rho A, a member of the Rho GTPase family 
and vice versa, with reduced expression of Cingulin in low density cell growth 
causing higher levels of active Rho A. Unexpectedly, levels of GEF-H1 (a guanine 
nucleotide exchange factor for Rho A) remains constant, suggesting that Cingulin 
might interact with GEF-HI and together inactivate Rho A (Aijaz et al., 2005).
Such results provide a molecular mechanism whereby the development of 
Tight Junctions in epithelial cells participate in the down-regulation of Rho A by 
GEF-HI in a Cingulin-dependent way.
Several studies have also linked TJs to the suppression of proliferation. Raf-1, 
a downstream effector of the ras oncogene which is associated with the control of 
proliferation and differentiation, appears to down-regulate the expression of 
Occludin in epithelial cells. But when Occludin is forcibly expressed lacking its first 
extracellular loop, the normal polarized state of the cell is recovered. However, when 
the second extracellular loop is knocked down, the proliferation of tumour growth 
progresses. This suggests that the second extracellular loop may play an important 
role in recovering the normal phenotype of the cell while its absence allows tumour 
growth in vivo (Wang et al., 2005).
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In the case of ZO-1, different studies point to this protein as fundamental in epithelial 
morphogenesis and differentiation due to its interaction with ZONAB (ZO-1 
associated nucleic-acid-binding protein), a Y-box transcription factor that promotes 
proliferation and differentiation (Matter and Baida, 2007).
1.4 T ight Junction and cancer
The link between altered TJs and epithelial tumour development has been 
confirmed by earlier studies placing TJs in the spotlight of cancer research. These 
studies showed dysregulation in TJ structures of several epithelial cancers including 
breast cancer.
Most cancers originate from epithelial tissues and are characterised by 
irregular growth and aberrant tissue morphology. It is absolutely necessary for 
tumour cells to have distinct adhesion behaviour; being significantly weaker in 
cancer cells. Thus, the communication between cells is highly affected and disorders 
in the signal transduction pathways that connect cell to cell arise. This change in cell 
surroundings encompasses a wide spectrum of changes, revealed in early and late 
stages o f  tumour growth, when the lost of polarity and uneven growth, as well as 
invasion and metastasis are a reality in cancerous epithelia. As tumour epithelial cells 
were examined in different types of cancer, early evidence was found of  disorganized 
structure of TJs (Swift et al., 1983) or even a lack of them in hepatocellular 
carcinoma, and reductions in the number of TJs strands when seen by freeze fracture 
in breast carcinoma (Robenek et al., 1981). Decreased transepithelial resistance
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(TER) and consequently increased TJ permeability has also been reported in TJs of 
colon tumours (Soler et al., 1999). In normal kidney epithelial cells, structural 
adjustments in TJs were observed during mitosis. However cell division itself does 
not increase epithelial TJ permeability, therefore inducing leakiness in the epithelial 
barrier. These results indicate that altered permeability may be due to disease states 
like cancer (Soler et al., 1993).
Taken together all this evidence from different cancer types appears to clearly 
indicate that a decrease in the epithelial barrier function and loss of TJ function are 
correlated. An extensive number of studies have shown that different protein 
members of TJs are directly or indirectly related to cancer progression, some of those 
have also been shown to correlate with staging and metastatic potential in various 
cancers (Table 1.3).
In bladder cancer the expression of Claudin-1, -4 and -7 was analysed by 
Boireau et al., Claudin-4 expression appears to be modified in 26/39 tumours 
compared with the exceptional modifications found in Claudin-1 and -7. Over­
expression of Claudin-4 was found in different carcinomas followed by remarkable 
down-regulation in invasive/high grade tumours. Delocalisation of Claudin-1 and -4 
was seen in most human bladder tumours as well as in the bladder cell line HY-1376 
(Boireau et al., 2007).
In colorectal cancer, Resnick et al., studied the expression pattern of Claudin- 
1, -4, Occludin and ZO-1 and their possible role in prognosis of disease was 
evaluated in a cohort of 129 TNM  stage II tumours using tissue microarray 
technology. They found that in that order 75%, 58%, 56% and 44% of the tumours
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examined displayed normal to elevated expression levels of Claudin-1, -4, Occludin 
and ZO-1 respectively. Low expression levels of Claudin-1 and ZO-1 were related to 
high tumour grade. Taking all these results together, it was confirmed that loss of 
Claudin-1 might be a strong candidate for disease recurrence and poor patient 
survival in stage II colorectal cancer (Resnick et al., 2005). An earlier study by 
Tokunaga et al. examined the expression of Occludin in a cohort of 40 rectal 
carcinoid tumours using an anti-Occludin monoclonal antibody. The results showed 
that Occludin was not found in most of the rosette-like or trabecular structures in 
carcinoid tumours, however 20% presented a small number of rosette-like tubular 
structures presented Occludin as a dot or short line. These studies indicate that 
Occludin could be a useful marker of polarized glandular structures, a helpful tool to 
distinguish true glands from rosettes in human rectal carcinoid tumours (Tokunaga et 
al., 2004). The levels of expression of Claudin-1 and -2 were examined in 
adenocarcinoma tissues as well as normal mucosa by Kinugasa et al. 
Immunohistochemistry and quantitative reverse transcription-polymerase chain 
reactions (RT-PCR) were used in the study. Results showed up-regulation in both 
Claudins at m RNA level as well as at protein level clearly linking these results to 
tumour invasion (Kinugasa et al., 2007). The expression of Claudin-3, -4 and -7 was 
identified upregulated in gastric carcinoma when gene expression was analyzed by 
microarrays in three oesophageal adenocarcinomas, one case of Barrett's oesophagus, 
and three normal oesophagi. Claudin -3 showed a marked increase in m RNA 
expression compared with normal oesophagus while Claudins- 4 and -7 were 
moderately up-regulated. Claudin-4 and -7 protein expressions were highly up- 
regulated in Barrett's oesophagus but minimally in squamous and gastric mucosa.
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Claudin-3, -4 and -7 expressions showed high-grade in dysplasia, adenocarcinoma, 
and metastases specimens using Immunohistochemical staining. All these findings 
suggested that alterations in Claudin proteins are an early event in tumorigenesis of 
oesophageal adenocarcinoma (Montgomery et a l., 2006). Usami et al. analyzed the 
expression of Claudin-7 in squamous cell carcinoma of the oesophagus showing that 
Claudin-7 levels at the metastatic lymph nodes are significantly reduced compared to 
expression levels at the invasive front of the primary tumours. This suggests that the 
reduction may be linked to tumour progression and subsequent metastatic events 
(Usami et al., 2006).
An early study from Kimura et al., investigated Occludin in combination with 
ZO-1 in normal epithelia and cancers in the human digestive tract by 
immunostaining. In normal epithelium ZO-1 and Occludin were expressed together 
as a single line at the apical cell border. However, in the oesophagus only ZO-1 was 
expressed. When looking at cancer tissues, both proteins followed the same pattern 
of expression in normal epithelium as in differentiated adenocarcinoma cells. 
Conversely, in poorly differentiated adenocarcinomas both expressions were reduced 
indicating a correlation between tumour differentiation and expression o f  Occludin 
and ZO-1 (Kimura et al., 1997).
Disruptions in the TJ structure have also been seen in lung cancer. An early 
study of 68 lung carcinomas and surrounding normal tissue found strong staining of 
Occludin in the apico-luminal borders of the branchial epithelia and bronchial glands 
as dots or short lines. When looking at cancer tissue, staining of Occludin was found 
in all cells that faced lumen in all adenocarcinomas including bronchioalveolar
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carcinomas and followed the same staining pattern as that of the normal epithelia.
This suggests that Occludin could be an ideal indicator to differentiate those glands 
that form tubulo-papillary structures in human lung carcinoma tissues (Tobioka et al., 
2004b). Using semi-quantitative reverse transcription-PCR on 27 pairs of lung 
squamous cell carcinomas and normal lung tissue, Liu et al., confirmed differential 
expression of Claudin-1 in 82.1% (23/28) of lung tumour tissue (Liu et al., 2007). 
Paschoud et al., investigated different patterns of expression of a large panel of TJ 
proteins in lung squamous cell carcinomas and adenocarcinomas using quantitative 
RT-PCR. Significant changes in transcript levels were found when looking at 
squamous cell carcinomas in JAM-1, Occludin, Claudin-1, -3, -4, -7, Cingulin, ZO-2 
and -3. Only Claudin-1 was shown to be down-regulated while the other proteins 
were up-regulated. In adenocarcinomas, transcript levels were compared to bronchial 
cells and a significant down-regulation in the levels of Claudin-1, -3, -4, -7, ZO-2 
and -3 was observed (Paschoud et al., 2007).
In prostate cancer, down-regulation of Occludin was seen in polygonal cells 
of Gleason grades 4 and 5, however, Occludin expression still occurred in cells 
facing the lumen in all grades of cancer. These results suggest that Occludin in 
prostate cancer is associated with loss of cell polarity and occurs at the same time as 
the formation of the complex glandular architecture of Gleason grade 4 pattern or 
complete loss in Gleason grade 5 pattern (Busch et al., 2002). A study from Sheehan 
et al., shows the pattern of expression of several Claudins in prostatic 
adenocarcinomas from 141 tissues samples. Decreased expression of Claudin-1 
correlated with high tumour grade and biochemical disease recurrence, Claudin-7 
appears to be decreased and also correlated with high tumour grade. However,
Claudin-3 correlated with advanced tumour stage and recurrence, while Claudin-4 
correlated with advanced stage (Sheehan et al., 2007).
Normal endometrium glands, endometrial hyperplasia and endometroid 
carcinoma grade 1 samples were analyzed by Tobioka et.al. All samples were seen to 
express Occludin. However, in endometrioid carcinomas grades 2 and 3, Occludin is 
not present in solid areas. Occludin expression was decreased in parallel with the 
increase in carcinoma grade, and the decrease in expression correlated with 
myometrial invasion and lymph node metastasis (Tobioka et al., 2004a). Claudin-4 
was over-expressed in epithelial ovarian cancer, although this expression did not 
correlate with survival or other clinical endpoints. However, Claudin-4 over­
expression was correlated with changes in barrier function after treatment with 
Clostridium perfringes  enterotoxin in a dose-Claudin-4 dependent non-cytotoxic 
manner (Litkouhi et al., 2007). When Claudin-4 protein and transcript level were 
analyzed in 110 patients with different histological types of epithelial ovarian 
carcinomas Tassi et al., found them to be significantly up-regulated in both primary 
and metastatic tumours compared to normal human ovarian surface epithelium cell 
lines. At protein level, Claudin-7 appears to be significantly higher in tumours of 
primary and metastatic origin when compared to normal ovaries, despite grade of 
differentiation, histologic type and pathological state. Complementary results show 
Claudin-7 to be over-expressed in all main histological types of epithelial ovarian 
carcinomas, in single neoplastic cells dispersed in the peritoneal cavity and pleural 
effusions. The data presented in this study suggested that Claudin-7 may be a useful 
novel marker in the disease (Tassi et al., 2008).
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The blood-testis barrier is composed of TJ, Adherens Junctions and Gap 
Junctions. Of all these structures, TJ is the main structural component in the Sertoli 
cell barrier. A study by Fink et al., found an association between ZO-1 and -2 with 
the blood-testis barrier region in men with normal spermatogenesis. ZO-1 and -2 
immunostaining were observed in normal tubules and at different stages of human 
testicular carcinoma in situ. When looking at carcinoma in situ tubules, the staining 
appears to be cytosolic, scattered and weaker. This data was complemented with 
Western blot and RT-PCR confirming that the disruption of Sertoli cell barriers in 
carcinoma in situ is linked to aberrant distribution of ZO-1 and ZO-2 (Fink et al., 
2006).
In human pancreatic endocrine tumours and ductal carcinomas, the protein 
and m RNA expression of different members of the Claudin family was analysed by 
Borka et al. Claudin-1, -2, -3, -4 and -7 revealed strong staining while Claudin-2 
stained diffusely in normal acini and ducts. Langerhans islands presented only for 
Claudin-3 and -7 expression. The majority of endocrine tumours were negative for 
Claudin- 1, -2 and -4. Claudin-2 was present in half of the ductal adenocarcinomas 
whereas Claudin-3 was totally negative. Claudin-3 and -7 were detected in all 
endocrine tumours. When looking at the level of expression, differences were seen 
between endocrine tumours and ductal adenocarcinomas, worth mentioning is the 
high expression of Claudin-3 in endocrine tumours and Claudin-7 in ductal 
carcinomas making those proteins suitable targets for adjuvant therapy (Borka et al.,
2007). When ZO-1 expression level was investigated in pancreatic cancer, Kleeff et 
al., found that it was higher in pancreatic ductal carcinomas when compared to 
normal pancreas. Under the confocal microscope, ZO-1 was present in the apical and
apicolateral areas of ductular cells in the normal pancreas and in chronic pancreatitis. 
However, pancreatic ductal carcinomas displayed ZO-1 regardless of expression in 
cancer cell forming duct-like structures. In lymph nodes, metastatic pancreatic cancer 
cells displayed a random pattern of distribution of ZO-1. It appears to be presented 
from apical to apicolateral areas including diffuse staining in the membrane. All 
these findings suggested that in pancreatic ductal carcinomas over-expression of ZO- 
1 might help pancreatic cancer cells to metastasise (Kleeff et al., 2001).
1.4.1 T ight Junctions and breast cancer
An increasing number of studies have described the dysregulation of  the TJ 
proteins and how these changes also affect breast cancer progression.
When looking at transmembrane proteins in the TJ, results have revealed that 
Occludin expression is down-regulated in several cancers including breast. When 
Occludin was over-expressed in the murine breast carcinoma cells AC2M 2, results 
showed that Occludin promotes detachment-induced apoptosis (anoikis) via 
regulation of a set of apoptosis-associated genes (Osanai et al., 2006). Further 
experiments from the authors have also shown that Occludin is associated with 
premature senenscence in AC2M 2 cells through the up regulation of negative cell 
cycle regulators such as p l6IN K 4A , p21IW afl/C ip l  and p27Kip. However, p53 was 
not affected. Taking all these findings together, loss of Occludin appears to be 
partially involved in the senescence-promoting program during mammary 
tumourigenesis (Osanai et al., 2007b). JAM -A has been implicated in the 
development of breast cancer. Niak et al., showed that levels of JAM -A were down- 
regulated in metastatic breast tumours. In vitro studies with breast cancer cell lines
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MCF-7, MDA-MB-231 and MDA-MB-468 revealed that over-expression of this 
protein results in a decrease in migration as well as invasion, whereas its knockdown 
promotes invasiveness (Naik et a l., 2008). However, McSherry et al., recently 
studied the role of JAM -A in MCF-7 and MDA-MB-213, revealing a link between 
high levels of JAM -A and poor prognosis in patients with breast cancer. An in vivo 
study has been reported, revealing that knockdown of JAM -A in MCF-7 cells 
significantly decreases migration (McSherry et al., 2009).
A number of studies have also implicated the Claudin family in breast cancer. 
Claudin-1 protein level has been reported to be reduced in breast tumours as well as 
in breast cancer cell lines such as MDA-MB-231 and MDA-MB-435. In these cell 
lines no genetic alterations were seen in the promoters or coding sequences with no 
explanation for the loss of expression of Claudin-1, therefore rejecting any tumour- 
suppressor effect for this protein (Kramer et al., 2000). In similar breast cancer cell 
lines, Hoevel et al., found no signal of expression of Claudin-1 nor Occludin, 
however, when Claudin-1 retrovirus was transduced into these cells, expression of 
Claudin-1 was found at the usual location at cell-cell contact sites, suggesting that 
other proteins might be responsible for targeting Claudin-1 in the TJ. In addition the 
paracellular permeability was altered in the transduced cells. The authors suggested 
that Claudin-1 over expression might be sufficient to exert TJ paracellular barrier 
function in metastatic breast cancer cells in the absence of other transmembrane 
proteins such as Occludin. These results agree with the study by Kramer et al., 
suggesting that even though there is no evidence of any genetic changes, there must 
be some epigenetic or regulatory factors involved in the down-regulation o f  Claudin- 
1 (Hoevel et al., 2002). Furthermore, Claudin-1 has been seen to be a useful
prognostic marker in breast cancer patients. Morohashi et al., have revealed a 
correlation between recurrent breast tumours and low levels of Claudin-1 expression 
compared to primary tumours. Decreased expression of Claudin-1 was also 
associated with the lymph node metastasis-positive group and short-disease free 
patient group (Morohashi et al., 2007).
Examination of Claudin-16 in breast cancer cells, in vitro and in vivo  studies, 
have shown that when Claudin-16 is over expressed in the human breast cancer cell 
line MDA-MB-231, cells were significantly less motile and displayed reduced 
aggressiveness, with an increase in TJ function as the colonies became tighter. To 
complement this study, patient data revealed low expression of Claudin-16, mainly in 
patients who displayed high mortality (Martin et al., 2008a). Studies of Claudin-7 
have revealed the loss of expression in preneoplastic and invasive ductal carcinoma 
and this loss was mostly seen in high-grade lesions. The same situation was seen in 
lobular carcinoma where Claudin-7 was also absent. The authors suggested a link 
between the lack of Claudin-7 expression and cancer progression due to the 
increased cellular discohesion that is frequently seen in high-grade lesions, proposing 
that Claudin-7 might help tumour progression and increases metastatic potential. 
Moreover, when the breast cancer cell lines MCF-7 and T47D, which express high 
levels of Claudin-7, were treated with HGF, there was a resultant loss of Claudin-7 
after 24 hours of treatment as well as dissociation of these cell lines in culture, 
linking the loss of Claudin-7 and cell cohesion in breast cancer (Kominsky et al., 
2003). In concordance with the above mentioned study, Sauer et al., showed an 
inverse correlation between Claudin-7 level of expression and tumour grading. Grade 
2 and -3 invasive carcinoma revealed reduced expression of protein. This data
correlates with metastatic disease, including loco-regional recurrences and with 
heterogeneous staining pattern. However, these results do not correlate with tumour 
size or subtype (Sauer et al., 2005). Osani et al., demonstrated that the knock down 
of Claudin-6 in MCF-7 cells increases cell migration and invasion (Osanai et al., 
2007a). In agreement with Osani’s results, a recent study by Wu et al., revealed that 
over expression of Claudin-6 in the MCF-7 cell line resulted in a decrease in cell 
growth rate as well as migration and invasion. However, the transepithelial resistance 
was increased in the transfected cells, suggesting a possible role in breast cancer 
progression acting as a cancer suppressor (Wu et al., 2010).
Soini et al. analysed the pattern of expression of Claudin-2, -3, -4 and -5 
protein levels in breast carcinoma. The study revealed that Claudin-2 and -4 were 
highly expressed in non-neoplastic breast tissue whereas Claudin-3 and -5 appear to 
show high expression in ductal and acinar cells. Levels of expression in breast 
carcinoma were for Claudin-2 in 52%, Claudin-3 in 93%, Claudin-4 in 92% and 
Claudin-5 in 47% of the samples respectively. It is important to mention that there 
was no correlation between level of expression of these Claudin members and 
tumour grade or oestrogen receptor status. Levels of expression between different 
Claudins were seen to be associated, strong Claudin-2 expression was linked to 
Claudin-5 and -3. In the same way, strong Claudin-3 expression was associated to 
Claudin-5 and -4 (Soini, 2004). A similar study analysing levels of m RN A  compared 
to protein levels for Claudin-1, -3 and -4 in malignant breast tumours and benign 
lesions was carried out by Tokes et al., revealing that whereas Claudin-3 and -4 
mRNA and protein levels did not show any difference in expression between 
invasive tumour and the surrounding normal tissue, Claudin-1 m RNA appeared to be
highly down-regulated when compared with the control group. However, Claudin-3 
and -4 proteins were detected in all primary breast carcinomas in one study by 
Kominsky et al., in addition, when compared to normal epithelium, these two 
Claudin members were over-expressed in 62% and 26% of samples respectively 
(Kominsky et al., 2004). Additionally, Claudin-1 was located in the membrane of 
ductal cells and in some of the ductal carcinoma in situ, whereas in invasive tumours 
Claudin-1 was not presented or its distribution was diffuse in the tumour cells. This 
data provided further evidence of how Claudin-1 is involved in invasion and 
metastasis of breast cancer. High levels of Claudin-4 distribution was seen in normal 
epithelial cells and was almost lost in mucinous, papillary, tubular breast carcinoma 
as well as in areas of apocrine metaplasia (Tokes et a l ,  2005).
Studies focusing in cytoplasmic plaque proteins of the TJ have revealed how 
ZO-1 staining was found to be decreased or even lost in 69% of breast cancer using 
immunohistochemistry, whereas normal breast tissue showed intensive staining in 
the area where TJs were localized. When infiltrating ductal carcinoma was analysed 
Hoover et al., found a fall in staining of 42% when tissue was well differentiated, in 
83% of moderately differentiated and 93% when tumours were hardly differentiated. 
In addition to these results, it was reported that staining for ZO-1 correlated with 
tumour differentiation, and particularly with the glandular differentiated tumours 
implying that down-regulated level of ZO-1 might be a link to cancer progression 
(Hoover et al., 1998). Martin et al., investigated levels of expression of ZO-1, -2, -3 
and MUPP-1 in patients with primary breast cancer. Immunohistochemical staining 
for ZO-1, -2 and -3 revealed low intensity in tumour samples when compared with 
paired background sections and a delocalisation of ZO-1 in the TJ. Looking at
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mRNA levels, the level of expression of all these proteins was reduced in tumour 
tissues; however the differences were not statistically significantly. This study also 
reported a decrease of ZO-1 and MUPP-1 expression in patients with poor prognosis 
and with increasing tumour grade (Martin et al., 2004b). A study from Polette et al., 
suggested a link between ZO-1 and cell invasion in breast cancer cells by modulating 
membrane-type 1 matrix metalloproteinase (MT1-MMP) which appears to be over­
expressed in many types of cancer including breast. In invasive breast cancer cell 
lines, MDA-MB-435, BT549, and Hs578T, ZO-1 was localized in the cytoplasm 
whereas Occludin was absent. Quite the opposite happened in non-invasive cell lines, 
MCF-7 and BT20, which exhibited membrane staining for ZO-1 as well as for 
Occludin and did not express MT1-MMP. This data also suggested a possible role 
for ZO-1 in the regulation of M T1-MM P through the (3-catenin/TCF/LEF pathway 
which regulates the transcription of different genes implicated in tumour invasion 
(Polette et al., 2005). ZO-2 has also been seen to be down-regulated in breast 
adenocarcinoma (Chlenski et al., 2000). Glaunsinger et al., reported the importance 
of ZO-2 in the tumour-inducing capacity of the adenovirus type 9 (Ad9) E4 protein. 
Expression of mutant ZO-2 protein with no E4 binding site inhibits Ad9 E4- induced 
transformation (Glaunsinger et al., 2001).
Similar studies, looking at associated/regulatory proteins have reported that 
the level of expression of Ponsin and Vinculin correlates with poor prognosis in 
patients with breast cancer (Martin and Jiang, 2009). The Par complex (Par3-Par6- 
aPKC) has been related to breast cancer progression. In particular the level of 
expression of Par6B appeared to be up-regulated in breast cancer tissues. Over 
expressing Par6 in the breast epithelial cell line MCF-10A resulted in higher
proliferation rates which depended on interactions between Par6, aPCK and Cdc42. 
Down-regulation of aPCK or Cdc42 inhibits the capacity of Par6 to enhance 
proliferation, demonstrating that Par6 promotes cell proliferation in breast cancer 
cells (Nolan et al., 2008). Opposite to Par6, Par3 has been reported to be down- 
regulated in squamous cell carcinomas showing a correlation with positive lymph 
node metastasis and poor differentiation (Zen et al., 2009). Immunohistochemistal 
staining for Scrib, member of the Scribble complex, appeared to be reduced and 
mislocalised in human breast cancer tissues (Navarro et al., 2005). A  study by Zhan 
et al., suggested a role for Scrib in breast cancer development, where knockdown of 
Scrib in the MCF-10 cell line altered cell polarity and caused inhibition of the 
capacity of the oncogene c-myc to induce apoptosis in breast epithelial cells (Zhan et 
al., 2008).
To evaluate how different agents could induce changes in TJ functions,
Martin et al., studied the effect of selenium (Se), gamma linolenic acid (GLA) and 
iodate (I) in two different breast cancer cell lines, MDA-MB-231 and MCF-7. Even 
though the cell lines have different responses to the agents the study revealed how I, 
Se and Gla, independently or in combination, can induce changes in the TJ 
enhancing the transepithelial resistance. In addition to this, these three agents were 
also able to reverse the effect of the hormone 17-p estradiol on this cell line, which 
also causes modifications in the paracellular permeability of the endothelial cell line 
HUVEC decreasing the transepithelial resistance of the TJ (Ye et al., 2003). A 
remodelling of the structure of TJs after treatment has also been reported, where the 
proteins Occludin.and ZO-1 showed increased intensity when immunofluorescence 
staining was analysed as well as relocation in the cell membrane (Martin et al., 2007).
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Hepatocyte growth factor (HGF) is a cytokine that has been involved in cell 
motility, mitogenesis and morphogenesis in a broad range of cells including cancer 
cells. Treatment of cancer cells with HGF was seen to induce invasiveness as well as 
angiogenesis in vitro and in vivo (Jiang et al., 2005). In the host laboratory, HGF has 
also been reported to disrupt the TJ in endothelial cells (Jiang et al., 1999b),an effect 
that can be reversed by highly unsaturated lipids (Jiang et al., 1998). When breast 
cancer cell lines MDA-MB-231 and MCF-7 were treated over time with HGF, 
different TJ proteins such us Occludin, JAM-1 and -2, and Claudin-1 and -5 appeared 
to be regulated both at mRNA and protein levels as well as did their localisations 
inside the TJ (Martin et al., 2004a).
All these results certainly indicate the potential involvement of different TJ 
proteins in the cascade of events related to breast cancer progression. Further studies 
will provide greater understanding of the role of these proteins in breast cancer and 
will clarify their contributions to tumour development.
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Cancer type Claudin type
Changed
expression
Reference
Breast
Claudin-16
Claudin-7
Claudin-1
Claudin-3, -4
Down-regulated
Down-regulated
Down-regulated
Up-regulated
(Martin et al., 2008a) 
(Kominsky et al., 2003) 
(Kramer et al., 
2000),(Hoevel et al., 2002; 
Morohashi et al., 2007), 
(Tokes et al., 2005) 
(Kominsky et al., 2004)
Colon Claudin-3,-4,-7 
Claudin-1,-2 
Claudin-1 
Claudin-7 
Claudin-1,-4
Up-regulated
Up-regulated
Down-regulated
Down-regulated
Up-regulated
(Montgomery et al., 2006) 
(Kinugasa et al., 2007) 
(Resnick et al., 2005) 
(Usami et al., 2006) 
(Resnick et al., 2005)
Ovarian
Claudin-1,-2,-4
Claudin-7
Claudin-5
Down-regulated
Up-regulated
Up-regulated
(Litkouhi et al., 2007) 
(Tassi et al., 2008) 
(Turunen et al., 2009)
Pancreatic
Claudin-4 
Claudin-3,-7
Down-regulated
Up-regulated
(Borka et al., 2007) 
(Borka et al., 2007)
Prostate
Claudin-1,-7 
Claudin-5
Down-regulated
Up-regulated
(Sheehan et al., 2007) 
(Seo et al., 2010)
Bladder Claudin-4 Up-regulated (Boireau et al., 2007)
Lung Claudin-1
Claudin-3,-4,-7
Claudin-5
Claudin-5
Down-regulated
Up-regulated
Up-regulated
Down-regulated
(Paschoud et al., 2007) 
(Paschoud et al., 2007) 
(Paschoud et al., 2007) 
(Paschoud et al., 2007)
Hepatocellular Claudin-5 Down-regulated (Sakaguchi et al., 2008)
Table 1.3: Changes in expression levels of different Claudin members in human 
cancers.
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1.5 Claudins, a multi-gene family
1.5.1 Structure of Claudins
To date the Claudin family is composed of 24 members in mammals having 
molecular weights ranging from 22 to 27 kDa (Table 1.4). There have been 54 
Claudins identified in the fish Takifugu and 15 in D anio rerio. Invertebrates also 
express Claudins despite their lack of TJs, e.g. Drosophila m elanogaster  appears to 
have 6 Claudins. Claudins were originally thought to be simple sealing proteins at TJ. 
In fact, the name of Claudin derives from the latin word “claudere” which means to 
close.
Claudins were first identified by Furuse et al., using the same isolated 
fraction from chicken liver from which Occludin was first identify by Tsukita’s 
group in 1989 (Tsukita, 1989). They showed for the first time that a group of proteins 
existed with similar sequence to each other and with four transmembrane domains 
where the N- and C- terminal domains are orientated towards the cytoplasm, but with 
no similarity to Occludin. Claudin members have since been divided into two groups. 
The so called “Classic Claudins”, which include members with high sequence 
homology like Claudin-1 to -10, -14,-15, -17 and -19. And the “Non-classic”
Claudins which include Claudin-11, -13, -16, -18, and -20 to -24 (Krause et al.,
2008).
The cytoplasmatic C-terminal domain in Claudin varies between members in 
length and sequence, ranging from 21 to 63 residues. While the N-terminal domain is 
relatively short, 7 amino acid sequence, the intracellular loop is composed of 12
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amino acids. The first extracellular loop is a 52 amino acid sequence which is highly 
conserved in different members with two conserved cysteines that influences 
parcellular charge selectivity [Gly-Leu-Trp-x-x-Cys-(8-10 aa)-Cys]. Some studies 
suggest that this loop determines the charge selectivity of the paracellular transport 
(Figure 1.6). The second extracellular loop is shorter, ranging from 16 to 33 amino 
acid residues. It is worth mentioning that this loop might fold in a helix-turn-helix 
motif which seems to be a participant in the Claudin-Claudin interactions (Piontek et 
al., 2008). It has been observed that this loop functions as a receptor for the 
Clostridium perfringens  enterotoxin or CPE (section 1.5.2).
The cytoplasmic tails have the most varied sequences in the topology of the 
Claudins, their lengths range from 21 to 63 amino acid residues, suggesting the 
involvement of this structure in isoform-dependent paracellular selectivity. All 
members have a PDZ domain in their COOH- terminal tail (as already stated in 
section 1.2.1) that allows them to interact with other proteins in the TJ such as ZO-1, 
-2, and -3, MUPP, and PATJ. The interaction with cytoplasmic plaque proteins as 
ZO-1 links Claudins to the actin cytoskeleton (Van Itallie and Anderson, 2006). To 
date, there is no information about the function of the NH2 domain.
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Claudin name Alternative name
Gene
location
CLDN1 Senescence-associated epithelial membrane protein 1 (SEM P1)
3q28-
q29
CLDN2 - Xq22
CLDN3 Clostridium Perfringens Enterotoxin Receptor 2; CPETR2 7q 11
CLDN4 Clostridium Perfringens Enterotoxin Receptor 1; CPETR1 7 q ll
CLDN5 Transmembrane Protein Deleted In Velocardiofacial Syndrome; TM VCF 2 2 q ll
CLDN6 - 16pl3
CLDN7 - 17pl3
CLDN8 - 21q22
CLDN9 - 16pl3
CLDN10 - 13q3
CLDN11 Oligodendrocyte Transmembrane Protein; OTM 3q26
CLDN12 - 7q21
CLDN13 - 21q2
CLDN14 deafness, autosomal recessive 29, included; DFNB29, INCLUDED 21q22
CLDN15 - 3q28
CLDN16 Paracellin-1 21q2
CLDN17 - 3q34
CLDN18 -
3q21-
q23
CLDN19 - lp34
CLDN20 - 6q25
CLDN21 - 11 q2
CLDN22 - 4q35
CLDN23 - 8p23
CLDN24 - 4q35
Table 1.4: The Claudin gene family. Information on gene location.
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Figure 1.6: Model o f Claudin protein structure.
CPE-binding site
21-36a
N -term inal dom ain
C-term inal dom ain
PD Z-interacting dom ain
1.5.2 Claudin interactions
Most epithelia and endothelia express a m ixture of different Claudin 
m em bers and more than two different Claudin members are co-expressed in a single 
cell (M orita et al., 1999a). Consequently, these observations have raised the question 
of whether different Claudin proteins are co-polym erised to form TJ strands as 
heteropolym ers, and whether Claudins interact between each other in a hom ophilic 
manner, between two m olecules of the same Claudin member, or heterophilic 
manner between two different Claudin members. However, little is known about the 
m olecular mechanism s taking place during assem bly and strand formation.
To assess all these questions, an early study by Furuse et al., showed that 
when using co-expression of m ultiple Claudin isoforms in mouse L fibroblasts, they 
concentrated at cell-cell contact areas form ing a well-developed netw ork o f TJ 
strands. However, when these cells were co-cultured they found by 
im m unoprecipitation that different Claudin m em bers can interact within and between 
TJ strands, but these interactions were restricted to specific com bination o f isoforms 
(Furuse et al., 1999).
These heterotypic interactions are assumed to occur in the plasm a membrane 
of the same cell (c/s-interaction) or between plasma m em branes o f opposing cells 
(rrarc.v-interaction), in a sim ilar way these interactions were defined in cadherins 
(Ahrens et al., 2002).
Hom ophilic rrans-interactions, also named homotypic interactions 
(Daugherty et al., 2007), have been seen for Claudin-1,-2,-3 (Furuse et al., 1999),
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Claudin-5 (Morita et al., 1999c), Claudin-6,-9, -14 (Nunes et al., 2006), C laudin-11 
(M orita et al., 1999b), and Claudin-19 (M iyamoto et al., 2005). All these Claudin 
isoforms were able to form TJs when transfected into TJ free cells. H om ophilic cis- 
interaction, or hom omeric interaction (Daugherty et al., 2007), has been described 
for Claudin-5 and -5 using fluorescence resonance energy transfer (FRET) and 
electron m icroscopy (Piontek et al., 2008).
Heterophilic trans- interactions, also termed as heterophilic interactions 
(Daugherty et al., 2007), have been observed for Claudin-1 and -3, C laudin-2 and -3 
(Furuse et al., 1999) and for Claudin-3 and -5 (Daugherty et al., 2007). The 
heterophilic interactions for at least these isoforms require com patible structural 
features in both extracellular loops. It has not been possible to dem onstrate a 
heterophilic trans-interaction for Claudin-1 and -2 (Furuse et al., 1999), Claudin-1 
and -4 , Claudin-3 and -4, and Claudin-4 and -5 (Daugherty et al., 2007). These 
results dem onstrated that only specific Claudins are able to interact with each other. 
Heterophilic cis- interactions, or heteromeric interactions (Daugherty et al., 2007), 
were found for Claudin-2 and -3, Claudin-3 and -4 and assumed for Claudin-1 and -2, 
respectively (Furuse et al., 1999).
1.5.3 Physiological functions o f Claudins
Paracellular transport through pores in the TJ differs in several important 
features from transcellular transport across the membrane. Firstly, it happens through 
the intercellular space of neighbouring cells. Secondly, this transport is passive and 
dependent on an electrochemical gradient. As discussed before (section 1.3), TJs 
play a central role in the intercellular space in epithelia and endothelia, and therefore
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the key factor of paracellular transport. These pores, now known to be form ed by 
Claudins are the major determinants of paracellular transport processes (Tsukita and 
Furuse, 2000).
The role of different Claudin members has been studied by three different 
approaches: by over-expression or down-regulation of Claudins in different cell lines, 
by knockdown of Claudin genes in mice and by the study of the phenotype o f human 
diseases arising due to Claudin mutation (see section 1.5.5) (Angelow et a l., 2008). 
Taking together all the data from these studies, it is more than evident that the 
combination and mixing ratios of different Claudin isoforms determ ine the 
selectivity of paracellular transport across epithelia and endothelia.
To study the effect of different Claudins on conductance, m onolayers of 
M adin-Darby canine kidney (M DCK) epithelial cells expressing a single type of 
Claudin have been used. There are two types of M DCK cell based on transepithelial 
electrical resistance, type I or “tight” cells, and type II or “ leaky” cells.
A clear outline of results has been revealed, showing that the expression of 
C laudin-1,-4,-8,-14 and -15 significantly increases resistance when expressed in low- 
resistance M DCK type II cells. W hereas, the expression of Claudin-2 in high 
resistance M DCK type I cells decreases resistance (Van Itallie and A nderson, 2004).
A C laudin-19 study in the same cell line has reported an increase in resistance and 
decrease in permeability to m onovalent and divalent cations, but anions and urea 
were unaffected (Angelow et al., 2007). Over-expression of Claudin-7 in the renal 
epithelial cell line of porcine proximal tubule LLC-PK1 has revealed an increase in 
resistance and a dram atic reduction of dilution potentials compared to wild type cells
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(Alexandre et al., 2005). Claudin-4, over-expression in the ovarian cancer cell line 
OVCA433, containing a mutation sim ulating its phosphorylated state, decreases the 
TJ strength (D 'Souza et al., 2005). Claudin-5 transfected in the human colonic cell 
Caco-2, low transepithelial resistance cell line, showed a significant increase in 
barrier function (Amasheh et al., 2005).
The knockout of specific Claudin genes in mice also indicates that Claudins 
are the major participants of the selective size, charge, and conductance properties of 
the paracellular pathway. A very significant example has been seen in the Claudin-1 
knockout mice, which die within 1 day o f birth from dehydration (Furuse et al.,
2002). C laudin-11 null mice exhibit neurological and reproductive problem s, 
showing the importance of this isoform in forming the paracellular physical barrier 
of the TJ required for sperm atogenesis and normal central nervous system  (Gow et 
al., 1999). Claudin-14 knockout in mice showed a rapid degeneration o f cochlear 
outer hair cells leading to deafness, suggesting the role of Claudin-14 as a cation- 
restrictive barrier in the maintenance o f the ionic composition in this type of cells 
(Ben-Y osef et al., 2003).
Colegio et al., have shown, by swapping the first, second and both 
extracellular domains between Claudin -2 and -4 in M DCK type II cells, that charged 
amino acid residues on the first extracellular domain of Claudins m ediates the 
paracellular perm eability for ions (Colegio et al., 2003). However, a recent study 
using chimeras of Claudin-2 and -4 in M DCK type II cells suggested that the 
extracellular dom ains are sufficient to increase the permeability, but the participation 
of the carboxy-terminal PDZ binding m otif is also necessary indicating that an
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interaction with other TJ cytoplasm ic plaque proteins like as ZO-1, ZO-2, ZO-3 or 
MUPP-1 are also needed in order to form pores (Van Itallie et al., 2009).
Examples of cation pore-form ing Claudins are Claudin-2 (Amasheh et al., 
2009) as well as C laudin-16 that forms a M g2+-selective channel in the thick 
ascending limb of Henle (Schneeberger, 2003).The confirmation for anion pore- 
form ing Claudins is less clear, nevertheless Claudin-10 has been identified as an 
anion-selective paracellular pore (Van Itallie et al., 2006). Using polyethylene glycol 
oligom ers (PEGs), small uncharged solutes, with increasing radii, Van Itallie et al., 
measured the size of the pore formed by Claudin-2. This study has revealed that this 
pore has a high capacity for compounds charged and uncharged below 4A and a 
lower capacity for larger solutes (Van Itallie et al., 2009). To date there are no other 
studies on the sizes of pores formed by other Claudin isoforms.
The particular role played by a number of Claudin family m em bers are yet to 
be identified. Examples are Claudin-6, -9, -12, -13,-17, -18, and 20-24. Claudin-6, -9 
and -13 studies have closely linked these isoforms to the m aturation of the epidermis 
or the barrier function in different cell types such as embryonic stem cells (ES) 
(Krause et al., 2008). Studies for C laudin-12 showed that it is expressed in 
endothelia and epithelia of the m ouse intestine (Fujita et al., 2006) as well as in the 
inner ear and brain endothelial cells. C laudin-18 has also been identified in the inner 
ear (Kitajiri et al., 2004). For other Claudin family member such as C laudin-17, -20, 
-22 and -23, only the m RNA expression levels have been identified in the duodenum  
of rats (Charoenphandhu et al., 2007). The existence of Claudin-23 and -24 has only 
been established from the analysis of the human genome (Gerhard et al., 2004).
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1.5.4 Regulation o f Claudins
The paracellular barrier m odulated by Claudin members could be affected by 
a wide range of physiologic factors including cell signalling pathways, hormones, 
cytokines, and disruption of the cell-cell contacts. This field is still em erging and 
little is known about the mechanism that regulates the Claudin family. However, 
post-translational modifications, including phosphorylation, lipid m odification and 
removal of Claudins by endocytosis, appear to be potential m echanism  for the 
regulation of Claudins.
A number of studies have revealed that Claudin function can be highly 
regulated by phosphorylation. It is widely accepted that most Claudin m em bers have 
potential serine and/or threonine phosphorylation sites in their cytoplasm atic COOH- 
terminal domain. Results after phosphorylation contribute in some cases to increase 
the barrier function of the TJ and in other cases to reduce it. For exam ple, Protein 
Kinase-A (PKA) phosphorylation of Claudin-5, probably at the amino acid site 
around Thr207, results in an increase of the barrier function in porcine blood-brain 
barrier endothelial cells treated with cyclic AM P (cAM P) (Ishizaki et al., 2003). 
However, PKA-dependent phosphorylation of Claudin-3, at the amino acid site 
T h rl9 2  in the cytoplasmatic COOH-term inal domain, in the ovarian cancer cell line 
OVCA433 resulted in a decrease of the TJ strength (D 'Souza et al., 2005). Yamauchi 
et al., found in M DCK type II cells that the threonine-serine kinase W NK4, binds 
and phosphorylates endogenous C laudin-1,-2,-3 and -4 and that the human disease- 
causing mutant o f W NK4 is associated with increased paracellular chloride 
perm eability without increasing sodium perm eability (Yamauchi et al., 2004). A
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different study showed sim ilar results and revealed that Claudin-7 is also a substrate 
to W NK4 on Ser206 in its cytoplasmatic COOH-term inal domain (Tatum et al., 
2007). Different studies have reported how other kinases are also linked to Claudin 
m em bers such as M APK (mitogen-activated protein kinase) phosphorylating 
Claudin-1 (Fujibe et al., 2004), Claudin-4,-7,-8 and -9 (Carrozzino et al., 2009). Rho 
kinase phosphorylating Claudin-4 (Tanaka et al., 2005) and EphA2 phosphorylating 
Claudin-5 (Yamamoto et al., 2008).
Endocystosis is a critical step in the rem odelling o f the TJ structure. To 
assure the correct sealing of the intercellular space of epithelial and endothelial cells 
this process has to be thoroughly regulated. Live observation and electron 
m icroscopy have revealed, in confluent Eph cells, that the endocytosis of Claudins 
was aided when wounding the cellular sheet and that other TJproteins such as 
Occludin and ZO-1 appeared to be detached from Claudins before this process 
occurred (Ikenouchi et al., 2003).
Other potential post-translational modification is palm itoylation. Van Itallie 
et al., shown that mutation of palm itoylation sites in M DCK type II cells alter the 
localization of Claudin-14, however, the stability and assembly of the TJ strands 
were not affected, indicating that alterations in transepithelial resistance in m utants 
might be due to the translocation of Claudin-14 (Van Itallie et a l ,  2005).
When looking at the level of gene expression, the zinc finger-containing 
transcription factor Snail, which plays a pivotal role in epithelial-to-m esenchym al 
transition (EM T), emerged as a regulator of the Claudin gene expression binding 
directly to Claudin promoters. Claudin genes, as well as E-Cadherin and Occludin,
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contain E-box motifs that trigger Snail and thus repress transcription (Ikenouchi et al.,
2003). A study in M DCK type II cells by Ohkubo et al. reported a possible second 
mechanism for Snail, finding that Snail down-regulates protein levels of Claudin-1 
however, mRNA was unaffected, suggesting that Snail may regulate Claudin 
translation (Ohkubo and Ozawa, 2004).
Further experiments using M DCK type II cells expressing Snail showed an 
increase in the paracellular permeability for chloride and sodium. They also reported 
a slight decrease in Claudin-2 expression but a significant decrease in Claudin-4 and 
-7 (Carrozzino et al., 2005). These results suggest that the increase in Snail 
expression has different effects in different Claudin members, resulting in selective 
changes in the cell barrier function.
Other transcription factors have also been reported. An early study by Niimi 
et al., showed that one isoform lacking the C-term inal cytoplasm atic domain of 
C laudin-18 is regulated by the T/EBP/NKX2.1 hom eodom ain transcription factor 
which is expressed in the lung, thyroid and stomach (Niimi et al., 2001). The 
transcription factor GATA-4 is also connected to one Claudin member, Claudin-2. 
GATA-4 binds to the promoter of Claudin-2 when the transcription factors CDX or 
H N F -la  are present suggesting that GATA-4 is totally necessary for the expression 
of Claudin-2 (Escaffit et al., 2005).
Hepatocyte growth factor (HGF) and epidermal growth factor (EGF), have 
been seen to regulate Claudin fam ily members. Both are cytokines that are involved 
in cell motility, m itogenesis and m orphogenesis in a broad range of cells including
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cancer cells where HGF can induce invasiveness as well as angiogenesis in vitro and 
in vivo (Jiang et al., 2005)
Two different studies revealed that both cytokines have sim ilar effects when 
treating M DCK type II cells with HGF and EGF. Both increased the transepithelial 
resistance linked to a reduction in the expression of Claudin-2 and activation o f the 
extracellular signal-kinase (ERK) 1/2. ERK 1/2 inhibitor, U0126, induces Claudin-2 
expression in M DCK type I cells which showed no levels of Claudin-2, in contrast to 
M DCK type II, which seems to have high levels of this Claudin isoform  (Lipschutz 
et al., 2005). In addition to this EGF, aside from increasing the transepithelial 
resistance in M DCK type II, induces cellular rem odelling and enhances the 
expression levels of Claudin-1, -3 and -4 (Singh and Harris, 2004). All these results 
indicate the importance of ERK 1/2 in determ ining the paracellular perm eability in 
M DCK cells. Peter et al., studied the effect of EGF in the non-small cell cancer lung 
(NSCLC) cell line, their results showed that after treatment with EGF, levels of 
Claudin-2 expression is increased however, transepithelial resistance is reduced 
(Peter et al., 2009).
HGF decreases transepithelial resistance and increases paracellular 
perm eability in human endothelial cells HUVEC after treatment. The level of 
expression of Claudin-1 seems to be reduced overtime whereas no changes were 
observed in the levels of Claudin-5 (M artin et al., 2002). W hen breast cancer cells, 
M DA-M B-231 and M CF-7, were treated with HGF, the transepithelial resistance 
was once more reduced. Claudin-1 transcripts levels were reduced in M DA-M B-231 
cells through time, whereas changes in M CF-7 cells were less significant. W hen
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looking at Claudin-5, significant changes in expression were seen in both cell lines 
(Martin et al., 2004a).
Overall, it is clear that HGF and EG F modulate changes in expression of 
different Claudin family members and therefore altering the physiological function 
of TJs in different cell types including breast cancer cells.
1.5.5 Diseases involving Claudins
The effect of the disease progression on epithelial and endothelial barriers is 
alm ost always to make them leakier. In normal differentiated cells, a high degree of 
cellular organization is typically observed, but tumour cells exhibit abnorm al 
structure and behaviour. This reflects a change in the TJ itself, such that it either 
disappears entirely or its permeability increases significantly. Usually in disease 
situations, the TJ barriers do not become “tighter” .
It is increasingly apparent that changes in TJ functions are found in cancer 
developm ent, as thoroughly reviewed in section 1.4. But in addition to cancer disease, 
there are a growing number of diseases reported to involve changes in the TJ 
functions. These include autoimm une diseases, infections and allergies (Table 1.5). 
This section will focus on Claudins and their aberrant expressions in diseases other 
than cancer.
A number of Claudins have been implicated in m utations leading to human 
diseases. Much of the information provided by these studies is currently helping to 
elucidate the role of Claudins and their importance in the developm ent of severe 
diseases. For instance, mutation in Claudin-16 that introduces a prem ature stop
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codon resulting in cleavage of the C-terminal cytosolic tail leads to recessive renal 
hypom agnesemia causing failure of the kidney (M uller et al., 2006). Claudin-19 
presented a similar deficiency in regulating magnesium reabsorption as well as retina 
developm ent (Konrad et al., 2006). M utations provoking a prem ature stop codon in 
Claudin-1 caused severe chronic disease characterized by inflamm ation and fibrosis 
of the bile ducts named Neonatal Ichthyosis and Sclerosing Cholangitis Syndrome 
(NISCH), leading to liver failure (Hadj-Rabia et al., 2004). M oreover, these patients 
also suffer from dry ichthyotic skin and thicker stratum corneum, a sim ilar phenotype 
to Claudin-1 knockout mice in which anim als died after dehydration due to “ leaky” 
TJs (Zimmerli et al., 2008). Claudin-11 (Gow et al., 2004) and -14 (W ilcox et al., 
2001) m utations were associated with congenital deafness in mice and hum ans 
respectively, suggesting the role of these proteins in the cation-restrictive barrier that 
m aintains the normal ionic concentration in the ear. Velo-Cardio-Facial/ DiGeorge 
syndrom e (VCF), which is characterized by a broad range of phenotypes including 
conotruncal heart as well as facial dysmorphology, has been associated with 
m utations in chromosome 2 2 q l l ,  which maps to Claudin-5. It has been demonstrated 
that 80% of the patients displaying these syndrom es have a deletion in the region 
coding for Claudin-5 (Sirotkin et al., 1997).
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Diseases provoked by m utations Claudin type Reference
Hypom agnesem ia with hypercalciuria 
and nephrocalcinosis Claudin-16 (M uller et al., 2006)
Hypomagnesis and visual impairment Claudin-19 (Konrad et al., 2006)
Congenital deafness Claudin-11,-14 (Gow et al., 2004; W ilcox et al., 2001)
Neonatal Ichthyosis and Sclerosing 
Cholangitis Syndrome (NISCH) Claudin-1
(Hadj-Rabia et al., 2004; 
Zimmerli et al., 2008)
V elo-Cardio-Facial/ DiGeorge 
syndrom e (VCF) Claudin-5
(M orita et al., 1999a; Sirotkin et 
al., 1997)
Im m unity-related Disease Claudin type Reference
C rohn’s disease and ulcerative colitis C laudin-2,-5,-8 (Zeissig et al., 2007)
M ultiple Sclerosis C laudin-11 (Gow et al., 1999)
D erm atophagoides pteronyssinus Claudin-1 (Wan e ta l.,  1999)
H elicobacter pylori Claudin-4,-5 (Fedwick et al., 2005)
Clostridium perfringens Claudin-3,-4 (Fujita et al., 2000)
Rotavirus, HIV Claudin-1,-7 (Dickman et al., 2000; Zheng et 
al., 2005)
Table 1.5: Claudin proteins involved in genetic and imm une-related diseases.
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Claudin expression has also been seen to be altered in response to 
inflammation and to pathogens resulting in changes to paracellular perm eability. 
These changes in the TJ structure offer a perfect route for antigen penetration. Virus 
and pathogens have evolved numerous strategies to enter the cell cycle, however, 
before they can start to replicate and cause infection they firstly have to reach the 
apical surface of polarized epithelial cells. Recent studies have shown that 
Clostridium perfringens food poisoning, which is released into the intestinal lumen, 
binds directly to the second extracellular loop domain of Claudin-3 and -4 resulting 
in a inhibition of TJ reorganization as well as prom oting endocytosis (Fujita et al., 
2000). Infection causing by H elicobacter pylori in the stomach alters the gastric 
epithelial barrier by activating myosin light chain kinase reducing levels of 
expression of Claudin-4 and -5, therefore increasing the perm eability in the cell 
(Fedwick et al., 2005). Rotavirus infections were also responsible for altering 
paracellular permeability by decreasing transepithelial resistance and changing the 
localization of Claudin-1 in Caco-2 cell line (Dickman et al., 2000). Claudin-7 has 
been involved with Human inmm unodeficiency virus (HIV). CD4 is a prim ary 
receptor used by HIV to penetrate the epithelium. Zheng .et al., have revealed that 
Claudin-7 enhances the viral susceptibility of CD4(-), suggesting that HIV can 
penetrate across the epithelial barrier through a direct interaction with TJ proteins 
(Zheng et al., 2005)
Allergens like D erm atophagoides pteronyssinus can cause disruption in the 
TJ structure by increasing paracellular perm eability allowing the pathogen to cross 
the epithelial barrier and by cleaving the extracellular domains of Claudin-1 (Wan et 
al., 1999). Multiple sclerosis, an inflamm atory demyelinizing disorder o f the central
nervous system (CNS), has been linked to C laudin-11. C laudin-11 is presented in the 
CNS as well as in the testis and plays a pivotal role in the paracellular barrier of both 
as implied through the neurological and reproductive failures seen in C laudin-11 
knockdown mice (Gow et al., 1999). Another example of Claudin m isregulation has 
been seen in Crohn’s disease and ulcerative colitis, which provokes not only gastric 
problem s but inflammatory too. The TJ structure is altered as Claudin-5 and -8 were 
down-regulated as well as the pores formed by Claudin-2 which in this case was 
highly up-regulated (Zeissig et al., 2007).
1.5.6 C laudins as emerging targets for cancer
Due to the high specificity of expression patterns of Claudins in cancer, the 
possibility of Claudins being utilised as useful molecular markers has been raised. 
Regardless of their exact functions in cancer cells, Claudin protein expression may 
have a significant clinical relevance. Research in the past has been focused on the 
expression of members of the Claudin family in a number of cancer types as 
described in section 1.4. Studies have revealed how some of the Claudins were up- 
regulated in cancer progression while others were down-regulated. This data opens 
up the possibility of the potential value of Claudins as targets for therapeutic 
intervention. A number of key points have arisen from various studies into targeting 
Claudins for cancer therapy.
1. Claudins are cell surface proteins that contain two extracellular dom ains
which are accessible as target sites for therapy.
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2. Claudin members have been found to be over-expressed in a num ber of 
different cancers showing different expression patterns between normal and 
tumour cells.
3. Claudins could be more accessible in tumour cells due to an increase in TJ 
permeability compared with normal cells (Soler et al., 1999) even if Claudins 
are not over-expressed in that tumour type.
As previously stated, Claudins, are transmem brane proteins with two 
relatively large extracellular loops, and present them selves as prom ising targets for 
antibody therapy. This therapy is based on antibodies against Claudins that will 
specifically recognize one of these loops and therefore induce leaky TJ or even 
destroy them (Tsukita et al., 2008); or antibodies that will simply, after specific 
binding to the C-terminal domain of the Claudins, provide evidence for the antibody- 
based therapy approach (Kominsky, 2006).
Cell tumour lysis can be achieved by attachm ent of toxins to the cell surface, 
or by stim ulating a response from the immune system. The second extracellular loop 
of some Claudins have appeared to be a receptor for the Clostridium perfringens  
enterotoxin (CPE), usually associated with Clostridium perfringens type A, which is 
known for causing cytolisis in mammalian cells due to its effects on m em brane 
perm eability. This binding allows the formation of a large m ultiprotein m em brane- 
pore complex, which alters the osmotic equilibrium in the cell causing lysis.
Although several Claudins have shown binding affinity to CPE like Claudin-4, -6, -7, 
-3, -14, -8 (Fujita et al., 2000) only Claudin-3 and -4 have been seen to form this 
complex. Taking these results in consideration, and based on the evidences from 
different studies that revealed over expression of these two Claudins m em bers in
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breast, pancreatic, colon, lung as well as ovarian cancers (see table 1.3), Claudin-3 
and -4 might be perfect candidates for CPE-based therapy. More recently Kom insky 
et al., performed similar experiments treating several breast cancer cell lines 
expressing Claudin-3 and -4, such as M CF-7, SKBr3 and T47D, as well as cell lines 
lacking both proteins, such as HS578T and M DA-M B-435, with CPE. Results 
revealed that breast cancer cell lines lacking these particular Claudin proteins were 
totally resistant to the cytotoxic effects caused by the enterotoxin but not the 
Claudin-expressing cells, resulting in complete cytolysis. To com plem ent the in vitro 
study, they investigated the cytolytic effects of CPE on the T47D breast cancer cell 
line in vivo, resulting in a significant reduction in tumour volume as well as cell 
necrosis (Kom insky et al., 2004). Recent studies have used Pseudom onas  
aeruginosa  exotoxin as a method of cancer-targeting therapy. The exotoxin binds to 
the cell surface, enters the cytosol by endocytosis, releasing PSIF which inhibits 
protein synthesis. Saeki et al., have reported that the artificial complex C-CPE- PSIF 
interacts with Claudin-4 through C-CPE binding domain and shows in vivo anti­
tumour activity against the 4T1 breast cancer cell line, causing a significant reduction 
in tumour growth (Saeki et al., 2009). Similar results were obtained when studying 
metastasis in the lung using the Claudin-4 expressing cell line B16, where the 
treatm ent with the complex C-CPE- PSIF revealed reduction in tumour growth and 
metastasis without any side effects in the mice (Saeki et al., 2010). A  related study 
by Kakutani et al., reported the fusion between C-CPE and the diphtheria  toxin A 
(DTA) which also inhibits proteins synthesis in gastrointestinal L cells expressing 
different Claudin proteins. Results revealed specificity from the DTA-C-CPE 
complex to Claudin-4 expressing cells (Kakutani et al., 2010).
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Therefore, exhaustive administration of the enterotoxin CPE to cancer cells 
might be a potential approach for cancer therapy. The key question to be addressed in 
the near future is how to avoid cellular toxicity in the surrounding normal cells 
caused by the administration of CPE, or whether there are other toxin displaying 
affinity to different Claudin proteins in the cell.
Claudins are indeed unusual proteins in the TJs structure as they are 
presented in a variety of tissues with different properties. Their m ixture and different 
ratios between the 24 members confers specific barrier properties to each cell. These 
special features make the modulation of Claudins a prom ising method to deliver and 
enhance absorption of drugs to a target tissue through the paracellular pathway as 60% 
of these targets are located at the cell surface (Kondoh and Yagi, 2007).
Overall these findings indicate that further study and preclinical testing are 
required to assess the usefulness of Claudins as emerging targets for cancer.
1.6 Claudin-5
Claudin-5 was firstly described by M orita and colleagues in 1999 (M orita et al., 
1999a). It was initially identified as a deleted protein in patients who suffer from the 
velo-cardio-facial syndrome hereditary disease and was termed TM V CF 
(transm embrane protein deleted in velo-cardio-facial syndrome) and the gene was 
mapped to chromosome 2 2 q l l  (Sirotkin et al., 1997). A different group described, in 
the same year as M orita, the expression of Claudin-5 in brain capillary endothelial 
cells and originally termed this protein MBEC1 (mouse brain endothelial cell 1)
(Chen et al., 1998). In both studies the concentration of TM VCF/ MBEC1 were not
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examined. Claudin-5, TM VCF and MBEC1 have been identified as the same protein 
(Morita et al., 1999c). M orita et al., subsequently developed a specific antibody 
against Claudin-5 revealing a high level of expression in the brain, lung and 
endothelial cells of the blood vessels concluding that Claudin-5 was an endothelial- 
specific component of the TJ strand (Morita et al., 1999c). However, several studies 
have reported Claudin-5 to be expressed in certain epithelial TJs, such as, the 
stomach, rat liver and pancreas (Rahner et al., 2001) as well as in cell lines like HT- 
29/B6, an epithelial cell derived from human colon (Amasheh et al., 2005). 
Surprisingly, when looking at the level o f expression of Claudin-5 in the human 
colonic cell Caco-2, Claudin-5 was not present although it is present in the human 
intestine. Sim ilar results were seen in M DCK-C7 (presenting “tight” TJ) and 
MDCK-C1 (presenting “ leaky” TJ). To com plem ent the study, they m easured the 
transepithelial resistance in Caco-2 and M DCK-C7 following transfection with 
FLAG-Claudin-5 cDNA. The results revealed an obvious increase in resistance of 
Caco-2 transfected cells, but no differences were seen in M DCK-C7. These results 
suggested a role for Claudin-5 as a “ sealing” protein in the TJs of epithelial cells as 
the over-expression caused changes in the paracellular barrier of this particular cell 
line (Caco-2) making it tighten, whereas in cells that exhibit high transepithelial 
resistance (M DCK-C7) no changes to the barrier properties were observed (Amasheh 
et al., 2005). Studies focusing on blood-brain barrier (BBB) also have proposed a 
“sealing” role for Claudin-5 (W olburg et al., 2003) (Nitta et al., 2003). BBB protects 
the brain from the blood surroundings within the central nervous system (CNS), and 
most importantly m aintains hom eostasis of the brain environment, which is crucial 
for neural activity and function. Extrem ely close TJs between endothelial cells of
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brain capillaries prevent the passage of hydrophilic molecules from blood to brain 
and vice versa. Mice genetically altered to lack Claudin-5 were generated in a study 
by Nitta et al. These mice have shown a normal developm ent and m orphology of 
blood vessels in the brain, however, in terms of the barrier function, these endothelial 
cells showed an unexpected feature: a size-selective loosening of the BBB, in other 
words, only small molecules (<800Da) were allowed to pass across the TJ but no 
larger molecules were affected. M oreover, Claudin-5 deficient mice die within 10 
hours of birth (Nitta et al., 2003). Therefore, it appears that loss o f Claudin-5 from 
the TJ com plexes in the brain can comprom ise barrier function m aking it “ leakier” 
while keeping their structural integrity, dem onstrating that Claudin-5 specifically 
tightens the BBB for molecules <800Da. The majority of the drugs in clinical use are 
included in this range, subsequently Claudin-5 might be interesting in term s o f drug 
delivery to brain tumours or neurodegenerative disease.
Not much is known regarding the transcriptional regulation of Claudin-5. In 
porcine blood-brain barrier endothelial cells, cyclic AM P (cAM P) increases Claudin- 
5 gene expression in a protein kinase A (PKA) independent and dependant way.
PKA activation by cAM P enhances the signal of Claudin-5 along cell borders and in 
the cytoplasm  as well as increasing the TER in dependent and independent pathways. 
It was also reported that the amino acid site Thr2(,7in the cytoplasm atic COOH- 
terminal domain is the phosphorylation site for PKA (Ishizaki et al., 2003). A 
parallel study in the rat lung endothelial cell line (RLE) which displays failed TJs, 
revealed that when mutations in the Thr207 of Claudin-5 were introduced, the barrier 
function was altered while in the forced expression of Claudin-5 the TJ structure was 
partially formed allowing only the passage of the small molecules. These results
highlight how the phosphorylation of Thr207 site by PKA provokes changes in the 
Transendothelial resistance of the cells as well as loosening o f the Claudin-5 barrier 
against small molecules (Soma et al., 2004). Studies examining the effect of Ethanol 
(EtOH) in the BBB have revealed that the perm eability of the BBB is altered via 
structural alterations of the TJ (Jonsson and Palmblad, 2001). W hen bovine brain 
m icrovascular endothelial cells (BBM EC) were treated with EtOH, a decrease in the 
transepithelial resistance was observed. Claudin-5 staining was decreased and 
phosphorylation of myosin light chain (M LC) as well as Claudin-5 and occludin 
were confirmed. This suggests that EtOH activates myosin light chain kinase 
(M LCK) leading to Claudin-5 phosphorylation. These results reported a different 
phosphorylation pathway from the one suggested by Ishizaki et al., (Haorah et al., 
2005). A more recent study in brain endothelial cells bEnd3 has shown another 
possible Claudin-5 kinase. Yamamoto et al., using a recombinant o f Claudin-5 and 
Occludin, have reported that Rho kinase (RhoK) directly phosphorylates site Thr207 
on Claudin- 5. As a result, reduced Transepithelial resistance was observed 
(Yamam oto et al., 2008). As m entioned in section 1.5.2, HG F regulates the level of 
expression of Claudin-5 in breast cancer cells M DA-M B-231 and M CF-7 (M artin et 
al., 2004a).
It has been reported that endothelial vascular protein VE-cadherin expression 
and aggregation at the TJ appears to be a requirem ent for the transcriptional up- 
regulation of Claudin-5. Taddei et al., have proposed a pathway in the absence of 
VE-cadherin through which the inactivation of the complex formed by the forkhead 
box transcription factor FoxO l and p-catenin results in down-regulation of Claudin-5 
gene. However, when VE-cadherin is expressed in the cell FoxO l becomes
phosporylated whereas p-catenin is sequestered at the plasma membrane. 
Nevertheless, it is important to notice that the lack of VE-cadherin and therefore of 
Claudin-5 expression did not alter the structure of the TJ although the paracellular 
permeability was significantly decreased (Taddei et al., 2008). The description of the 
murine Claudin-5 promoter region has already been reported. The m urine Claudin-5 
gene is mapped on chromosome 16 and the complete nucleotide sequence o f the 
promoter was found to be 1131bp. The promoter constructs were transfected into the 
murine brain cEND and m icrovascular M yEND endothelial cells. The study 
examined the influence o f the inflammatory cytokine TN Fa and the synthetic 
glucocorticoid dexamethasone on Claudin-5 prom oter activity and in Claudin-5 
mRNA levels. Treatment with TN Fa resulted in a decrease in the prom oter activity 
as well as strong down-regulation of Claudin-5 m RNA levels in both cells. 
Conversely, treatment with dexamethasone revealed an increase in the prom oter 
activity and therefore in Claudin-5 m RNA levels. This effect was more noticeable in 
cEND cells, suggesting a tissue-specific regulation of Claudin-5 via glucocorticoids 
(Burek and Forster, 2009). A recent study on HUVEC, human umbilical vein 
endothelial cells, revealed that the human Claudin-5 gene is regulated by the sex 
determ ining region Y-box SOX18, a specific-regulatory factor in endothelial cells. 
Over-expression of SOX18 induced an increase in Claudin-5 expression at m RNA 
and protein level in confluent culture cells of HUVEC whereas the effect on single 
isolated cells was not evident. Silencing SOX18 resulted in a significant decrease of 
Claudin-5 mRNA and protein levels whereas in other proteins of the TJ such as 
Occludin levels remain unaltered. These results indicate that SOX18 is specifically 
involved in the regulation of Claudin-5 and is dependent on cell density (Fontijn et
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al., 2008). A recent study in vitro and in vivo has described Claudin-5 as a novel 
oestrogen target in vascular endothelium. Treatment of murine brain and heart 
endothelial cells, cEND and M yEND respectively, with 17p-Estradiol (E2) has 
revealed an increase in transepithelial resistance and up-regulation of Claudin-5 
levels. Similar results were obtained in vivo after E2 treatment. However, in ER(3 
knockout mice significantly lower levels of Claudin-5 were detected. Thus, this data 
suggested Claudin-5 as a new oestrogen target in vascular endothelium  (Burek et al., 
2010).
Martin et al., studied the effect of selenium (Se), gamm a linolenic acid (GLA) 
and iodate (I) in HECV, human umbilical vein endothelial cells. Se, GLA and I in 
combination or individually can induce changes in the TJ enhancing the 
transepithelial resistance via regulation of Claudin-5 as well as Occludin and ZO-1. 
Claudin-5 showed an increase in staining intensity after treatment. This effect was 
more evident when I was present, in particular when combined with Se after 0.5h of 
treatment. These three agents were able to reverse the effect of the horm one 17-J3 
estradiol on this cell line (Martin et al., 2006).
Claudin-5 has been linked to the follicular developm ent in the m arm oset 
ovary. The study in vivo on this primate has revealed that vascular endothelial 
growth factor (VEGF) inhibition might induce changes in expression o f Claudin-5 
thus comprom ising the follicular developm ent as a result of alterations in the TJ 
structure (Rodewald et al., 2007). Subsequently an in vitro study using a co-culture 
of human umbilical vein endothelial cells (HUVEC) and luteinized granulosa cells 
(LGC) has examined the paracrine effect of human chorionic gonadotrophin (hCG),
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and its relation with ovarian hyper stimulation syndrome (OHSS), a disease 
characterized by increased capillary permeability. Results, after treatm ent with hCG, 
have revealed down-regulation of Claudin-5 protein expression, an increase in 
endothelial permeability as well as an increase in VEGF concentration. However, 
when cells were treated with VEGF inhibitor, down-regulation of Claudin-5 and 
changes in permeability were not seen. These results suggested that hCG does not 
directly regulate Claudin-5. Instead hCG might be involved in the regulation of 
VEGF which appears to be responsible for the reduction in Claudin-5 expression and 
subsequent changes in cell permeability (Rodewald et al., 2009).
Studies of fluorescent tagged Claudin-5 in the HEK-239 cells (human 
embryonal kidney cell line 239) and the M DCK cell line have shown that Claudin-5 
is able to form homodimers in the plasma m embrane of the same cell, m oreover it 
was demonstrated that the second extracellular loop is responsible for the self­
association (Blasig et al., 2006). A subsequent study, using fluorescence resonance 
energy transfer (FRET) and electron m icroscopy, demonstrated that hom ophilic cis- 
interaction occurs for Claudin-5 and -5 (Piontek et al., 2008).
1.6.1 Role o f Claudin-5 in breast cancer progression
Currently, within the literature there are a limited num ber o f studies 
exam ining Claudin-5 in human cancer, with very few focusing on breast cancer.
Increased Claudin-5 expression has been associated with aggressive 
behaviour in serous ovarian carcinomas. Turune et al., studied 85 serous ovarian 
cancer tissue samples. Imm unostaining results revealed strong Claudin-5 staining in
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advanced stage and high grade carcinomas. W hen looking at Claudin-5 expression, 
only 25-30% of patients who were Claudin-5 positive were still alive at 5 years 
follow-up compared to 60% of patients who were Claudin-5 negative (Turunen et al., 
2009). Examination of Claudin-5, as well as Claudin-1,-3 and -4, in 118 cases of 
gastric carcinoma revealed that the lowest expression of all these Claudin members 
was in Claudin-5. Nevertheless, strong Claudin-5 expression was associated with 
levels of E-cadherin, high levels of cell proliferation and apoptosis. The results also 
revealed that expression of these Claudin members was lower in diffuse-type gastric 
carcinoma (Soini et al., 2006). A similar study in human lung squam ous cell 
carcinoma and adenocarcinom a has reported high levels of Claudin-5 in cylindric 
cells, pneumocytes and adenocarcinamas, and low or even undetectable levels of 
expression in basal cells and squamous cell carcinoma. These results indicate the 
possible role of Claudin-5 as a diagnostic tool to distinguish between 
adenocarcinom as and squamous cell carcinom as in lung cancer patients (Paschoud et 
al., 2007). Examination of Claudin-5 in 48 prostate cancer patients has reported that 
35% of patients showed low expression of Claudin-5 in comparison with 65% that 
displayed a high level of expression. From those who were classified in the low- 
expression group, 88% had a Gleason score of 7 or even higher and 12% had a 
Gleason score of 6 points or lower, whereas those classified in the high-expression 
group 52% had a Gleason score of 7 or higher and 48% had a Gleason score of 6 
points or lower. Therefore it can be concluded that Claudin-5 is associated with a 
Gleason score of 7 points or higher in prostate cancer patients (Seo et al., 2010). In 
hepatocellular carcinoma, Claudin-5 has been reported to be down-regulated. Low 
levels of Claudin-5 and vasculobiliary invasion have been correlated with patients
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displaying poor prognosis. Taking these results together, a possible role for Claudin- 
5 as a prognostic factor in hepatocellular carcinoma has been suggested (Sakaguchi 
et al., 2008).
1.7 Aim s of this study
The Claudin family are TJ proteins expressed in endothelial and epithelial cells. 
As already stated, they participate in the formation of tissue barriers between 
different tissue compartm ents by regulating the efflux of m olecules through TJ 
complexes. At least 24 different Claudin members are known today, all of which are 
thought to vary in expression depending on location and cell type.
The role of Claudin proteins in carcinogenesis and progression to metastasis 
is an active area of investigation as a result of the frequent finding of altered Claudin 
expression in cancer. To date, the majority of studies on cancer have focused on 
Claudin-1, -3, -4, -7 , -10 and -16, but very little is known about Claudin-5.
Therefore the aims of this thesis were to investigate the role of Claudin-5 in breast 
cancer by:
1. Determining the level of expression and distribution of Claudin-5 in 
human breast cancer and normal background tissues, using 
imm unohistochem ical staining and RT Q-PCR and analysing the levels of 
transcripts against clinical param eters such as grade of tumour, metastasis 
and clinical outcome of patients in order to investigate a possible link
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between expression levels of Claudin-5 and aggressiveness in cells and 
patient outcome.
2. Investigating the in vitro effects of knockdown and forced expression of 
Claudin-5, in the M DA-M B-231 breast cancer cell line and in HECV 
human endothelial cells, on the growth, invasion, migration, adhesion, 
motility, tubule formation, transepithelial/transendothelial electrical 
resistance (TER) and electrical cell-substrate impedance sensing (ECIS).
3. Investigating in vivo the effects of over expression of Claudin-5 in growth 
of the human breast cancer cell line M DA-M B-231 and HECV cells.
4. Assessing the role of Claudin-5 on control of epithelial and endothelial 
motility involving the N-W ASP and ROCK signalling cascade. This is a 
new avenue of research in determ ining the functions o f Claudin-5 which 
in past studies is named as a “sealing” protein o f TJ structure.
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Chapter 2 
General Materials and Methods
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2.1 Standard solutions
2.1.1 Solutions for cell culture
All standard chemicals and reagents used in my work, unless otherwise 
specified, were obtained from Sigma (Dorset, UK).
0.05M ED TA
One gram of KC1 (Fisons Scientific Equipment, Loughborough, U K ), 5.72g 
of Na2H P0 4 , lg  of K H 2 PO 4 , 40g of NaCl and 1.4g EDTA (Duchefa Biochemie, 
Haarlem, The Netherlands) was dissolved in distilled water to make a final volume 
of 5L. We adjust the solution to pH 7.4 before it was autoclaved and stored for use.
Trypsin (25mg/ml)
Five hundred milligrams of trypsin was dissolved in 20ml 0.05M  EDTA. The 
solution was mixed and filtered through a 0.2 pm minisart filter (Sartorious, Epson, 
UK), aliquoted in 250 pi samples and stored at -20°C until required. For use in 
routine cell culture one aliquot was diluted in a further 10ml of ED TA  solution and 
used for cell detachment.
Penicillin (120mg/ml)
Six hundred milligrams crystapen injection benzylpenicillin sodium 
(Britannia Pharmaceuticals Limited, Surrey, UK) was dissolved into 5ml sterile 
injection waster (B.Braun, Germany).
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Streptomycin Sulphate (250mg/ml)
Five grams of streptomycin sulphate was dissolved in 20ml sterile injection 
water, filtered thrugh a 0.2 pm minisart filter and stored at -20°C until required.
Balanced Saline Solution (BSS)
Seventy nine and a half grams of NaCl, 2.2g of KC1, 2.1g o f K H 2 P O 4 and 1.1 
g of Na2H P0 4  was dissolved in distilled water to make a final volum e of 10L. We 
adjusted the solution to pH 7.2 before used.
2.1.2 Solutions for m icrobiological m ethods
Luria Bertani (LB) agar
Ten grams of tryptone (Duchefa Biochemie, Haarlem, The Netherlands), 5g 
of yeast extract (Duchefa Biochemie, Haarlem, The Netherlands), lOg of NaCl and 
15g of agar was dissolved in distilled water up to a final volume of 1L, the pH 
adjusted to 7.0 and the solution was autoclaved. When required the solution was 
heated to liquid and cooled slightly before adding selective antibiotics (if required). 
The solution was then poured into 10cm2 petri dish plates (Bibby Sterilin Ltd., Staffs, 
UK), allowed to cool and harden, inverted and stored at 4°C.
LB broth
Ten grams of tryptone, 5g of yeast extract and 10 g NaCl was dissolved in 
distilled water up to a final volume of 1L and the pH adjusted to 7.0. It was 
autoclaved and allowed to cool before adding selective antibiotic (if required) and 
storing at room temperature.
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2.1.3 Solutions for use in RNA and DNA m olecular biology
DEPC treated water
Two hundred and fifty m icrolitres diethyl pyroncarbonate (DEPC) was added 
to 4750jul o f distilled water. The solution was then autoclaved before use.
5X  Tris, Boric acid, EDTA buffer (TBE)
A 5x stock solution comprising 545 g of Tris-Cl (M elford Laboratories Ltd., 
Suffolk, UK), 275g of Boric acid (M elford Laboratories Ltd., Suffolk, UK) and 
46.5g of disodium EDTA (Duxhefa Biochemie, Haarlem, The Netherlands) were 
dissolved in distilled water and made up to a final volume of 10L. The solution was 
stored at room temperature and diluted to IX  concentrate prior to use in agarose gel 
electrophoresis.
Ethidum bromide
Ethidum bromide powder (lOOmg) was dissolved in 10ml of distilled water. 
The container was wrapped in alum inium  foil to protect the solution from the light 
and stored safely before use.
2.1.4 Solutions for protein work
Lysis Buffer
Two millimolar C aC L , 0.5% of Triton X-100, lm g/m l leupeptin, lm g/m l 
aprotinin and 10 mM sodium orthovanadate was dissolved in distilled water and 
stored at 4°C until it was required.
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10% Ammonium Persulfate (APS)
One gram of ammonium persulfate was dissolved in 10ml of distilled water, 
and separated into 2.5ml aliquots and stored at 4°C until it was required.
10X Running buffer
A 10X stock solution (0.25M  Tris, 1.92M glycine, 1%SDS, pH 8.3) was 
made by dissolving 303 g of Tris, 1.44Kg of glycine and lOOg of SDS in 10L 
distilled water.
Transfer buffer
A  5 litre stock solution comprising 72g glycine, 15.15 g Tris and 1L 
Methanol (Fisher Scientific, Leicestershire, UK) were dissolved in distilled water up 
to the a final volume of 5L.
I OX TBS
A lOx TBS stock solution comprising 121g Tris and 400.3g NaCl were 
dissolved in distilled water, made up to a final volume of 5L and adjusted to pH 7.4.
Ponceau S staining
As supplied (Sigma, Dorset, UK).
Am ido black stain
Two and a half grams of amido black (Edward Gurr Ltd., London, UK) was 
dissolved in 50ml of Acetic acid (Fisher Scientific, Leicestershire, UK). 325 ml of 
distilled water was added and the solution was mixed.
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Am ido black destain
A hundred millilitres of Acetic acid and 250ml of ethanol were added to 
650ml of distilled water.
2.1.5 Solutions for cell and tissue staining
DAB chromogen
The DAB (Diaminobenzidine) chromagen was prepared fresh by m ixing the 
following reagents in order: 2 drops of wash buffer, 4 drops of DAB (Vector 
Laboratories Inc., Burlingame, USA) and 2 drops of H2O2 up to 5ml o f distilled 
water. The container was wrapped in aluminium foil to protect the solution from the 
light.
ABC  complex
The ABC complex was prepared using a kit (Vector Laboratories Inc., 
Burlingame, USA) by mixing the following reagents in order: 4 drops of reagent A 
were added to 20ml of wash buffer, followed by the addition of 4 drops of reagent B 
and mixed well. This was made up at least 30 m inutes before being used.
2.2 Anim als, cell lines and cell culture
All cell culture work was carried out in class II m icroflow cabinets. Pipettes, 
culture medium, and all other cell culture equipm ent was either purchased sterile or 
autoclaved prior to use. All cells were cultured in an incubator at 37°C in 5% carbon 
dioxide.
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2.2.1 Cell lines, breast tissue and animals
The human breast cancer cells line MDA-MB-231 and the human endothelial 
cell line, HECV (ICLC Genova, Italy) were used in this study. The cells were 
routinely maintained in Dulbecco's Modified Eagle's medium supplem ented with 10 % 
foetal calf serum (FCS), penicillin, and streptomycin (Sigm a-Aldrich TD). Full 
details of four cell lines are provided in Table 2.1.
Claudin-5 expression was screened in a panel of other cell lines. Cell lines in 
this panel consisted of: M DA-M B-157, M DA-M B-463, BT-549, M CF-7, M DA-M B- 
436, ZR-751, M DA-M B-435S, BT-474, M DA-M B-231, BT-474KC, D U -145, PNT- 
19, PNT-2C2, PANC-1, M iaPaCa, Cor- L677, MCR5, RT-112, A-431, Ha- 
Cat ,HRT-18,HT-115, HECV and HUVEC.
All cell lines were obtained from ATCC, Rockville, M aryland, USA or 
ECACC, Salisbury, UK. The PNT1A and PNT2C2 cell lines were generous gifts 
from Professor Norman M aitland (University of York, England, UK).
A total of 133 breast samples were obtained from breast cancer patient (27 
background normal breast tissue and 106 breast cancer tissue), with the consent of 
the patients and ethical committee. These tissues were collected im m ediately after 
mastectomies, and snap-frozen in liquid nitrogen. The pathologist (ADJ) verified 
normal background and cancer specim ens, and it was confirmed that the background 
samples were free from tumour deposit.
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The 4-6 week old CD -I athymic nude mice used in the in vivo  tumour 
developm ent model were obtained from Charles Rivers Laboratories (Kent, England, 
UK) and maintained in filtertop cages under ethical conditions.
Cell line Organism Morpholo. Ethnicity Gender Age Source and Feature
MDA-
MB-231
Homo
sapiens epithelial Caucasian female
51 years 
adult
Organ: mammary gland; 
breast
Disease:
adenocarcinoma
Derived from 
metastatic site: pleural 
effusion
HECV Homo endothelial
Organ: umbilical vein
Tissue: vascular 
endothelium
sapiens Caucasian female newborn
Disease: normal
Table 2.1: Cell lines used in this study.
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2.2.2 Preparation o f growth medium
Cells were routinely cultured in D ulbecco’s M odified Eagle’s M edium 
(DMEM / Ham ’s F-12 with L-Glutamine (PAA Laboratories, Somerset, UK), 
supplemented with streptomycin (Streptomycin Sulphate salt, Sigma-Aldrich Co), 
penicillin (Benzylpenicillim, Britannia, Pharmaceutical, Ltd.) and 10% heat 
inactivated foetal calf serum (Invitrogen, Paisley, UK).
Transfected cell lines, containing the pEF6/ V5-His TOPO TA plasmid 
v e c to r , were cultured for 10 days in selection medium containing 5pg/ml o f  
Blasticidin S. and later were selection was completed were routinely cultured in a 
maintenance medium containing 0.5pg/ml o f  Blasticidin S.
2.2.3 M aintenance o f cells
HECV and MDA-MB-231 cell lines were cultured in an incubator (Sanyo 
M DA15AC ) and maintained in supplemented DM EM /Ham ’s F12 m edium  prepared 
as described above. Cells were grown to confluence in either 25 cm 3 or 75 cm 3 tissue 
cultured flasks loosely capped (Greiner Bio-One Ltd., Gloucestershire, UK) at 37°C 
in 5% carbon dioxide and 95% humidification. The flasks were left to reach 
confluency before commencement of experimental work.
All cell culture work was carried out following aseptic techniques inside a 
class II laminar flow cabinet and autoclaved instruments to keep conditions sterile.
2.2.4 Trypsinization of cells
Cell lines were grown until they reached approximately 80-90% confluence. 
Confluence was assessed by visually evaluating the coverage of cells over the
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surface of the tissue culture flask using a light microscope. The culture medium was 
removed and the cells briefly rinsed at room temperature with 1-2 ml of trypsin 
Ethylenediam inetetraacetic acid (Sigma-Aldrich, Gillingham, Dorset, UK), which 
contains trypsin 0.01% (v/w) and EDTA 0.05% (v/w) in BSS buffer, for several 
minutes. The detached cell suspension was transferred to a 20 ml universal container 
(Greiner Bio-One Ltd., Gloucestershire, UK) and centrifuge at 1600 rpm for 8 
m inutes to pellet the cells. The supernatant was aspirated and the pellet was 
resuspended in 5 ml of cell culture medium.
The cells were then re-cultured into new tissue culture flasks, counted for 
immediate experimental work or stored by freezing in liquid nitrogen.
2.2.5 Cell counting
Cells were counted in a haemocytom eter counting chamber using an inverted 
microscope (Reichert, Austria) at 10 xlO m agnification for further in vivo  and in 
vitro cellular functional assays. The dimensions of each 16 square area containing the 
cells to be counted, is 1mm x lm m x 0.2 mm which allowed the number o f cells per 
millilitre to be determined using the following equation:
Cell number/ml= (number of cells counted in 16 small squares -*■ 2) x (1 x 104)
2.2.6 Cell storage in liquid nitrogen
The cell lines were stored in liquid nitrogen after detachment from a large 75 
cm 3 and pelleted in a centrifuge as described in section 2.2.4. The freezing medium 
was prepared by supplem enting standard culture medium (as described above) with 
10% Dimethylsulphoxide (DM SO) (Sigma-Aldrich, Gillingham, Dorset, UK).
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Following resuspension, which was dependent on the number of samples to be frozen, 
lm l of cells were transferred into 1.8 ml cryospreservation tubes (Nunc, Fisher 
Scientific, Leicestershire, UK). Tubes were wrapped loosely in 3 layers of tissue 
paper and stored overnight at -80°C in a deep freezer before storage in liquid 
nitrogen tanks for long term storage.
2.2.7 Recovery o f cells from liquid nitrogen
Frozen cells were removed from liquid nitrogen and placed in a warm water 
bath at 37°C for 1-2 minutes to facilitate rapid thawing. After completely thawing the 
cell suspension was transferred to a universal container containing 10 ml of pre­
warmed medium and allowed to revive for 10 min before being centrifuged at 1600 
rpm for 8 minutes. The supernatant was aspirated, the pellet resuspended in 5ml of 
pre-warmed medium and placed into a fresh 25cm 3 tissue culture flask and incubated 
at 37°C, 95% humidification and 5% CO2. Following incubation, the flask was 
examined under a light microscope to ensure a sufficient number of healthy adherent 
cells.
2.3 G eneration o f mutant H ECV and M DA-M B-231
2.3.1 Production of forced expression sequences
We designed primers using the Brecon Designer programme (Palo Alto, 
California, USA) which were synthesised by Invitrogen (Invitrogen, Inc., Paisley,
UK) according to the mRNA sequence of Claudin-5, which is capable o f amplifying 
the whole coding sequence (Table 2.2). Briefly, Claudin-5 was found to be highly
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expressed in placenta tissue, subsequently cDNA from this tissue was used to 
generate the full length sequence of Claudin-5. These primers, together with placenta 
cDNA, were used in a PCR reaction following these parameters:
• Step 1: Initial denaturing period: 94 °C for 5 minutes.
• Step 2: Denaturing step: 94 °C for 15 seconds.
• Step 3: Annealing step: 55°C for 15 seconds, repeated over 36 cycles.
•  Step 4: Extension step: 72°C for 30 seconds.
• Step 5: Final extension period: 72 °C for 7 minutes.
High fidelity long and accurate PCR was performed using DuraScript ™ RT- 
PCR kit (Sigma-Aldrich, Gillingham, Dorset, UK). The resultant gene products 
were excised from the gel and extracted using GelElute™  Gel extraction kit (Sigma- 
Aldrich, Dorset, UK). To confirm presence and correct size before being inserted 
into the plasmid vector the extracted band was electrophoretically run on a 2% 
agarose gel following the TOPO TA cloning procedure, as described in section 2.3.3.
2.3.2 K nockdown of gene transcripts using ribozyme transgene sequences
Hammerhead ribozymes are small self-cleaving RNAs, first discovered in 
viroids and satellite RNAs of plant viruses (Forster and Symons, 1987) that catalyze 
a specific phospodiester bond isomerization reaction in the course of rolling-circle 
replication. They have a catalytically active m otif consisting of three base-paired 
helical stems (I, II, III) flanking a central core of 15 mostly invariant nucleotides 
(Haseloff and Gerlach, 1989). The conserved central bases are essential for the 
hammerhead ribozym e’s catalytic activity.
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The expression of Claudin-5 was targeted at mRNA level using Hammerhead 
ribozyme trangenes that specifically cleaved a GUC site (Table 2.3). The secondary 
mRNA structure of Claudin-5 was first generated by using Zuker’s RNA mFold 
software (Zuker, 2003) (Figure 2.1). A suitable GUC ribozyme target site was then 
selected from within the secondary structure of Claudin-5. This allowed the 
Hammerhead catalytic region of the ribozyme to interact and accurately cleave the 
specific GUC sequence within the target mRNA transcript (Figure 2.2).
Ribozymes were synthesised using a Touchdown PCR procedure following these 
parameters:
• Step 1: Initial denaturing period: 95 °C for 5 minutes.
• Step 2: Denaturing step: 94 °C for 15 seconds.
• Step 3: Various annealing step: 60°C for 30 seconds, 58°C for 30 seconds,
56°C for 30 seconds, 54°C for 30 seconds, 52°C for 30 seconds, 50°C for 30 
seconds and 48°C for 30 seconds.
• Step 4: Extension step: 72°C for 30 seconds.
• Step 5: Final extension period: 72 °C for 7 minutes.
The transgenes were electrophoretically run on a 2% agarose gel and cloned in a 
suitable vector which was followed by transformation and transfection.
Expression
product
Primer
name
Expression primer sequence (5’-3’)
Predicted 
size (bp)
Claudin-5
CL5expRl GACGTAGTTCTTCTTGTCGT 547
CL5ExpF2 ATGGGGTCCGCAGCGTTGGAGATCCT
p-aclin
BACTF ACTGAACCTGACCGTACA 580
BACTR GGACCTGACTGACTACCTCA
Orieniation
checking
T7F
T AAT ACG ACTC ACT AT AGG
Table 2.2: Primers for amplifying Claudin-5 coding sequence.
Ribozyme
target
Primer name Ribozyme sequence (5’ -  3’)
Claudin-5
CL5RiblF ACT AGT CCG C AGCGTT GG AG ATTT CGT CCT C ACGG ACT
CL5RiblR
CTGCAGACAGCACCAGGCCCAGCTGATGAGTCCGTGAG
GA
CL5Rib2F
CT GC AGC AGGT GGTCTGCGCCGTCACCTG ATG AGTCCG 
TGAGGA
CL5Rib2R ACTAGTGACCGCCTTCCTGGACCACAACATTTCGTCCTC
ACGGACT
Orientation
checking
T7F T AAT ACG ACT C ACT AT AGG
Table 2.3: Primers used for ribozyme synthesis.
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dG =  -306.11
Figure 2.1: The secondary structure o f  human Claudin-5 mRNA.
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Target mRNA
Helix III Helix I
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c u GA 
A
Hammerhead ribozyme G A G U
C — G 
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G— C 
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A G
G U
Helix II
3'
5'
Figure 2.2: Secondary structure of the Ham merhead ribozyme with bound substrate 
(arrow).
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2.3.3 TOPO cloning reaction
The pEF6/V5-His TOPO TA Expression system provides a highly efficient, 5 
minute, one-step cloning strategy ("TOPO Cloning") for the direct insertion of Taq 
polymerase-am plified PCR products into a plasmid vector for high-level expression 
in mammalian cells. No ligase, post-PCR procedures, or PCR prim ers containing 
specific sequences are required. Once cloned, analyzed, and transfected into a 
m am malian host cell line, the PCR product can be constitutively expressed.
The plasmid vector pEF6/ V5-His TOPO TA plasmid vector (Invitrogen, Inc., 
Paisley, UK) was used in the current study in accordance with the protocol provided 
(Figure 2.3).
The TOPO cloning reaction was set up in a pre-labelled PCR tubes for each 
ribozyme or expression sequence used:
• PCR product (ribozyme or expression sequence): 4pl
• Salt solution: lpl
• TOPO vector: lp l
The reaction was mixed gently and then left for 5 minutes at room temperature. 
Following ligation, the cloning reaction was transformed immediately into 
Escherichia coli for successful efficiency in the transformation.
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Determine strategy for PCR
Produce PCR product
*" TOPO* Cloning Reaction:
Mix together PCR product and pEF6 V5-His-TOPO*
Incubate 5 minutes 
at room temperature
C T  Transform into TOP 10 E. colt cells""
Select and e colonies
Prepare puri 
transfection into
tied plasmid for 
mammalian cells
Transfect mammalian cell line and 
assay for expression o f PCR product
Figure 2.3: Flow chart of pEF6/ V5-His TOPO TA plasmid vector cloning procedure.
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f iE 3T^
pEF6/V5-His
TOPO®
5840 bp
Figure 2.4: Schematic o f  pEF6/ V5-His TOPO TA plasmid vector plasmid (Figure 
duplicate from pEF6/V5-His TOPO TA Expression kit protocol)
94
I QUJd
2.3.4 Transform ation o f competent Escherichia coli
Five microlitres of the cloning reaction was transformed into the chemically 
competent Escherichia coli (OneShottm TOPIO E.Coli, Invitrogen Inc., Paisley, UK) 
and very gently mixed by stirring the m ixture using the pipette tip, avoiding any 
damage to the bacteria. This suspension was then placed on ice for 30 min, before 
being heat-shocked at 42°C for 30 seconds and immediately placed back on ice for 2 
min. Following this, 250pl o f pre-warmed SOC was added. The cells were incubated 
at 37°C for lhour and shaken horizontally in a universal container at 200 rpm on an 
orbital shaker (Bibby Stuart Scientific, UK). The resultant transformation mix was 
then spread onto two selective agar plates (containing 100 pg/ml ampicillim ) at two 
different volumes, lOOpl and 200pl, and allowed to grow overnight at 37°C in an 
incubator. The pEF6/ V5-His TOPO TA plasm id vector encodes two antibiotic 
resistance genes that allow cells containing the plasmid to grow under ampicillin and 
Blasticidin S (as shown in figure 2.4).
2.3.5 Selection and orientation analysis o f positive colonies
Any colonies which grew on the selective plates should contain the pEF6/ 
V5-His TOPO TA plasmid vector, otherwise cells without the plasm id vector will 
not survive in the presence of the antibiotics. Analysis of the colonies is required to 
determine which of the colonies grown on the plate contains the ribozym e or 
expression sequence and have been inserted into the plasmid in the correct 
orientation to allow successful amplification of the sequences.
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Screening involves PCR of 10 colonies randomly selected, using the forward 
primer specific to the plasmid (T7F), and the reverse primers to the ribozym e or 
expression sequence. Individual colonies were examined in order to test DNA 
presented by using a sterile pipette tip and touching the selective colony. Thus, it was 
placed into the PCR reaction mixture ready for specific amplification of the desired 
sequence. This will ensure that amplified products, at the expected size, are in the 
plasmid and inserted in the correct orientation. For each colony, two PCR reactions 
were carried out as follows (full prim er sequences are given in table 2.3):
• Ribozyme orientation reaction 1:
1 Oju.1 -  2X REDTaq ReadyM ix PCR Reaction mix
9jul -  PCR water
0.5pl -  T7F plasmid specific forward primer
0.5pl -  Ribozyme specific primer (C L 5R iblR )
• Ribozyme orientation reaction 2 :
IOjiI -  2X REDTaq ReadyM ix PCR Reaction mix
9pl -  PCR water
0.5pl -  T7F plasmid specific forward primer
O.Sjul -  Ribozyme specific prim er (CL5Rib2R)
Each reaction was subjected to the following conditions:
• Step 1: Initial denaturing period: 95 °C for 5 minutes.
• Step 2: Denaturing step: 94 °C for 30 seconds.
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• Step 3: Annealing step: 55°C for 30 seconds.
• Step 4: Extension step: 72°C for 30 seconds.
• Step 5: Final extension period: 72 °C for 7 minutes.
Steps 2, 3 and 4 were repeated over 40 cycles.
The mixture was run on a 2% agarose gel. Thus, colonies showing the full 
sequence of Claudin-5 and the correct orientation of the insert were taken off the 
plate and used to inoculate 10 ml of ampicilin selective LB broth in universal 
containers and were horizontally shaken at 225 rpm overnight
2.3.6 Plasm id extraction, purification and quantification
Plasmid extraction was carried out using Sigma GenElute Plasmid M iniPrep 
Kit (Sigm a-Aldrich, Dorset, UK), according to the provided protocol. Five millilitres 
of the LB broth previously inoculated with the correct colony and cultured overnight 
was centrifuged at 3000 rpm for 10 m inutes to obtain a pellet of bacteria. The 
supernatant was discarded and the bacterial pellet resuspended in 200 pi o f 
resuspension solution (containing RNAase A) and mixed through pipetting. To lyse 
the cells, 10 ml of cell lysis buffer was added and the solution was mixed gently 
inverting the container. Following 5 m inutes incubation at room tem perature, 350pl 
of the neutralisation solution was added and then centrifuged at 12.000 x g in a micro 
centrifuge. The cell lysate was filtered in a Mini Spin Column placed inside the 
collection tube allowing the plasmid to bind to the column and spun at 12000 x g for 
30 seconds. The flow-through was discarded. Seven hundred and fifty m icrolitres of 
wash solution containing ethanol is added to the column before spinning at 12000 x g
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for 30 seconds and the flow-through discarded. The column was again spun at 12000 
x g for 30 seconds to remove any rem aining flow- through before transferring the 
Mini Spin Column to a clean collection tube. Plasmid DNA was eluted through the 
addition o f lOOpI o f elution solution and the column was spun at 12000 x g for 1 
minute. The plasmid DNA was then run on a 0.8% gel to check both plasmid purity 
and size.
2.3.7 Transfection o f mammalian cells using electroporation
Following plasmid purification and quantification, 2 pi o f  the extracted 
plasmid was used to transform the HECV and M DA-M B-231 cell lines.
Confluent HECV and M DA-M B-231 wild type cell lines were detached from 
the tissue culture flasks using trypsine/EDTA, pelleted and resuspended as 
previously described. One millilitre of cells were added to an electroporation cuvette 
(Eurgenetech, Soutampton, UK) together with the purified plasmid. The cuvette was 
loaded into the electroporator (Easyject, Flowgene, Surrey, UK), and a pulse of 
electricity (450 V) supplied. This will produce small perforations in the cell wall 
integrity allowing passage of the plasm id DNA across the membranes to be 
integrated in the cells. The mixture was imm ediately transferred into 10 ml o f pre­
warmed medium and place in an incubator under the usual incubation conditions.
2.3.8 Establishm ent o f transform ed H um an Endothelial cell line HECV and the 
breast cancer cell line M DA-M B-231
The pEF6/ V5-His TOPO TA plasmid vector used in this study, encodes two 
antibiotic resistance genes: ampicillin and Blasticidin S.
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The ampicillin resistance gene allows initial selection of prokaryotic bacterial 
cells containing the plasmid. Blasticidin S antibiotic inhibits protein synthesis in both 
prokaryotes and eukaryotes and is used to specifically select for mammalian cells 
containing the pEF6/ V5-His TOPO TA plasmid vector .The combination o f both 
antibiotic resistance genes provides an accurate selection throughout the cloning 
process.
Following overnight incubation in supplemented DM EM  medium, cells were 
move to an initial 10 days of intense selection through a selection medium containing 
5pg/ml o f Blasticidin S to kill all the cells that did not incorporate the plasmids and 
only rem aining cells should all contain the plasmid. After this, cells were maintained 
in m aintenance medium containing 0.5pg/m l o f  Blasticidin S (all m edia were 
described in section 2.2).
All cells were routinely tested to appraise the efficacy and stability o f both 
the expression and the ribozyme transgene sequences using RT-PCR. Once the 
plasmid incorporation was assessed into the mammalian cell lines, the transfected 
cells were used in a series of in vitro studies to evaluate the forced expression and 
knockdown of the Claudin-5 gene.
2.4 M ethods for detecting m RNA
2.4.1 Total RNA isolation
RNA is susceptible to degradation by RNAases, therefore special care has to 
be taken to minimise this during its isolation.
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Cells were grown until reaching a confluent state (85-90% confluent), after 
the aspiration of culture medium 1ml of ABgene Total RNA Isolation Reagent 
(TRIR) kit (ABgene, Surrey, UK) was added to the cell monolayer. The resultant cell 
lysate was transferred through a pipette into a 1.8ml eppendorf tube (A laboratories, 
Hampshire, UK). The homogenate was stored for 5 minutes at 4 °C to allow complete 
dissociation of nucleoprotein complexes before adding 0.2ml of chloroform and 
energetically shaking the samples for 15 seconds, samples were centrifuged in a 
refrigerated centrifuge (Boeco, W olf laboratories, York, UK) at 12000g (4 °C) for 15 
minutes. The homogenate forms two phases: the organic (DNA and proteins) and 
aqueous phase (RNA). DNA and proteins are in the organic phase while RNA is in 
the aqueous. Carefully, the aqueous phase was removed and transferred to a pre­
labelled eppendorf tube containing an equal volume of isopropanol, the samples 
were then stored at 4°C  for 10 minutes before centrifuging at 12000g (4°C) for 10 
minutes. RNA precipitation then forms a white pellet at the bottom of the eppendorf. 
The supernatant was discarded and the RNA pellet was washed twice with 1ml of 75% 
ethanol prepared using DEPC water (DEPC water is a histidine specific alkylating 
agent that inhibits the action of RNases which depend on histidines active sites for 
their activity. It is used to reduce the effects of any RNases that might be present) by 
vortexing and subsequent centrifugation at 7500g (4 °C) for 5 minutes. At the end of 
the procedure, as much ethanol as possible was removed before briefly drying the 
pellet in a Hybridiser drying oven (W olf laboratories, York, UK) at 50 °C for 5-10 
minutes (it is important not to let the RNA pellet dry completely as it will decrease 
its solubility). Finally, the RNA pellet was dissolved in 50-1 OOjul o f DEPC water 
before quantification.
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2.4.2 RNA quantification
The concentration and purity of RNA was assessed by m easuring with a 
U V I101 Biotech Photometer (WPA, Cambridge, UK), that has been set to detect 
ssRNA (pg/ pi) in a 1:10 dilution in DEPC water at A260nm wavelength. All 
samples were measured in a Starna glass cuvette (Optiglass limited, Essex, UK).
The RNA samples were either stored at -80 °C for further use or used 
immediately for reverse transcription (RT).
2.4.3 Reverse transcription-polymerase chain reaction (RT-PCR) o f RNA
Following RNA isolation and quantification, RT-PCR was used to convert 
RNA into complementary DNA (cDNA) using DuraScript ™ RT-PCR kit (Sigma- 
Aldrich, Dorset, UK). According to the m anufacturer's instructions, which are 
sketched below, a 20pl reaction m ixture was added to an eppendorf:
• 0.5pg - total RNA template (volum e depends on the concentration)
• PCR water (volume= 8pl- volum e of the RNA template)
• 1 pi - deoxynucleotide mix (500M m o f  each dNTP)
• 1 pi - anchored oligo (dT) 23
The tube was then mixed gently and centrifuged before placing the mix in a T-Cy 
Thermocycler (Creacon Technologies Ltd., The Netherlands) and heating at 25 °C for 
5 minutes. This initial step helps to denature the secondary structure of the RNA 
allowing more effective reverse transcription. Tubes were then placed on ice before 
centrifuging and adding the following components to the samples:
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• 6pl - PCR water
• 2pl - 10X buffer for DuraScript ™  RT
• I jliI -  RNase inhibitor
• lp l -  DuraScript reverse transcriptase
The resultant total volume in each eppendorf was 20pl. The samples were mixed, 
centrifuged and placed back in the thermal cycler to be heated at 42 °C for 30 
minutes. The cDNA samples were diluted to 1:4 with PCR water and the success of 
the sample was confirmed using a conventional PCR probing for P-actin. The 
sam ples were stored at -20 °C until required.
2.4.4 Polym erase chain reaction (PCR)
PCR was carried out using REDTaq ReadyM ix PCR Reaction mix (Sigma- 
Aldrich, Dorset, UK). A 20 pi reaction was prepared for each sample as follows:
• lOpI - REDTaq ReadyM ix PCR Reaction mix
• lp l -  specific forward prim er
• lp l -  specific reverse prim er
• 5 p l -P C R  water
• 3 pi -cD N A
Primers were designed using the Brecon Designer program me (Palo Alto, 
California, USA) and were synthesised by Invitrogen (Paisley, UK). All primers 
were diluted to a concentration of lOpM before being use for the PCR. The PCR 
reaction was set up in a 200pl PCR tube (ABgene, Surrey, UK), m ixed and placed in 
a T-Cy therm ocycler (com pany info) under the following conditions:
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• Step 1: Initial denaturing period: 94 °C for 5 minutes.
• Step 2: Denaturing step: 94 °C for 30 seconds.
• Step 3: Annealing step: 55°C for 30 seconds.
• Step 4: Extension step: 72°C for 30 seconds.
• Step 5: Final extension period: 72 °C for 7 minutes.
Steps 2, 3 and 4 were repeated over 36 cycles.
PCR products were visualized on a 2% agarose gel through staining with 
ethidium  bromide after electrophoresis. In all cases a negative control where PCR 
water replaced cDNA was included in the reaction.
2.4.5 A garose gel DNA electrophoresis
The amplified DNA was separated according to size using 2% agarose gel 
electrophoresis.
Agarose gels were made by adding the required amount of agarose (Melford 
Chem icals, Suffolk, UK) to TBE solution. The m ixture was then heated to a fully 
dissolve the agarose, poured into the electrophoresis cassette and a plastic comb was 
then inserted into the gel creating loading wells. Once the gel w as set at room 
tem perature for about 30-40 m inutes, TBE running buffer was carefully poured into 
the electrophoresis tank. The PCR products were loaded into the wells, 8pl of a 1Kb 
ladder (Invitrogen, Paisley, UK) or lOp.1 of the sample. The samples were then 
electrophoretically separated using a power pack (Gibco BRL, Life Technologies 
Inc.) at a constant 95V for 30-50 m inutes to allow sufficient separation o f the 
samples.
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2.4.6 DNA staining and detection
The PCR products were stained using ethidum  bromide stain (lOmg/ml) 
diluted in TBE buffer used in the run for 10 m inutes on a rocking platform  to ensure 
an even staining of the agarose gel. The gel was visualised under ultra violet light 
using a UV illuminator (UVitech, Cam bridge, UK). If necessary, the gel can be 
returned to the stain for extra staining or to a container of distilled water to reduce 
the background staining.
2.4.7 Q uantitative RT-PCR (Q-RT-PCR)
Q-RT-PCR is capable of detecting m inuscule quantities o f cDNA within a 
sample. The Am plifluor system was used to detect and quantify transcript copy 
number o f Claudin-5 in tumour and background samples. The cD N A  was generated 
as described above. Sixteen microlitre reactions were prepared for each sample as 
follows:
• Forward Z prim er - 0.5 ( lpm o l/p l)
• Reverse primer - 0.5 (lO pm ol/pl)
• Q-PCR M aster Mix - 8 pi
• Probe Am piflour -  0.5 (1 Opmol/pl)
• PCR water -  2.5 pi
• cDNA - 4 pi
One of the prim ers used will have a Z-sequence 
(CA CCG AG TCG TACACTTTGC) at 1:10 of the other prim er and probe. The 
Am plifluor probe contains a region specific to the Z-sequence together with a hairpin
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structure labelled with a fluorescent tag (FA M -490). The fluorescent tag whilst being 
in the hairpin does not produce any signal, however, the specificity o f  the 3 ’ region 
of the Am plifluor probe to the Z-sequence causes the incorporation of the uniprimer 
(Table 2.4). As a result, following incorporations will cause the disruption of the 
hairpin structure and detectable signalling o f the fluorescent tag within this structure.
The intensity of fluorescence within each sample compared to a range of 
standards of known transcript copy num ber allows the calculation of transcript copy 
num ber within each sample (Figure 2.5). D etection o f GAPDH copy number within 
these sam ples was later used to allow further standardisation and normalisation of the 
samples.
Sample cDNA was amplified and quantified over a large num ber of shorter 
cycles using an iCycler10 thermal cycler and detection software (BioRad laboratories, 
Ham m elhem pstead, UK) (Figure 2.6) under the following conditions:
• Step 1: Initial denaturing period: 94 °C for 5 minutes.
•  Step 2: Denaturing step: 94 °C for 10 seconds.
•  Step 3: Annealing step: 55°C for 15 seconds.
• Step 4: Extension step: 72°C for 20 seconds.
Steps 2, 3 and 4 were repeated over 60 cycles.
The camera used in this system  is set to detect signal during the annealing 
stage. Specific Q-PCR prim ers were verified using a positive control known to 
express Claudin-5 and a negative control, where PCR water replaced cDNA, was 
included to exclude any contam ination in the reaction.
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Gene of 
interest
Primer name Primer sequence (5’-  3’)
Claudin-5
(Q-PCR)
CL5Zr2 A CTGAA CCTGA CCGTA C ACCG AGTCGT ACACTTTGC
CL5F2 TTCCTGGACCACAACATC
(3-act in 
(Q-PCR)
BACTINZR A CTGAA CCTGA CCGTA CGCTCGGTG AGG ATCTTCA
BACTINF1 GGACCTGACTGACTACCTCA
GAPDH
(Q-PCR)
GAPDHZR A CTGAA CCTGA CCGTA CAG AG ATGATGACCCTTTTG
GAPDHF1 CTGAGT ACGTCGTGGAGTC
Table 2.4: Primers used for Q-PCR.
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Figure 2.5: Q-PCR standard curve (on IQ5).
Figure 2.6: BioRad iCycler iQ5 Real Time PCR System.
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2.5 M ethods for detecting protein 
2.5.1 SDS-polyacrylam ide gel electrophoresis (SDS-PAGE) and W estern 
blotting
2.5.1.1 Cell lysis and protein extraction
Upon reaching adequate confluency (90%), the cell m onolayer was removed 
from the base of the cell culture flask using a disposable cell scraper. The detached 
cells and the medium were transferred to a universal container using a sterile transfer 
pipette and centrifuged for 5 minutes at 2000 rpm to pellet the cells at the bottom of 
the container. The supernatant was decanted and the pellet resuspended in 200- 
250pl o f  lysis buffer (see section 2.2.4), transferred to a 1.8ml eppendorf tube (A 
laboratories, Hampshire, UK) and placed on a Labinco rotating wheel for 1 hour 
(W olf Laboratories, York , UK) in order to extract protein from the cell lysate. The 
lysis solution was then centrifuged at 13000 rpm for 15 minutes in a microcentrifuge 
to remove cellular debris and collect the protein. The supernatant was transferred to a 
clean eppendorf tube to wait quantification prior to use in W estern blotting.
2.5.1.2 Protein quantification o f cell lysates
Determination of protein concentration of cell lysates was based on a protocol 
provided by the supplier Bio- Rad DC, from whom the protein assay kit was 
purchased (Bio-Rad laboratories, Ham m elhem pstead, UK). Firstly, a serial dilution 
of bovine serum albumin (BSA) standard samples with known concentration of 
lOmg/ml (Sigma, Dorset, UK) were prepared in the same cell lysis buffer to give a 
working concentration range between lOmg/ml to 0.005mg/ml. Five m icrolitre of
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either the sample or standard was pipetted into a 96 well plate before adding 25pl o f 
‘working reagent A ’ followed by 200pl o f  reagent B. ‘Working reagent A ’ was 
prepared by mixing each millilitre o f  reagent A with 20pl o f  reagent S. (final volume 
depends on the number of samples to quantify) (If the samples do not contain 
detergent this step can be skipped and reagent A is used as supplied). The mixture 
was left for 45 minutes allowing the colorim etric reaction to set. Absorbance of both 
samples and standards was read at 620nm using an ELx800 plate reading 
spectrophotom eter (Bio-Tek, W olf laboratories, York, UK). A standard protein curve 
was constructed for the bovine serum albumin standards and used to establish sample 
concentration. All protein concentrations were adjusted to the desired working 
concentrations of between 1 -  2mg/ml by diluting in cell lysis buffer followed by 
further dilutions in a l:l(v /v ) with 2X Lamelli sample buffer concentrate (Sigma- 
Aldrich, Dorset, UK). Samples were then boiled at 100°C for 5 m inutes allowing 
denaturation of the samples before being stored at -20°C until required.
2.5.1.3 Preparation for im m unoprecipitates
Cell lysate of the protein of interest was probed with Claudin-5 antibody 
(1:100 dilution) and placed on a Labinco rotating wheel for 2 hour (W olf 
Laboratories, York, UK) allowing Claudin-5 antibody to bind to their targets. One 
hundred microlitres of conjugated A/G protein agarose beads (Santa-Cruz 
Biotechnologies Inc., CA, USA) were added to each sample to make the antibody- 
protein complex insoluble, followed by overnight incubation on the rotation wheel. 
The supernatant was discarded and the pellet was washed in 200pl o f  lysis buffer and 
resuspended in 200jnl o f2 X  Lamelli sample buffer concentrate (Sigm a-A ldrich,
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Dorset, UK), then denatured for 5 m inutes by boiling at 100 °C. Samples were then 
stored at -20 °C prior to use.
2.5.1.4 Loading samples
SDS-PAGE was undertaken using an Om niPAGE VS10 vertical 
electrophoresis system (OminPAGE, W olf Laboratories, York, UK). Acrylamide 
gels were made up at a concentration appropriate to the molecule being analysed. 
They were prepared in a universal container and added between the two clean, dry 
glass plates and assembled on a casting stand. The amount of each ingredient 
required to make up to 15ml, sufficient for both the 8% gel (proteins in the range of 
50KDa to 50()KDa) and the 15% gel (proteins in the range o f 3KDa to lOOKDa) 
resolving gels is indicated below:
Component 8% Gel 15% Gel
Distilled water 6.9ml 3.4ml
30% acrylamide mix 4.0ml 7.5ml
1.5M Tris (pH 8.8) 3.8ml 3.8ml
10% SDS 0.15ml 0.15ml
10% ammonia persuphate 0.15ml 0.15ml
TEMED 0.009ml 0.006ml
Using a disposable plastic pipette, we applied the resolving gel between the 
glass plates and immediately covered the top with distilled water to ensure that the 
gel sets with a smooth surface. After approximately 30 minutes, we discarded the
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distilled water and the stacking gel was added to the top of the resolving gel. A 
plastic comb was placed gently at the top of the stacking gel and the gel allowed to 
set. The components and quantities required to prepare 5ml of the stacking gel 
solution (enough for two gels) are shown below:
Component
Distilled water 3.4ml
30% acrylam ide mix 0.83ml
1.0M Tris (pH 8.8) 0.63ml
10% SDS 0.05ml
10% ammonia persuphate 0.05ml
TEM ED 0.005ml
Once the stacking gel had set after approximately 30 minutes, the comb was 
carefully removed without tearing the edges o f the wells. The loading cassette was 
placed into an electrophoresis tank filled up with IX  running buffer until the wells 
were completely covered.
Samples were loaded into the wells using a 50pl syringe (Ham ilton) with a 
flat-tipped needle at equal volumes approxim ately 15f^l. Control wells with lOpl o f 
molecular weight marker SDSH2 (Sigma-Aldrich, Dorset, UK), were always used.
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2.5.1.5 Running gel
The proteins were then separated according to m olecular weight using 
electrophoresis at 125V, 40mA and 500W . Different lengths of time were used 
depending on the protein size and gel percentage.
2.5.1.6 Preparation of membrane and W estern blotting
Following SDS-PAGE the protein samples were transferred onto a Hybond 
nitrocellulose membrane (Amersham Bioscience UK Ltd, Bucks, UK). Gels were 
taken out from the electrophoretic tank and separated from the glass plates after 
removing the stacking gel with a plastic edge. The nitrocellulose m embrane and four 
sheets of filter paper were cut (7.5cm x 7.5cm) and immersed in IX  transfer buffer to 
ensure correct binding o f the protein to the membrane for 20 minutes. The ‘sandwich’ 
of paper-nitrocellulose-gel-paper was set up for protein transfer from the gel to the 
membrane and placed in a SD10 SemiDry M axi System blotting unit (W olf 
Laboratories, York, UK). The surface o f this sandwich was carefully smoothed out to 
remove the air bubbles which may interfere during the protein transfer.
Electroblotting was performed at a constant current of 15V, 500mA, 8W  for 40-45 
minutes.
Once completed, membranes were removed and immersed in Poceau S. Stain 
(Sigma-Aldrich, Dorset, UK) for approxim ately one minute at room tem perature 
followed by a wash in distilled water until protein bands were visible on the 
membrane. This allows us to verify that the proteins have been transferred to the 
membranes as well as indicate where the molecular marker is placed without
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interfering with successive im m unoprobing steps. M embranes were then stored at 
4°C in 10% milk blocking solution (10% skim m ed milk, 0.1% polyoxyethylene (20) 
sorbitan monolaurate (Tween 20) in TBS) until required.
2.5.1.7 Specific protein detection using antibody probing
M embranes were transferred into a clean 50ml falcon tube (Nunc, Fisher 
Scientific, Leicestershire, UK) and incubated in fresh 10% milk blocking solution for 
30 minutes with agitation in a roller mixer (Stuart, W olf Laboratories, York, UK). 
The blocking solution was then discarded and 5ml of specific primary antibody 
(1:500) made up in 3% milk solution (3% skimmed milk, 0.1% polyoxyethylene (20) 
sorbitan monolaurate (Tween 20) in TBS) was added to the falcon tube followed by 
1 hour of incubation of the membranes with agitation (see Table 2.5). After the 1 
hour of incubation, the primary antibody solution was removed and the membranes 
were washed 3 times for 10 minutes, each wash with 3% milk solution, to ensure 
complete removal of the primary antibody. The m em branes were then incubated in 
5ml of HRP conjugated secondary antibody (1:1000) solution made up in 3% milk 
solution with agitation for 1 hour (Table 2.5). The solution was discarded and 
m em branes were washed 3 times in TTBS (TBS containing 0.1% tween 20), 
followed by a final 10 minute wash in TBS to remove any residual detergent.
2.5.1.8 Chem ilum inescent detection o f protein
The Supersignal W est Pico Chem iluminescencent Substrate (Thermo 
Scientific, IL., USA) was used to detect the horseradish peroxidase (HRP) in the 
membranes. The two substrates were mixed in a 1:1 ratio with a final volum e of
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0.125m l/cm 2. Once the TBS was decanted, the membrane was placed in a clean 
falcon tube and covered for 5 minutes with the chemiluminescence working solution 
with agitation. Excess reagent was then removed and the membrane was placed on 
the tray that the UVITech imager (UVITech, Inc., Cambridge, UK) provides. The 
chemiluminiscence signal was captured and visualized in the computer connected to 
the imager. The membranes were exposed to several exposure times and images 
captured. The protein bands were then quantified by using UVIband software 
(UVITEC, Inc., Cambridge, UK).
M embranes were stained in Am ido Black stain for 1 minute followed by 
immersion in destain until bands were clearly seen and a wash in distilled water. This 
provides a permanent record of the membrane for further comparison with the 
images captured with the imager.
2.5.2 Imm unohistochem ical staining for frozen sections (IHC) o f breast sample 
tissues
Frozen sections of breast tumour and background tissue were cut at a 
thickness o f 6 pm using a cryostat (Leica). The sections were mounted on super frost 
m icroscope slides (Fisher Scientific, Leicestershire, UK) air-dried and then fixed in a 
mixture of 50% acetone and 50% methanol. The sections were then placed in 
Optimax wash buffer (Menerium, Oxford, UK) for 5-10 min to rehydrate. Sections 
were incubated for 20 min in Horse serum albumin (Vector Labs., Peterborough, UK) 
blocking solution and probed with Claudin-5 antibody (1:100 dilution) for one hour, 
and without primary antibody as a negative control to verify the binding specificity. 
Primary antibodies were purchased from Santa-Cruz Biotechnologies Inc. (Santa-
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Cruz, CA, USA). Following extensive washings, sections were incubated for 30min 
in the universal secondary biotinylated antibody (ABC Standard k i t , Vector 
Laboratories, Peterborough, UK). Following extensive washings, the sections were 
incuabated in the dark for 5 min with the Diamino-benzine chromogen (Vector 
Laboratories, Peterborough, UK). Sections were then washed and counter stained in 
G ill’s haematoxylin and dehydrated in ascending grades o f methanol before clearing 
in xylene and mounting under a cover slip.
2.5.3 Im m unofluorescent staining (IFC)
A 16-well chamber slide (Nunc, Fisher Scientific, Leicestershire, UK) was 
treated with 100 pi free serum medium for 1 hour. Medium was discarded and 20000 
cells in 200 pi aliquots were seeded into each well and left in the incubator overnight 
to form a confluent monolayer. The medium was then aspirated and the cells fixed in 
absolute ethanol for 20 minutes at -20°C. Cells were rehydrated in BSS for 10 
minutes and permeabilised in 0.1% Triton X-100 for 5 minutes followed by 3 washes 
in TBS. Blocking was performed using 10% Horse serum (Vector Labs., 
Peterborough, UK) in TBS for 40 m inutes followed by a wash in TBS. The slides 
were probed with primary antibody for 1 hour 1:100 dilution made up in 3% Horse 
serum in TBS. Cells were washed 4 times in 3% Horse serum followed by 4 washes 
in TBS. Secondary antibody was prepared using 1:1000 dilution and cells were 
incubated for 1 hour in the dark according to the primary antibody used which was 
labelled with FITC or TRITC . Cells were washed in 3% Horse serum followed by 8 
washes in TBS, mounted in FluorSave (M erck KGaA, Darmstadt, Germany) and 
stored in foil at -4°C until viewed using an Olympus BX51 Fluorescence microscope.
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Antibody name Host species
Antibody
concentration
Suplier & catalogue 
num ber
Polyclonal Anti­
rabbit (whole 
molecule) IgG 
Peroxidase conjugate
goat 1:1000
Sigma
A-9169
Polyclonal Anti­
mouse (whole 
molecule) IgG 
Peroxidase conjugate
Rabbit 1:1000
Sigma
A-9044
Polyclonal Anti-goat 
(whole molecule) 
IgG Peroxidase 
conjugate
Rabbit 1:1000 Sigma
A-5420
M onoclonal Anti- 
Claudin-5
mouse 1:500
Abnova
H00007122-A01
Polyclonal Anti- 
Claudin-5
rabbit 1:100
Santa-Cruz 
Biotechnologies Inc.
SC-28670
M onoclonal Anti- 
Actin
mouse 1:500
Santa-Cruz 
Biotechnologies Inc.
SC-8432
Polyclonal Anti-N- 
W ASP
goat 1:500
Santa-Cruz 
Biotechnologies Inc.
SC-10122
M onoclonal Anti- 
ROCK 1
mouse 1:500
Santa-Cruz 
Biotechnologies Inc.
SC-17794
Polyclonal Anti­
rabbit IgG FICT
sheep 1:1000
Sigma
F-7512
Table 2.5: Antibodies used during course of study.
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2.6. Tum our cell function assays 
2.6.1 In vitro tumour cell growth assay
The growth capacity of the cells used in this study was determined using an 
in vitro tumour growth assay. Cells were detached and counted (as described before 
in section 2.2.4 and 2.2.5). A number of 3,000 cells were seeded into a 96 well plate 
(Nunc, Fisher Scientific, Leicestershire, UK) in 200pl o f normal medium. Four plates 
were seeded to obtain density readings after 4 hours (day 0), 1 day, 3 days and 4 days. 
W ithin each experiment four duplicates were set up. After appropriate incubation 
periods, cells were fixed in 4% formaldehyde in BSS for 5-10 minutes before 
staining for 10 minutes with 0.5% (w/v) crystal violet in distilled water. Following 
washings the crystal violet was then extracted from the cells using 10% acetic acid. 
Absorbance was determined at a wavelength o f 540nm  on a plate reading 
spectrophotom eter (ELx800, Bio-Tek, W olf laboratories, York, UK).
Using the following equation, cell growth was presented as percentage 
increase by comparing the absorbances of each incubation period:
Percentage increase = [(Day 3 or 5) -  (Day 1)] /  Day 1 X 100
2.6.2 In vitro tumour cell M atrigel invasion assay
The invasive capacity of the cells used in this study was assessed using an in 
vitro tumour cell Matrigel invasion assay. This assay measures the capacity of cells 
to penetrate and invade through a basem ent membrane artificially form ed by using 
Matrigel (M atrigel1 M, BD Bioscience,Oxford, UK) and migrate through 8pm pore 
size, which is sufficiently large enough to allow cells to pass through.
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Cell culture inserts (BD Falcom™  Cell Culture Inserts, BD Bioscience, 
Oxford, UK) were placed into a 24-well plate using forceps and coated in Matrigel. 
The working solution of Matrigel was prepared at a concentration of 0.5m g/m l in 
PCR water, adding 100pl to each insert and allowing to dry overnight. Once dried 
the inserts were rehydrated in lOOpl sterile water for 1 hour. The water was then 
aspirated and cells were seeded in the inserts over the top of the artificial basement 
m embrane at a density of 30,000 cells in 200pl per well. The plates were then 
incubates for 3 days at 37 °C with 5% CO2.
After the incubation period, the M atrigel layer together with the non-invasive 
ceils was cleaned from the inside of the insert with tissue paper. The cells which had 
migrated through the pores and invaded into the M atrigel were fixed in 4% 
form aldehyde (v/v) in BSS for 10 minutes before being stained in 0.5% crystal violet 
(w/v) in distilled water (Parish et al., 1992). The cells were then visualized under the 
microscope under X40 magnification, 5 random fields counted and duplicate inserts 
were set up for each test sample.
2.6.3 In vitro cell-matrix adhesion assay
The capacity of tumours cells to adhere to a basement m em brane created 
artificially by using Matrigel (M atrigel™ , BD Bioscience,Oxford, UK) was 
examined using an in vitro tumour cell M atrigel adhesion assay.
One hundred microlitres o f free serum medium that contained 5pg o f  
Matrigel was added in each well of a 96- well plate and dried at 55°C for 2 hours in 
an oven. The membrane was then rehydrated in lOOpl o f serum free medium for 30
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minutes before the cells were seeded in the wells. Approximately 45,000 cells were 
seeded onto the Matrigel basement m embrane in 200pl o f normal medium and 
incubated at 37°C with 5% CO2 for 40 minutes. After the incubation period, the 
medium was aspirated and the m embrane washed 5 times with 150pl o f  BSS to 
remove the non-attached cells, then fixed in 4% formaldehyde (v/v) in BSS for 10 
m inutes before being stained in 0.5% crystal violet (w/v) in distilled water (Jiang et 
al., 1995a). The number of adherent cells were counted from 5 random fields per 
well and 5 duplicate wells per sample, under a microscope at X40 magnification.
2.6.4 In vitro tumour cell motility assay using Cytodex-2 beads
A number of 1X106 cells from each cell line were incubated in universal 
containers with 20 ml of normal growth medium containing 1ml of Cytodex-2 beads 
(GE Healthcare, Cardiff, UK) for 2 hours. The medium was aspirated and the beads 
were washed twice in growth medium to remove non-adherent or dead cells. After 
the second wash the beads were resuspended in 5 ml of normal growth medium. 
Three hundred microlitres of this solution was then transferred into each well of a 
24-well plate, 5 duplicate wells per sample, and incubated overnight. Following 
incubation, any cells that had migrated from the Cytodex-2 beads and adhered to the 
base of the wells were washed gently in BSS, fixed in 4% form aldehyde (v/v) in BSS 
for 10 minutes before being stained in 0.5% crystal violet (w/v) in distilled water 
(Jiang et al., 1995b). Five random fields were counted per well.
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2.6.5 In vitro tumour cell migration (wound healing) assay
The migration of the cells across a wounded surface of a confluent m onolayer 
was examined to assess the migratory properties of HECV and M DA-231-M B cell 
lines. Cells at a density of 40,000 cells per well were seeded in a 24 well plate and, 
upon reaching confluence, the medium was changed and the m onolayer was scraped 
with a fine gauge needle to create a wound. A few drops o f mineral oil were added to 
avoid evaporation of the medium. The plate was placed on a heated plate (Leica 
GmbH, Bristol, UK) to keep a constant tem perature of 37°C. Cells were 
photographed after wounding and every 15 m inutes during 1 hour with a CCD 
camera attached to a Leica DM IRB m icroscope (Leica GmbH, Bristol, UK) at X 20 
magnification (Jiang et al., 1999a).
Cell migration was analysed using Image J software (free software) by 
m easuring the distance between the two wounded fronts at 4 points per incubation; 
the arbitrary values obtained were converted into pm by multiplying each value by
1.6 as previously calibrated using a calibrated grid. The distance between the 
m igrating fronts at each point time was determined by subtracting the distance 
between the two fronts at any of the specific times selected from that at the initial 0 
minute starting point.
2.6.6 In vitro tubule formation
M atrigel endothelial cell tube formation assays were set up to assess any 
impact on angiogenic effect following treatm ent with different cell m otility-related 
inhibitors (see Table 2.6). One hundred microlitres o f free serum medium that
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contained 250pg o f Matrigel was seeded in each well o f a 96- well plate and left to 
gel in an incubator for 30 minutes. Once the M atrigel was set, it was rehydrated in 
lOOpI o f serum free medium for 30 minutes before the cells were seeded in the wells. 
40,000 HECV cells were seeded onto the M atrigel basement m embrane in lOOpl o f 
normal medium and incubated at 37 °C with 5% C 02fo r 1 hour. After the incubation 
period, the medium was carefully aspirated and a second layer o f  Matrigel (250pg) 
was added on top following treatment of these cells. The membrane was then 
incubated at 37°C with 5% CO2 for 30 m inutes followed by addition o f  lOOpl of 
normal medium (Sanders et al., 2010). Cells were incubated overnight allowing 
tubules to form.
The number of tubules was counted under low magnification and images 
were captured from 5 random fields. Total tubule perim eter/field of these images was 
later quantified using ImageJ software
Inhibitor name Inhibitor concentration
Suplier & catalogue 
num ber
N-W ASP-Inhibitor
Wiskostatin
50pM
Calbiochem  (Gibbstown, 
USA) 
681660-1M G
Rock Inhibitor Y-27632 50nM
Santa Cruz 
B iotechnologies Inc. 
sc-3536
Arp 2/3 Inhibitor 
CK-0944636
10 mM
Chemvid Inc. (San Diego, 
USA) 
8012-5102
Table 2.6: Cell motility inhibitors used during course of study.
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2.6.7 In vivo co-culture tumour growth and development model
Athymic nude mice (nu/nu) (Charles Rivers) were maintained in filter top 
units according to Home Office regulation. The mice were weighed and the size of 
the growing tumour measured using vernier callipers under sterile conditions every 
week. Those mice that developed tumours exceeding 1cm3 or suffered 25% weight 
loss during the experiment were terminated under Schedule 1 according to the UK 
Home Office and the UK Coordinating Com m ittee on Cancer Research (UKCCCR) 
instructions. At the end of the experimental work, animals were weighed, terminated 
under Schedule 1 and tumours were removed if of sufficient size. Tum our volume 
was determined, at each point, using the following formula:
Tum our volume = 0.523 x w idth2 x length
Each experimental group consisted of 5 mice and each mouse was injected 
with a mix of 2 x l0 6 cancer cells in 100 pi in a 0.5 mg/ml M atrigel suspension in both 
flanks.
2.7 Functional assessment o f Tight Junction
2.7.1 M easurem ent o f transepithelial and transendothelial resistance in HECV  
and M DA-M B-231 cell lines (TER)
Cells were seeded into 0.4 pm transparent pore size inserts ( Greiner bio-one, 
Stonehouse, UK) at a density of 50,000 cells in 200pl o f ordinary medium within 
24 well plates, grown to confluence, the medium removed and replace with fresh
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Dulbecco’s Modified Eagle’s medium containing 15Mm Hepes, L-Glutamine 
( Lonza Laboratories, Verviers, Belgium). Medium alone was added to the base o f 
the wells (control) or with 50ng/ml HGF (a kind gift from K. Matsumoto, Osaka 
University, Japan). The concentration o f  HGF (50 ng/ml) used for these experiments 
was selected based upon previous laboratory experience (Martin et al., 2008b). 
Resistance across the layer o f  HECV and MDA-MB-231 cells was measured using 
an EVON volt-ohmmeter (EVON, World Precision Instruments, Aston, Herts, UK), 
equipped with static electrodes (WPI, FL, USA) (Martin et al., 2004a). One electrode 
was placed in the upper and one in the lower chamber o f  the well and resistance 
measured at intervals from 0 to 240 minutes (Figure 2.7). At the end o f  each 
experiment the medium was removed, cells were stained with crystal violet and 
examined under the microscope to ensure that the cell layers had remained attached 
throughout the course o f the experiment.
Electrodes
Upper Chamber
0.4 pm pore insert 
Well in 24 well plate —
Confluent layer of cells 
Lower Chamber
Figure 2.7: Measurement o f  TER using an EVON volt-ohmmeter.
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2.7.2 ECIS (electric cell-substrate im pedance sensing) for m onitoring cell 
attachm ent and cell motility analysis in HECV and M DA-M B-231 cell lines
The 1600R model of the ECIS instrument (Applied Biophysics Inc, NJ, USA) 
was used for motility assay (wounding assay), wounding/cell modelling analysis in 
the study model. Cell modelling was carried out using the ECIS RbA m odelling 
software, supplied by the manufacturer (Figure 2.8).
The 8W 10 arrays (8 well format with 10 probes in each well) were used in 
the present study. The array surface was treated with 200pl o f lOmM L-Cysteine 
solution for 20 minutes, which binds to the gold surface via its thiol group forming a 
m onom olecular layer, followed by two washes in Dulbecco’s M odified Eagle’s 
medium with 15Mm Hepes, L-Glutamine (Lonza Laboratories, Verviers, Belgium). 
An electrode check was run to check the impedance value of the cell-free wells 
containing just fresh medium and to assess the integrity of the arrays. The arrays 
were seeded at a density of 40,000 cells in 400 pi o f  D ulbecco’s M odified Eagle’s 
medium with 15Mm Hepes, L-Glutamine to achieve confluent m onolayers following 
treatment with motility-related inhibitors (see Table 2.6). After 24 hours in culture, 
the confluence and viability of the cell monolayer was confirmed by a light 
microscope, thus another electrode check was run to check the impedance value of 
the array to ensure correct position of the contacts (Keese et al., 2004). The 
m onolayer of HECV and M DA-M B-231 cells was electrically wounded with a 5V 
AC at 4,000Hz for 30 seconds (Figure 2.9). Impedance and resistance of the cell 
layer were immediately recorded every millisecond for a period of up to 5 hours.
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Attachment and Migration were modelled using the ECIS RbA cell modelling 
software.
Figure 2.8: ECIS instrument (panel 1). The 8W10 array (panel 2). Micrographs taken 
from ECIS before (panel 3) and immediately after wounding (panel 4).
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Figure 2.9: ECIS illustrations. The current flows between a 250 pm diameter 
electrode and in the spaces under and between the cells, as the cell membranes are 
essentially insulators.
127
2.8 Designed images
All images used in the introduction of this thesis were produced by Servier 
Medical Art.
2.9 Statistical analysis
Results data was analyzed using SigmaPlot software (version 11.0). The 
statistical comparisons between the test and the control cell lines, using as control 
wild type cells and cells containing a closed pEF6/ V5-His TOPO TA plasmid vector 
when possible, were made using a Students two sample t-test and by Two-way 
Anova test when the data was found to be normalized and have equal variances. In 
all cases 95% confidence intervals were used. All the graphs were created using 
M icrosoft excel software.
Patient data was analyzed using both SigmaPlot and SPSS, etc.
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Chapter 3
Expression of Claudin-5 in normal and 
cancer human breast tissues
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3.1 Introduction
Tight Junctions (TJs) have been widely reported as being not only merely 
intercellular seals; they are also key structures in paracellular transport, gene 
transcription, cell signalling and cellular proliferation and differentiation. Therefore, 
in recent years they have become the focus of intense research. A substantial body of 
evidence for altered TJ structure in cancer developm ent has been reported in the last 
several years.
Claudin proteins are seen as unusual proteins in the TJ structure as they are 
presented in a variety of tissues with different properties. The composition and 
distribution between the 24 members confers specific barrier properties to each cell. 
The impact that the loss of any of the Claudin proteins, or the up-regulation in 
several carcinom as, exerts on epithelial cells is only now beginning to be unmasked. 
Therefore, the study of the pattern of expression of Claudins in normal and human 
cancer tissues might be a useful tool for ascertaining clinical prognosis for the 
disease. To date, a number of studies have reported on the role of the Claudin-5 in 
cancer progression, however, there have been none in breast cancer.
This study aimed to determine, for the first time, the levels of expression and 
distribution of Claudin-5 in a cohort of 133 patients with breast cancer (106) and in 
normal background tissue (27), in order to investigate a possible link between levels 
of expression of Claudin-5 and patient outcome.
130
3.2 Material and method
3.2.1 Collection of breast tissues
A total of 133 breast samples were obtained from breast cancer patients (27 
background normal breast tissue and 106 breast cancer tissue), with the consent of 
the patients and approved by the ethical committee. The pathologist (ADJ) verified 
normal background and cancer specimens, and it was confirmed that the background 
samples were free from tumour deposit.
3.2.2 RNA extraction and Q-PCR in tum our and normal breast tissue
RNA was isolated from both tumour and normal breast samples and used as 
templates for RT-PCR to convert RNA into complementary cDNA (see section 2.4.3 
for method). The levels of Claudin-5 transcripts from cDNA were determined by Q- 
PCR using specific primers. Refer to section 2.4.7 for further details.
3.2.3 Imm unohistochem istry staining o f Claudin-5
Immunohistochemistry staining of Claudin-5 was carried out using a specific 
antibody for the protein, followed by secondary antibody, ABC complex and DAB. 
For detailed IHC procedure refer to section 2.5.2.
3.2.4 Statistical analysis
Comparison between different patients groups were made using two sample t- 
test where appropriate. In order to assess the long term survival rates of patients with 
high and low levels of Claudin-5, the overall survival data was used to plot Kaplan- 
Meier survival curves (SPSS version 14).
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3.3 Results
3.3.1 Aberrant expression of Claudin-5 in human breast cancer
Levels of expression of Claudin-5 were examined at mRNA level using Q- 
PCR and normalised by GAPDH. Results revealed no significant difference between 
tumour and normal/background samples (p=0.38). However, in tissue sections, 
Claudin-5 was expressed at relatively high levels in tumour tissues, while in 
normal/background tissues levels were lower (Figure 3.1).
3.3.2 Immunohistochemical staining o f Claudin-5
In this study immunohistochemical staining was used to assess the location, 
distribution and the degree of staining of Claudin-5 in tumour and 
normal/background samples. In normal mammary tissues, Claudin-5 appeared as 
strong staining in the endothelial cells, lining vessels, whereas epithelial cells stained 
weakly for Claudin-5. The staining for Claudin-5 within the tumour sections was 
however, significantly decreased in both endothelial and epithelial cells (Figure 3.2).
Moreover, the staining distribution within cells from normal/background sections 
was concordant with TJ location. No such distribution was observed in cells from 
tumour sections. Here, the staining was weak, diffuse and not located at the TJs.
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Figure 3.1: Comparison o f levels o f  Claudin-5 in tumour samples compared with 
normal/background tissue (expressed as transcript copy number per 50 ng o f RNA).
133
Claudin-5
NPI 1 2293±15492
NPI 2 535±2977
NPI 3 324918±1258394
TNM 1 122580±689911
TNM 2 7.48±22.72
TNM 3 30.1±53
TNM 4 4.56±9.03
Alive & well 26983±226456
Died from breast cancer 332132±1256707
Table 3.1: Analysis of mRNA samples showing levels of Claudin-5 and tumour 
prognosis by NPI, nodal involvement (TNM ) and patient outcome.
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Figure 3.2: A comparison o f expression o f  Claudin-5 protein levels in 
normal/background (left panel) tissue and tumour breast tissues (right panel) is 
shown in consecutively increasing magnification. Regions o f  Claudin-5 expression 
located at the TJ area in endothelial cells are indicated by black arrows. Red arrows 
indicate Claudin-5 expression in epithelial cells.
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3.3.3 Claudin-5 and the predicted prognosis and TNM staging
The levels of the Claudin-5 transcripts were analysed using the Nottingham 
Prognostic Index (NPI), which indicates the predicted prognosis of the patients. NPI 
was calculated using the following equation [NPI= (0.2 X size) + grade + nodal 
status], where NPI< 3.4 is regarded as a good prognosis (NPI 1), NPI 3.4-5.4 as 
moderate (NPI 2) and NPI >5.4 as poor prognosis (NPI 3). Claudin-5 levels were 
sequentially increased with increasing NPI. There were higher levels of Claudin-5 
expression seen in patients with poorer prognosis (Table 3.1) (Figure 3.3), although 
this did not reach significance (p=0.34).
The levels of Claudin-5 were also analysed against tumour-node-metastasis 
(TNM ) (Table 3.1) (Figure 3.4). There were higher levels of Claudin-5 expression 
seen in TNM1 status when compared to TNM2 (p=0.19), TNM3 (p=0.19) and 
TNM 4 (p=0.19), but significance was not reached.
3.3.4 Claudin-5 expression in different tumour grade
When comparing the levels of Claudin-5 against tumour grade (Table 3.1) 
(Figure 3.5), higher levels of expression were seen in grade 2 when compared with 
grade 1 tumours although this was not statistically different (p=0.85). However, 
grade 3 showed lower levels when compared to grade 1 although this did not reach 
significance (p=0.34).
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Figure 3.3: Levels o f expression o f Claudin-5 in relation to NPI status (expressed as 
transcript copy number per 50 ng o f  RNA).
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Figure 3.4: Levels o f expression o f Claudin-5 in relation to TNM status o f  tumours 
(expressed as transcript copy number per 50 ng o f  RNA).
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Figure 3.5: Levels o f  Claudin-5 in relation to tumour grade (expressed as transcript 
copy number per 50 ng o f RNA).
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3.3.5 Claudin-5 expression correlated with clinical outcome and long-term  
survival
To determine whether Claudin-5 transcript levels were associated with long­
term survival, patients were classified according to expression levels of CL-5, guided 
by the Nottingham Prognostic Index (NPI) into two groups; those with high levels 
and those with low levels of Claudin-5. The cut off point was set at the level at which 
patients were classified as moderate prognoses or NPI 2. Patients who died of breast 
cancer had higher levels of Claudin-5 transcript when compared with patients who 
remained disease free although this did not reach significance (p=0.36) (Figure 3.6).
W hen long-term survival was analysed using Kaplan-M eier survival curves 
(Figure 3.7), patients with high levels of Claudin-5 transcript had a significantly 
shorter survival than patients with low levels of Claudin-5 (p=0.004); mean survival 
129.780 moths (118.120-141.441 months, 95% Cl) versus 66 months (41.520-90.480 
months, 95% Cl).
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Figure 3.6: Levels o f expression o f Claudin-5 in relation to patient outcome 
(expressed as transcript copy number per 50 ng o f  RNA).
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3.4 Discussion
This study has reported for the first time that Claudin-5 is aberrantly 
expressed in human breast cancer and has a link to the clinical outcome of the patient. 
From this data we have shown that Claudin-5 expression is decreased in breast 
tumour tissue compared to normal/background tissue, however this result did not 
correlate with IHC staining, where levels of Claudin-5 protein appear to be higher in 
normal/background tissues when compared to tumour sections. This discrepancy 
may be due to the non-discriminatory nature o f Q-PCR, as we cannot determine 
which cells express Claudin-5. Moreover, IHC is a semi-quantitative method. In 
early studies Claudin-5 was described as a protein highly expressed in endothelial 
cells of the blood vessels (Morita et al., 1999c) this might also help us to explain the 
disparity founded between the IHC and Q-PCR results. As explained in Chapter 1, 
tumour angiogenesis is the proliferation of a network of blood for the supply of 
nutrients as well as oxygen and for rem oving waste products, therefore Claudin-5 
theoretically should be highly expressed being a recognised member of the TJ 
structure in endothelial cells constituting these blood vessels. This, in itself, might 
reveal an angiogenic potential in assessing the aggressiveness of breast cancer.
For the clinical point of view, one of the most interesting observations from 
this study is the relationship between high levels of Claudin-5 and clinical outcome. 
Patients who died from breast cancer had higher levels of Claudin-5 compared with 
patients who remained disease-free. Furthermore, patients whose tumours expressed 
high levels of Claudin-5 had significantly shorter survival than those with low levels 
of expression of Claudin-5.
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The Nottingham Prognostic Index (NPI), has been used as a prognostic 
indicator with its reliability being validated in several studies (Suen and Chow, 2006). 
Claudin-5 showed a high expression at NPI 3 when compared to NPI 1 and NPI 2 
correlating these results with the poor prognosis seen when looking at clinical 
outcome for these patients as described above. Conversely, when Claudin-5 
expression was compared with tumour grade and TNM status of tumours no trend 
was observed. Claudin-5 showed no obvious correlation as Claudin-5 was decreased 
in grade 3 when compared to grade 1 and grade 2. The same trend was observed 
when comparing levels with TNM classification, where Claudin-5 expressed high 
levels at TNM 1, although none of these results reached significance.
In recent years, an increasing number of studies have revealed the differential 
expression of Claudins in human cancers (Oliveira and M orgado-Diaz, 2007). 
Although high levels of Claudin-5 have been reported in ovarian (Turunen et al., 
2009), prostate (Seo et al.) and lung cancers (Paschoud et al., 2007) and low levels in 
hepatocellular carcinoma (Sakaguchi et al., 2008), this is the first study to our 
knowledge to report levels of Claudin-5 in patients with breast cancer.
Collectively, these findings suggest that Claudin-5 is a potential prognostic 
factor in patients with breast cancer, as high levels of expression are clearly 
associated with indicators of poor prognosis as well as with high incidence of breast 
cancer-related death and shorter survival of patients. These results strongly indicate a 
prognostic value of Claudin-5 in breast cancer.
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Chapter 4
Cloning and verification of Claudin-5 
over-expression and knockdown
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4.1 Introduction
The role of Claudins in carcinogenesis and progression to metastasis is an 
active area of research due largely to the discovery that Claudin expression is 
frequently altered in cancer. Although their functional role in cancer progression 
remains unclear, the differential expression of these proteins between tumour and 
normal cells, in addition to their membrane localisation, makes them prime 
candidates for cancer therapy (Kominsky, 2006; Tsukita et al., 2008). The Claudin 
protein family was discovered in 1989 by Furuse et al., (Tsukita, 1989). Since the 
initial discovery of the first claudin, at least 24 human Claudins have been identified. 
They are generally expressed in both epithelial and endothelial cells and thus are 
found throughout the body.
It has been shown that expression of Claudin-5 selectively decreased the 
permeability of the blood-brain barrier ions (Nitta et al., 2003). A  very limited 
number of studies have examined patterns of expression of Claudin-5 in human 
cancer, however, as already discussed in Chapter 1, levels of Claudin-5 expression 
appear to be altered in ovarian, lung, prostate and hepatocellular carcinomas.
Previous work in our research group initiated an investigation into the 
expression of Tight Junction (TJ) molecules in breast cancer. The original pilot study 
identified a number of target m olecules that would allow for further investigation as 
having potential as breast cancer markers, prognostic indicators or possible 
therapeutic targets. One of these proteins of interest was Claudin-5.
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The aim of this study is primarily to establish the role of Claudin-5 in 
endothelial cells during the defence of cancer invasion as well as its role in breast 
cancer cells.
4.2 Materia] and methods 
4.2.1 M aterials
Polyclonal rabbit anti-Claudin-5 antibody (SC-28670) was obtained from 
Santa-Cruz Biotechnologies Inc. (Santa-Cruz, CA, USA) and polyclonal mouse anti- 
Claudin-5 antibody (H00007122-A01) was obtained from Abnova (Abnova GmbH, 
Heidelberg, Germany). Secondary antibody for Immunofluorescence staining was 
labelled anti-rabbit IgG-FITC from Sigma (Sigma-Aldrich, Dorset, UK). Secondary 
antibody for Western blotting was labelled anti-mouse peroxidase conjugated (A- 
9044) from Sigma (Sigma-Aldrich, Dorset, UK). All primers used were 
manufactured and provided by Invitrogen (Invitrogen, Inc., Paisley, UK), all their 
sequences are located in table 2.2.
4.2.2 Cell lines
HECV and MDA-MB-231 cell lines were chosen to investigate the effects of 
forced expressed and knockdown of Claudin-5. They were cultured in DM EM -F12 
medium as described in section 2.2.
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4.2.3 Generation of Claudin-5 knockdown and forced expression M DA-M B-231  
and HECV cells
Amplification of the Claudin-5 coding sequence was carried out using 
primers capable of amplifying the full length sequence of Claudin-5 (table 2.2) 
together with placental cDNA (previously shown to highly express Claudin-5) used 
as template.
Hammerhead ribozymes targeting Claudin-5, based on the secondary 
structure of Claudin-5 were used. For detailed procedures refer to section 2.3.
4.2.4 TOPO cloning of Claudin-5 coding sequence/transgenes into a pEF6/H is 
TOPO plasmid vector
Claudin-5 coding sequence or transgene was cloned into pEF6/ V5-His 
TOPO TA plasmid vector, followed by transformation of constructed plasmid into 
Escherichia coli. The correct colonies were then amplified, and the plasm id extracted. 
For detailed procedures refer to section 2.3.
4.2.5 HECV and M DA-M B-231 cell transfection and generation o f stable 
transfectants
Following plasmid verification, the plasmids were transfected into HECV and 
MDA-MB-231 cells and were placed in selection medium containing 5pg/ml 
Blasticidin S, following selection for up to 10 days. For detailed procedures refer to 
section 2.3.
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4.2.6 Synthesis o f com plem entary DNA and RT-PCR
RNA was isolated from the cells and RT-PCR was used to convert RNA into 
com plem entary cDNA as described in section 2.4. Conventional PCR was run to 
confirm  the products which were visualized on a 2% agarose gels.
4.2.7 Protein extraction, SDS-PAG E and W estern blotting analysis
Protein was extracted and quantified, followed SDS-PAGE as described in 
section 2.5. Proteins were transferred onto nitrocellulose membranes and probed with 
specific prim ary anti-Claudin-5 (full antibody data is given in table 2.5).
4.2.8 Im m unofluorescent staining
Imm unofluorescent staining of Claudin-5 in HECV and M DA-M B-231 cells 
was carried out using a specific antibody for the protein, followed by secondary- 
FITC antibody. For detailed IFC procedure refer to section 2.5.3.
4.3 Results
4.3.1 Screening of cell lines and tissues for Claudin-5 expression
The expression of Claudin-5 was examined in eleven breast cancer cell lines, 
including M DA-M B-157, M D A -M B-463, BT-549, M CF-7, M DA-M B-436, ZR-751, 
M DA-M B-435S, BT-474, M DA-M B-231 and BT-474KC. Relatively low levels of 
Claudin-5 were seen in most o f these cells or Claudin-5 was absent. However, BT- 
549, M DA-M B-436 and M DA-M B-231 showed moderately high levels of Claudin-5 
mRNA levels compared to the other breast cancer cell lines (Figure 4.1).
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The expression of Claudin-5 was also screened in three prostate cell lines, 
D U -145, PNT-19 and PNT-2C2, revealing that Claudin-5 was expressed at relatively 
low levels in PNT-2C2 cells and com pletely absent in DU-145 and PNT-19. 
Pancreatic cell lines PANC-1, M iaPaCa and Cor- L677, the fibroblast cell line 
MCR5 (used as a control as fibroblasts do not have TJ), the bladder cancer cell line 
R T -112, the human epithelial carcinom a cell line A-431, the human keratinocyte cell 
line HaCaT and the two colorectal cell lines HRT-18 and HT-115 showed negative 
levels of Claudin-5 after screening.
In the endothelial cell lines HECV  and HU V EC m RNA levels of Claudin-5 
were seen as expected, as Claudin-5 has previously been reported to be highly 
expressed in the blood vessels in an early study (M orita et al., 1999c). However, 
relatively low levels were seen in the H U V EC cell line when compared to HECV 
cells.
In all cell line samples, (3-actin expression was also examined to confirm 
cDNA quality and to demonstrate norm alised levels of cDNA within the separate cell 
lines.
This data demonstrated expression o f Claudin-5 in several breast cancer cell 
lines, in the prostate cancer cell line PN T-2C2 and in endothelial cell lines HECV 
and HUVEC, providing us with inform ation enabling us to choose a cell line with 
high levels of expression of Claudin-5. The M DA-M B-231 and HECV cell lines 
were among others selected to investigate the role of Claudin-5 in human endothelial 
and breast cancer cells and therefore they were established as in vitro cell models for 
this study.
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Expression of Claudin-5 was also investigated in three different human 
tissues such as placenta, breast and colorectal tissue in order to choose cDNA 
tem plates for the amplification of Claudin-5 expression sequence for further analyses 
(Figure 4.2 A).
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Figure 4.1: Screening of different cell lines for Claudin-5 mRNA levels using PCR . 
The arrows indicate the two cell lines chosen to be used in this study, the human 
breast cancer cell line MDA-MB-231 and the human endothelial cell line HECV.
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4.3.2 Am plifying Claudin-5 expression sequence
In order to investigate the effects o f over-expression of Claudin-5 in HECV 
and in the breast cancer MDA-M B-231 cell line, a m am malian expression construct 
was generated. The full length of Claudin-5 was am plified using specially designed 
primers. Using placenta tissue cDNA as a tem plate and an optimal annealing 
tem perature of 55°C PCR was carried out and the products were run on an agarose 
gel. The product of the correct size (547 bp) corresponding to the Claudin-5 coding 
sequence was excised from the gel and extracted using the GelElute™  Gel extraction 
kit (Sigm a-A ldrich, Dorset, UK). In order to verify that the band was successfully 
extracted and truly contained the Claudin-5 sequence, it was subsequently run on a 2% 
agarose gel (Figure 4.2 B).
4.3.3 C loning o f expression sequence into plasm id vector
Once the Claudin-5 coding sequence was verified and prepared, it was cloned 
into a pEF6/ V5-His TOPO TA plasmid vector. Thus, the constructed plasmid was 
transform into Escherichia coli and the colonies were analysed to verify not only that 
they contained the Claudin-5 plasm id, but that the plasm ids had incorporated the 
fragm ent in the correct orientation.
To achieve this, each o f the selected colonies was tested in two separate PCR 
reactions: one using C L 5expR l/ CL5expF2 to determine if the entire sequence of 
Claudin-5 had been inserted resulting in a 547bp product (sequences of prim ers table 
2.2) and another independent PCR to the one above m entioned using T7F/
CL5expR l to determine w hether the insert was ligated in the correct orientation
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(Figure 4.3 A). As T7F is located about 90bp upstream  of the Claudin-5 insert, 
considering the insert is ligated in the correct orientation, the resulting product after 
using T7F coupled with C L 5expR lprim er should be approxim ately 637bp in length. 
Therefore, the colony displaying full sequence and correct orientation can be taken 
for am plifications as it contains the full C laudin-5 sequence in the correct orientation. 
The positive colonies were carefully picked and grown up in a large volume of LB 
medium and underwent plasmid extraction (Figure 4.3 B).
Plasm id extraction was carried out and, so as to determine plasm id integrity, 
the purified plasmid was run on an agarose gel as well as used as a template in a PCR 
using specific primers for Claudin-5 to ensure correct orientation (Figure 4.4). A 
posteriori, the plasmid was sent off to G eneservice Ltd. (Source Bioscience, 
Cam bridge, UK) for sequencing in order to ultim ately verify that the insert within the 
plasmid contained the correct Claudin-5 sequence. The results showed a positive 
match between the sequence cloned into plasm id vector, and the human Claudin-5 
precursor sequence (Figure 4.5).
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Figure 4.2: (A) PCR products visualised on an agarose gel from different human 
tissues of Claudin-5 coding sequence. The placenta tissue was selected as a template. 
The correct size of the product is 547bp as indicated with the arrow. (B) Agarose gel 
showing PCR product using the Claudin-5 coding sequence from previous gel above 
and used as a template with Claudin-5 specific primers R lvsF2.
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Figure 4.3: (A) Agarose gel showing PCR for Escherichai coli colony analysis to 
verify that they contained the Claudin-5 plasmid and in the correct orientation. (B) 
Agarose gel showing purified Claudin-5 plasmid.
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Figure 4.4: Agarose gel showing PCR product using the extracted plasmid as a 
template with a full set of specific primers for Claudin-5.
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NM 001130861.11 Homo sapiens claudin 5 (CLDN5), transcript variant 1,
mRNA
GENE ID: 7122 CLDN5 | claudin 5 [Homo sapiens] (Over 10 PubM ed links) 
Score = 1164 bits (630), Expect = 0.0 
Identities = 639/643 (99%), Gaps = 1/643 (0% )
Strand=Plus/Plus
Oucry 7! GAGA I (X T G G G C C rG G T G G I G T G C C rG G T G G G (T G G G G G G G T (T G A T C ei'G G C G T G C G G G  130 
Sbjcl 1101 GAGA IX XTGGGCCTGGTG CTG TGCCTG G TG G G CTG G G G G G G TCTG A TCCTG G CG TG O G G G  1160 
U ucrv 131 ( '  rG CCCATGTGG CA GGTG A CCG CC'TrCCTG G A CC'A CA A CA TCG TG A CG G CG G A G A CCA CC 190 
Sbjcl 1161 M  XKX X 'A TG TG G C A G G TG A rC G C C TK  XTGC.AGCACAACA'IX G TG AGGGCGG AGArG AC C 1220 
Oucry 191 TG G A A G G G G CTG TG G A TG TCGTGOG TGGTGCAG AGCACCG GGCAC'ATGCAGTG CAA AGTG 250 
Sbjcl 1221 TGG AAGGG GCTGTG G A TG TCG TG CG TG G TG CA G A G CA CCG G G CA CA TG CA G TG CA A A G TG  1280 
Oucry 251 TA C G A C TC G G TG CTG G CTCTG A G O A CCG A G G TG CA G G CG G CG CG G G O G O rCA CCG TG A G C 310 
Sbjct 1281 T A C G A (T C G G T G (T G G O rC T G A G C A C C G A G G T G C A G G C G G C G C G G G C G C rC A C C G T G A G O  1340
Sbjcl 1341 GGG GTGOl GCI G G C G 'IT C G T rG C G C rc n  CGTGACGCTGGCGG GCX'.CGCA GTGCACCACC 1400 
O ucry 371 I G CG TG G CCCCG GGCCCGG OCAAGGO GOGTG TGGCOCTGACGGG AGGOG TGCTCTACCTG 430 
Sbjcl 1401 TGC OTGGCCCC'GGGCCCGGCCAAGGCGCGTGTGGC ('(T C A C G G G A G G C G T G C T C T A C C T G  1460 
Oucry 431 C TC TG C G G G C TG CTG iG CG CrCG TG O CA CTO TG C'TG O iTrCG CCA A CA TrG TCG TCCG CG A G  490 
Sbjcl 1461 IT rrG C 'G G G C rG C T G G C 'G C rC G  rGCX'AC'rC'rGCTrGG rrC G G C A A G A  lT G  rCG TGGGCGAG 1520 
O ucry 491 T r n  A C G A CCCG TO rG TG O CCG TG TCG CA G A A G TA O G A G CTG G G CG CA G CG CTG TA CA TC 550 
Sh|Cl 1521 I ' m  ACGACCGGTCTG I GCCC'G'rG CGGGAGAAG I A f'G A G C 'TG G G G G G A G CG CrG  l ACA 1'G 1580 
Oucry 551 G G C TG G G G G G CCA CCG CG CTG CTCA TG G TA G G CG G CTG O CTCTrG TG CTG CG G CG CCTG G  610
O ucry 61 I GiTCTGiCACCGGCGGTCCOGAOCTCAGOITC'CCCGTGAAGTAOl C AGCGCCG CG GCG GCCC 670 
Sbjcl 1641 O i l  T G C A C C G G C C G T C C C G A C C rC A G C nC C C C G T G A A G T A C rC A G C G C C G C G G C G G C C C  1700 
O ucry 671 AG G G G CA CCG G G G A G rA CG A CA A G A A G A A CI ACG TCA-AGGGC 712
Sbjcl 1701 AOG GCCACCGG CG A CTA CG A CA A G A A G A A CTA CG TCTG A G G G C 1743
Figure 4.5: Figure confirm ing that extracted plasm id shows a positive match for 
Claudin-5 when sequence com pared to the BLAST database.
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4.3.4 Generation o f Claudin-5 ribozym e transgenes
In order to silence the expression o f Claudin-5 in HECV and in the breast 
cancer MDA-M B-231 cell line, ribozym e transgenes of Claudin-5 were generated 
and cloned into a pEF6/ V5-His TO PO TA  plasm id vector and subsequently 
transfected into mammalian cells. This w ould allow  for com parison between the 
effects o f knocking down, and forced expression o f Claudin-5 in the above 
m entioned cell lines.
Based on the secondary structure o f Claudin-5, which was generated using 
Zuker’s RNA mFold program, an appropriate targeting site for the ribozyme was first 
designed. Ribozymes were generated using touchdow n PCR and followed by cloning 
into a pEF6/ V5-His TOPO TA plasm id vector (Figure 4.6 A). In order to verify the 
correct orientation of the ribozyme transgene, specific prim ers to the ribozyme 
transgene were paired with T7F respectively. Each colony was tested with two 
independent PCRs, once to confirm  the presence o f the transgene using specific 
prim ers for Claudin-5 ribozyme C L 5R ib lR / C L 5R ib lF  and CL5Rib2R/ CL5Rib2F 
resulting in a lOObp products, and another to confirm  orientation. For this purpose, 
T7F prim er was coupled with C L 5R ib lR  and CL5Rib2R respectively. If the 
transgene is correctly orientated, a PCR product should be seen at approxim ately 
200bp as the ribozyme sequence is around lOObp and T7F prom oter starts at 
approxim ately 90bp before insert (Figure 4.6 B).
Positive colonies were selected for further amplification and subsequent 
plasmid extraction. The plasm ids were then verified using DNA electrophoresis in 
order to verify successful plasm id extraction (Figure 4.7 A). In addition to this,
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conventional PCR was carried out using specific prim ers for Claudin-5 ribozyme 
C L 5R ib lR /C L 5R ib lF  and CL5Rib2R/ CL5Rib2F in order to demonstrate the 
presence of the ribozyme (Figure 4.7 B).
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Figure 4.6: (A) Ribozym es synthesis using touchdown PCR. (B) A garose gel 
showing PCR for Escherichai coli colony analysis to verify insertion and correct 
orientation of the transgene.
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Figure 4.7: (A) Plasmids were extracted and verified with DNA electrophoresis. (B) 
Agarose gel showing PCR products using specific prim ers for Claudin-5 ribozyme. 
and the extracted plasm ids as a tem plate in order to demonstrate the presence of the 
ribozyme.
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4.3.5 Transfection of HECV and M DA-M B-231 cells and verification o f the 
stable transfectants
Following plasmid extraction, the mammalian cell lines HECV and MDA- 
MB-231 were transfected. Both cell lines were electroporated and thus transfected 
with the Claudin-5 over-expression plasmid construct. They were named HECVcl5exp 
and M DAcl5exp, as well as empty plasmid control, HECV pef6 and M DApef6 
respectively. The cells were transfected followed by selection in Blasticidin S for 10 
days; RNA and protein were extracted from these cells as well as from wild type cell 
lines, named HECVwtand M DAwt. Successful forced expression was confirmed using 
RT-PCR (Figure 4.8) and immunofluorescent staining. Both of these methods 
demonstrated considerably higher levels o f Claudin-5 expression in both HECVGI5exp 
and M DAcl5exp when compared to both H ECV wtand M DAwtand HECVpef6and 
M DApet6 respectively. A housekeeping gene such as (3-actin was used in the PCR as 
internal control by showing standardized levels o f cDNA within the samples.
In order to silence the expression o f Claudin-5, ribozyme transgenes were 
used in both cell lines. Similarly to Claudin-5 over-expression, HECV and MDA- 
MB-231 were transfected with two different Claudin-5 targeting ribozymes, together 
with an empty plasmid control. Using RT-PCR, expression of Claudin-5 mRNA was 
absent in the case of ribozyme 2 (HECV CL5nb2 and M DACL5nb2) compared to the 
controls (HECVwt/M DAwt and H ECVpef 6/M D A pef6). Ribozyme 1 was unsuccessful in 
knockdown of Claudin-5 expression (Figure 4.8). A similar reduction in Claudin-5 
protein level was seen in HECV CL^ rib2 (Figure 4.10) and M DACL5rib2 (Figure 4.11) 
when carrying out double Immunofluorescence staining of HECV and M DA-M B-
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231 cells using anti-Claudin-5 (FITC) and Phalloidin (TRITC) in order to visualise 
possible changes in the distribution of the actin filaments. Differences in cell 
morphology was observed in HECV CL5nb2 and M D A CL5rib2 cells compared to the 
controls, where cell shape changed from flat, w ell-attached cells with a well defined 
cytoskeleton seen in HECVwt/M D A wt cells to round cells displaying a perinuclear 
staining of actin following Claudin-5 knockdown. In both HECV cl5exp and M DAcl5exp, 
imm unofluorescence staining revealed a reduction in actin filaments as well as 
elongated and starred cell morphology in M D A cl5exp.
A sim ilar reduction of Claudin-5 protein level was demonstrated in both 
HECV GL5nb2 and M DACL5nb2 cells, whereas an enhanced level of protein was seen in 
HECVcl5expand M DAcl5exp compared to the H E C V wt and M D A wt controls, when 
carrying out Western blotting analysis (Figure 4.9).
164
1028bp
Claudin-5
P-Actin
Figure 4.8: Agarose gel verifying over-expression and knockdown of Claudin-5 in 
mammalian transfected cells using specific prim ers for Claudin-5. RT-PCR 
demonstrates successful over-expression and silencing of Claudin-5 in ribozyme 2 
for HECV and MDA-MB-231 cell lines compared to the controls.
Claudin-5
Actin
Claudin-5
Actin
Figure 4.9: Western blotting analysis demonstrating enhanced level of Claudin-5 
protein in HECVcl5exp and M DAcl5exp compared to the HECVwt and M DAwt controls. 
Decreased levels of Claudin-5 protein were observed in HECVCL5rib2 and M DACL5nb2 
when compared to the controls.
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A Claudin-5 B Phalloidin C merged
HECV wt
HECV
CL5rib2
HECV
Figure 4.10: Double Immunofluorescence staining. (A) Confirming over-expression 
and knockdown in HECV cells o f  Claudin-5 levels using anti-Claudin-5 (FITC) Left 
hand column. HECVcl5exp demonstrated significantly stronger staining when 
compared to the control HECV"* (indicated by arrows) whereas, HECVGL5nb2 cells 
showed considerably less staining for Claudin-5 compared to the control HECV"* 
(indicated by arrows). (B) Arrows demonstrate actin filament staining pattern as 
detected by Phalloidin (TRITC). (C) Co-localization o f  Claudin-5 and actin filaments.
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Figure 4.11: Double Immunofluorescence staining. (A) Verification o f  Claudin-5 
over-expression and knockdown in M D A -M B -231 cell using anti-Claudin-5 (FITC) 
Left hand column. Claudin-5 expression was considerably stronger in the MDAcl5exp 
compared to the control MDA''* (indicated by arrows) whereas; Claudin-5 staining in 
M DACL5nb2 cells was much less compared to the control MDA"* (indicated by 
arrows). (B) Arrows demonstrate actin filament staining pattern as detected by 
Phalloidin (TRITC). (C) Co-localization o f  Claudin-5 and actin filaments.
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4.4 Discussion
The initial screening undertaken in this chapter revealed levels of expression 
of Claudin-5 in three of the eleven breast cancer cell lines examined, in endothelial 
cells and in the prostate cell line PN T-2C2. As the aim of this current study was to 
investigate the role of Claudin-5 in endothelial and breast cancer cells by altering its 
expression, the prostate cell line was discarded. Claudin-5 has been reported to be 
expressed in epithelial cell lines of the stom ach, liver, pancreas (Rahner et al., 2001), 
colon (Am asheh et al., 2005) as well as in the brain and lung (M orita et al.,
1999c).To our knowledge, no previous study has investigated the biological role of 
Claudin-5 in any of the two cell lines selected. How ever, an early study from Morita 
et al., revealed high levels of expression o f Claudin-5 in endothelial cells of the 
blood vessels (M orita et al., 1999c) and M artin et al., reported the regulation of 
Claudin-5 in M DA-M D-231 when cells were treated with H G F (M artin et al., 2004a).
The screening process provided data for the determ ination o f which cells to 
use for this study. In order to investigate the role o f Claudin-5 in endothelial cells 
and in breast cancer cells, we altered C laudin-5 expression in HECV and M DA-M B- 
231 cells as they were seen to express high levels of Claudin-5. W e constructed a 
m am malian expression vector containing the entire Claudin-5 coding region. 
Claudin-5 over-expression was verified at both the m RNA and protein level using 
PCR and im m unofluorescent staining. In addition, we used hamm erhead ribozymes 
to silence the expression of Claudin-5 after transcription in both cell lines. Claudin-5 
was successfully dow n-regulated by the use of ribozym e transgenes in vitro as 
proved at both the m RN A  and protein level. This would aid to confirm  that the effect
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of over-expressing Claudin-5 in HECV and M DA-M B-231 is due to its alteration 
and not to other external factors that could have had an effect on the natural 
behaviour of the cells.
These genetic manipulations will allow us to create established in vitro 
models providing us with information about the unknown biological role of Claudin- 
5 in endothelial and breast cancer cell lines.The impact of Claudin-5 manipulation on 
the function of cells were subsequently investigated using these cell models and are 
presented in the following chapters.
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Chapter 5
Effect of Claudin-5 expression on the 
aggressive nature of the MDA-MB-231 
human breast cancer cell line
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5.1 Introduction
The link between alterations in Tight Junctions (TJs) and epithelial tumour 
developm ent has been confirmed in early studies (Swift et al., 1983). The epithelium 
constitutes one of the primary physical barriers that protect the organism against 
infectious agents in the environment. M ost cancers, including breast cancer, originate 
from epithelial tissues. Cancer cells are characterised by abnormal and uncontrolled 
growth as well as presenting disorders in cell comm unication. Additional underlying 
changes include changes in cell-cell and cell-substrate adhesion, a fundam ental step 
allowing cancer cells to spread and ultim ately m etastasise. Consequently, the polarity 
of the cells and the paracellular transport is altered. Claudins are proteins in the TJ 
structure and the mixture and interaction of these proteins together with differences 
in expression patterns of the 24 members that comprise the family, place them in the 
front line of cancer research. The primary role of Claudins is in the regulation of 
paracellular selectivity through pores form ed by the proteins them selves (Tsukita and 
Furuse, 2000). However, new roles for Claudins as proteins involved in regulating 
cell phenotype and growth control are starting to emerge (Findley and Koval, 2009). 
This new data opens the door to a new concept of what role Claudins might have, 
changing the perception that they are more than simple sealing proteins.
The present study used a well characterized breast cancer cell line, MDA- 
M B-231, and following forced expression and knockdown of Claudin-5, cellular 
biological functions were investigated in response to Hepatocyte Growth Factor 
(HGF) in order to establish the functional role of Claudin-5 and a possible link with 
motility-related proteins in this particular breast cancer cell line.
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5.2 Materials and methods
5.2.1 Cell line
The breast cancer cell line M DA-M B-231 was used in this study to 
investigate the effect of Claudin-5; the sublines created were M DAcl5exp (forced 
expression) and M DACL5nb2 (knockdown). Experim ents also included M DAwt and 
M DApef6 as controls. Cells were continuously maintained in DM EM -F12 media as 
described in section 2 .2 .
5.2.2 In vitro tumour cell growth assay
The cells were seeded into four 96 well plates and incubated for a broad 
range of hours as described in section 2.6.1. Absorbance was m easured in order to 
determine cell number.
5.2.3 In vitro tumour cell M atrigel adhesion assay
The cells were seeded into a 96 well plate containing a layer of Matrigel as 
described in section 2.6.3. The number of cells that had adhered to the artificial 
basem ent membrane was counted.
5.2.4 In vitro co-culture M atrigel tum our cell invasion assay
The cells were seeded into inserts previously coated with M atrigel as 
described in section 2.6.2. The num ber of cells which had migrated through the layer 
of endothelial cells was counted.
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5.2.5 In vitro tumour cell motility assay using Cytodex-2 beads and the effect of 
H G F
The cells were incubated with Cytodex-2 beads as described in section 2.6.4. 
The number of cells that were carried by the beads and moved from the beads to the 
base of the well was counted. The same protocol was followed when cells were 
treated with HGF.
5.2.6 In vitro tumour cell migration (wound healing) assay
The migration of the cells across a wounded surface of a confluent monolayer 
form ed by the same cell line was examined as described in section 2.6.5.
5.2.7 Transepithelial resistance and the effect o f HGF
The cells were seeded into transparent inserts and the resistance across the 
layer was measured as described in section 2.7.1. The same protocol was followed 
when cells were treated with HGF.
5.2.8 ECIS
The cells were seeded into electrical arrays allowing the cells to adhere to the 
gold electrodes within the array as described in section 2.7.2 causing a change in 
resistance followed by electrical wounding of the formed monolayer. The same 
protocol was followed when cells were treated with HGF and motility-related 
inhibitors.
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5.2.9 Analysis o f protein levels o f N-W ASP and RO CK  1 using western blotting. 
Claudin-5 co-immunoprecipitation with N-W ASP and ROCK 1
W estern Blotting was used to demonstrate levels of expression of N-W ASP 
and ROCK 1 as described in section 2.5. Claudin-5 co-im munoprecipitation was 
carried out using cell lysate of M DAwt and M DAcl5exp and probed with antibodies 
against N-W ASP and ROCK1 as described in section 2.5.1.6. N-W ASP and ROCK1 
co-immunoprecipitation was carried out as described above and probed with 
antibodies against Claudin-5.
5.2.10 In vivo tumour growth and developm ent
The impact of Claudin-5 on tumour growth was assessed in an in vivo  system 
as described in section 2 .6 .8 ., where a broad num ber of factors may influence the 
effects of over-expression of Claudin-5 in this particular developm ent model.
5.3 Results
5.3.1 Effect o f altering Claudin-5 expression on M DA-M B-231 breast cancer cell 
growth
The MDA-MB-231 sublines M DAcl5exp and M DACL5rib2 alongside M DAw1 
and M DApef6 were examined following 1, 3 and 4 day incubation periods using an in 
vitro cell growth assay. No significant difference in the in vitro growth rate of the 
M DAwt and M DApef6 cells compared to M DAcl5exp or M DACL5rib2 were found 
following the three different incubation periods (Figure 5.1). However, the growth
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rate of M DAcl5exp at day 1, 3 and 4 was found to be increased when compared to the 
controls M DAwt and M DApef6; day 1 M D A wt (24.95% ± 10.58), M DApef6 
(27.49% ± 12.76) and M DAcl5exp (35.30% ±12.7), ( p=0.20 and p=0.35 respectively); 
day 3 M DAwt (370.45%±44.54), M D A pef6 (378.10% ± 110.41) and M DAcl5exp 
(411.61 % ±64.10), ( p=0.27 and p=0.57 respectively); day 4 M DAwt 
(664.02% ±94.57), M DApef6 (645.21%± 144.60) and M DAcl5exp (685.04% ±123.85), 
(p=0.87 and p=0.65 respectively). The opposite effect was observed in the incubation 
period day 3 and day 4 of M DACL5nb2 where the cell growth was decreased when 
compared to the controls; day 3 M D A wt (370.45% ±44.54), M DApef6 
(378 .10% ±110.41) and M DACL5rib2 (340.40% ±83.52), (p=0.49 and p=0.55 
respectively); day 4 M DAwt(664.02% ±94.57), M D A pef6 (645 .21%± 144.60) and 
M DA CL5rib2 (594.99%±121.60), (p -0 .34  and p=0.56 respectively).
5.3.2 Effect o f Claudin-5 on M DA -M B-231 breast cancer cell adhesion
The ability of M DAcl5exp and M D A CL5nb2 cells to adhere to m atrix was 
assessed in an in vitro Matrigel adhesion assay (Figure 5.2). There was a significant 
difference between the adherence of M D A CL5nb2 and M DAwt and M DA pef6 with 
M DACI 5rib2 cells being less adherent to m atrix (M D A wt 87.59±8.94, M DA pef6 
80.03±1 1.66  and M DACL5rib2 38.36±5.35, (p<0.001 for both controls). In the case o f 
M DAc|Sexp, the opposite effect was seen, however differences did not reach statistical 
significance when compared to the controls (M D A wt(87.59±8.94), M DA pef6 
(80 .03±11.66) and M DAcl5exp (96.56±21.85), (p=0.079 and p=0.062 respectively).
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5.3.3 Effect o f Claudin-5 on M DA -M B-231 breast cancer cell invasiveness
The invasive potential of the transfected cells M DAcl5exp and M DACL5nb2 was 
examined using an in vitro M atrigel invasion assay (Figure 5.3). Both cell lines were 
found to have no significant differences when com pared to the controls M DAwtand 
M DApet6. However, a non significant m arginal reduction in the invasive capacity of 
M DACL5nh2 was seen (M DAwt (17± 1.58), M D A pef6(16.4±2.30) and M D A CL5rib2 (15.8 
±1.48, (p=0.25 and p=0.63 respectively).
5.3.4 Effect o f Claudin-5 on M DA-M B-231 breast cancer cell m otility and the 
effect o f H GF
Transfected and control cells, either untreated or treated with HGF, were 
evaluated for their motility using a Cytodex-2 bead m otility assay to explore the 
possibility of Claudin-5 involvement in motility. M D A cl5exp cells did not show 
significant differences when compared to the controls (M D A wt (4.28±1.24), M DApef6 
(3.8±1.25) and M DAcl5exp (3.83±1.37), (p=0.238 and p=0.930 respectively). In 
contrast, M DACL5nb2 cells dem onstrated a significant reduction in cell motility 
compared to the controls (M D Awt (4.28±1.24), M DApef6(3.8±1.25) and M DACL5rib2 
(3.08±0.84), (p<0.001 and p=0.027 respectively). (Figure 5.4 A)
The cells were additionally evaluated after treatm ent with HGF. This 
motogen increased cell m otility in M D A cl5exp and control cells, M D A wt and M DApef6, 
when compared to untreated cells (M D A wt+ H G F(6.44± l .78), M DApef6+HGF 
(5.27±0.98) and M DAcl5exp+H G F (6±1.08), p<0.001 for both controls). In the case of 
M DACL5nb2, although a slight increase in the num ber of m otile cells was observed,
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the data was not found to be significant (M D A CL5nb2+HGF (3.65±1.84), p=0.18) 
(Figure 5.4 B).
5.3.5 Effect o f Claudin-5 on M DA -M B-231 breast cancer cell m igration
The effect of Claudin-5 over-expression and knockdown on cell m igration 
was assessed using a migration (wound healing) assay. M DAcl5exp showed an 
increased cellular migration compared to the controls 60 minutes after wounding 
(M D A wt (10.84±8.5), M DApef6(18.08± 16.62) and M DAcl5exp (39.64±24.81). A 
decreased cell migration was seen in M D A CL5nb2 after 60 m inutes when compared to 
controls (M D A wt(10.84±8.5), M DApef6 (18.08±16.62) and M D A cl5rib2 (2.66±2.82). 
Although the differences in motility are not statistically significant when comparing 
to the controls, the trend appears to be evident (Figure 5.5).
5.3.6 Effect o f Claudin-5 on M DA -M B-231 breast cancer cell Transepithelial 
resistance (TER) and their response to H G F
Transepithelial resistance was m easured to assess the effect of over­
expressing or knocking-down Claudin-5 on TJ functionality in M DA-M B-231 breast 
cancer cells. M DAGI5exp showed increased TER over a period of 4 hours in 
comparison with the control M D A wt (change in TER after 30 m inutes M DAwt (- 
2 1 1±1) vs. M DACi5exp (-204±2); 60 m inutes M D A wt(-233.66±0.57) vs. M D A c,5exp (- 
215.66±2.3); 2 hours M DAwt (-244.66±2.88) vs. M DAcl5exp (-244.66.33±0.57); 4 
hours M DAwt (-279.66±1.52) vs. M D A cl5exp (-267±1.73), p<0.01). Changes in TER 
were more evident in M D A CL5nb2 when compare to the control (change in TER after 
30 minutes M DAwt (-211±1) vs. M D A CL5rib2 (-141±16.77); 60 m inutes M DAwt (-
177
244.66±2.88) vs. M DACL5rib2 (-156.6±1.52); 2 hours M DAwt(-279.66±1.52) vs. 
MDAcLSrib2 (_168 66db2); 4 hours M DAwt (-279.66±1.52) vs. M DACL5rib2 (- 
184.66±5.85), p<0.001) (Figure 5.6).
Treatment of cells with HG F (50ng/m l) resulted in a significant reduction of 
the transepithelial resistance in transfected and in control cells when compare to 
untreated cells over a period of 4 hours (change in TER after 30 m inutes 
M DAW|+ H G F(-270±1.5), M DAcl5exp+H G F (-243±1.6), M DACL5rib2+HGF (-169±3.2); 
60 minutes M DAwt+H G F(-286±l .1), M D A cl5exp+H G F (-263.67±1.7), 
M DACL5rib2+HGF (-182.33±2.64); 2 hours M D A wt+H G F(-299±2.08), 
M DAci5exP+HGF ( .2 7 9 * 2 .3 ), M D A CL^ rib2+H G F (-202±2.08); 4 hours M DAwt+HGF (- 
340±1.1), M DAcl5exp+HGF (-299.67±1.15), M D A CL5rib2+HGF (-238.67±1), p<0.05) 
(Figure 5.7).
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Figure 5.1: Effect o f Claudin-5 on in vitro  cell growth o f  MDA-MB-231 cells using 
an in vitro cell growth assay. The cell growth o f  M DAclSexp and M DACL5nb2 did not 
show any significant difference when compared to MDA"* and M DA1**6 (mean ±SD, 
n=3).
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MDA WT MDA pEF6 MDA CL5exp MDA CL5rib2
Figure 5.2: Effect o f  Claudin-5 on in vitro cell adhesion o f  MDA-MB-231 cells using 
the in vitro Matrigel adhesion assay. The data presented is representative is the mean 
o f  at least 3 independent repeats and the error bars represent the standard error o f the 
mean. The adhesive capacity o f  M DACL5r,b2 was significantly decreased in 
comparison with the controls M D A ^ and M DA1*5*6 (** represents p<0.001 compared 
to both controls).
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MDA WT MDA pEF6 MDA CL5exp MDA CL5rib2
Figure 5.3: Effect o f  Claudin-5 on cell invasiveness o f  MDA-MB-231 cells using the 
in vitro Matrigel invasion assay. The data presented is representative is the mean o f 
at least 3 independent repeats and the error bars represent the standard error o f  the 
mean. The invasive capacity o f  M DAcl5exp and M DACL5nb2 did not show any 
significant difference when compared to MDA''* and MDA**®3.
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Figure 5.4: (A) Effect o f  Claudin-5 on in vitro cell m otility o f  MDA-MB-231 cells. 
The motility o f  MDACL5nb2 was significantly reduced in comparison to the controls 
(p<0.001 and p=0.027 respectively). (B) Effect on m otility after treatm ent with HGF. 
Transfected and control cells showed an increase in motility, however only the 
controls and MDAcl5exp results were significant (p<0.001). The data presented is 
representative is the mean o f  at least 3 independent repeats and the error bars 
represent the standard error o f  the mean.
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Figure 5.5: Effect o f Claudin-5 on in vitro cell migration o f  MDA-MB-231 cells. 
M DAcl5exp cells showed an increase in migration when compared to the controls 60 
minutes after wounding. The m igration o f  M DACL5nb2 was reduced in comparison to 
the controls at 60 minutes. However, no significant differences were found (mean 
±SD, n=3).
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Figure 5.6: (A) Effect o f  Claudin-5 on transepithelial resistance o f  MDA-MB-231 
cells. Significant changes were seen in M DAc,5exp and M DACL5nb2 over a period o f  4 
hours when compared to the control (p<0.01 and p<0.001 respectively). (B) A 
polynomial model was used to visualize the trend o f  the presented data. R2 indicates 
that the regression line clearly fits the data (mean ±SD, n=3).
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Figure 5.7: Effect o f  Claudin-5 on transepithelial resistance o f  MDA-MB-231 cells 
after treatment with HGF. Significant changes were seen on transfected and control 
cells over a period o f 4 hours when compared to the untreated cells (p<0.05) (mean 
±SD, n=3).
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5.3.7 Effect of Claudin-5 on M DA-M B-231 cell attachm ent to, and migration 
across an electrode
Electric Cell Impedance Sensing (ECIS) was used to monitor differences in 
attachment and migration following w ounding between transfected and control cells. 
This was done by culturing cells on small gold electrodes, applying AC current and 
m onitoring resistance changes caused by the adhesion or migration of cells onto the 
electrode. The cells were analysed for their adhesive capacity and migration after 
wounding to a gold electrode in real-time m easurem ents using a Two-W ay ANOVA 
test. This test was used as it enables the com parison of two groups, transfected cells 
vs. control, on two variables, time vs. treatm ent with inhibitors or HGF.
M DAcl5exp showed a significantly enhanced adhesive capacity compared to 
the control M DAwt (p=0.041). In the case o f M D A CL5nb2, the opposite effect was seen, 
as these cells displayed reduced adhesive capacity (p=0.002) (Figure 5.8 A).
W hile recovering after wounding (5V AC for 30 seconds), the transfected 
cells showed different patterns of m igration when compared to the control. The 
M DAcl5exp cells were significantly m ore m otile (p<0.001), whereas the opposite trend 
was seen in M DACL5nb2, where a significant reduction in migration was seen when 
compared to M DAWT p<0.001) (Figure 5.8 B).
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Figure 5.8: (A) Effect o f  Claudin-5 on the adhesion o f  MDA-MB-231 cells using 
ECIS. Significant differences were seen in transfected cells when compared to the 
control. MDAc,5exp showed a significantly enhanced adhesive capacity (p=0.041), 
however in MDACL5nb2 cells adhesion was significantly decreased (p=0.002). (B) 
Significant differences were seen after wounding, M DAcl5exp displayed increased 
migration, whereas the opposite effect was seen in M DACL5nb2 (p<0.001, n=3).
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5.3.8 Effect o f Claudin-5 on M DA-M B-231 cell m igration over an electrode and 
the effect o f pro- and anti-m otility agents
The Electric Cell Impedance Sensing (ECIS) m ethod was used to investigate 
the impact of HGF, the N-W ASP inhibitor (W iskostatin), the Arp2/3 inhibitor (CK- 
0944636) and the ROCK inhibitor (Y-27632) on the m otility of the transfected 
M DA-M B-231 cells. The cells were analysed for m igration rate across a gold 
electrode following wounding, in real-tim e m easurem ents using a Two-W ay 
ANOVA test.
Following electrical wounding (5V AC for 30 seconds) and treatm ent with 
HGF and motility inhibitors, diverse responses in cell m igration were observed. The 
transfected and control cells treated with H G F (50ng/m l), showed different rates of 
migration compared to the untreated cells. The m igration of the control, 
MDAwt+HGF, and transfected cells, M D A c,5exp+HG F and M D A CL5r,b2+HGF, was 
significantly enhanced after 5 hours o f treatm ent (p<0.001, p<0.001 and p=0.003 
respectively) (Figure 5.9).
W hen cells were treated with the N -W A SP inhibitor (50pM ), the migration 
rate of M DAwt+N-W ASP, M DAcl5exp+ N -W ASP and M D A CL5rib2+ N-W ASP was 
markedly reduced after 5 hours o f treatm ent when com pared to untreated cells 
(p<0.001, p=0.006 and p=0.018 respectively) (Figure 5.10).
Treatment of cells with the Arp2/3 inhibitor (lOnM ) adversely affected the 
motility of the M DAwt+Arp2/3 and the transfected cells, M D A cl5exp+ Arp2/3, when 
compared to untreated cells after w ounding (p<0.001 respectively). Surprisingly,
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MDACL3nb2+ Arp2/3 did not show a significant reduction in migration after treatment 
(p=0.06) (Figure 5.11).
The ROCK inhibitor (50nM ) was capable o f altering the m otility of 
M DAw,+ROCK when compared to the untreated cells (pcO.OOl). However, no 
significant differences were found in the transfected cells, M D A cl5exp+ ROCK 
M DAcl5exp+ ROCK, when compared to the untreated cells (p=0.403 and p=0.072 
respectively) (Figure 5.12).
All the results are summarized in Table 5.1.
5.3.9 Effect o f Claudin-5 on protein levels o f  N-W A SP and ROCK 1 and their 
interaction
M DAwt, M DAcl5exp and M DA CL5nb2 W estern blotting dem onstrated very low 
levels of the N-W ASP at protein level. Protein levels of RO CK  1 revealed similar 
high levels in the transfected and control cells (Figure 5.13 A).
Imm unoprecipitation of Claudin-5 followed by im m unoblotting with N- 
W ASP and ROCK 1 showed a protein-protein interaction betw een Claudin-5 and 
these motility-related proteins in M D A wt and M D A cl5exp (Figure 5.13 B). In keeping 
with this, immunoprecipitation with either N -W ASP (Figure 5.13 C) or ROCK1 
(Figure 5.13 D) followed by im m unoblotting with Claudin-5 produced consistent 
results.
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5.3.10 Effect o f Claudin-5 on M DA-M B-231 breast cancer cell tum our growth in
vivo
The growth and capability of developing tum ours of M DAG15exp in an in vivo 
model was examined and compared to the control M D A pef6 cells after subcutaneous 
injection into the athymic nude m ouse model. Over the period o f 33 days, no 
significant difference was observed betw een the two groups, the control (injected 
with M DApef6) and those injected with M D A cl5exp (p=0.291) (Figure 5.14).
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Figure 5.9: Effect o f Claudin-5 on MDA-MB-231 cell migration following treatment 
with HGF using ECIS. Migration was significantly increased in MDA^+HGF, 
MDAcl5exp+HGF and MDACL5nb2+HGF when compared to untreated cells (p<0.001, 
p<0.001 and p=0.003 respectively, n=3).
191
t.t,
1
.4
1 3S
125
3
1 IS
Tim e (hra)
»-
1 25
1 2
1 15
1.1
1 05
MDA + N-W ASP1
O 95
°  9O O 5 1 5 3 5 4 51 3 4 5
Figure 5.10: Effect ofClaudin-5 on MDA-MB-231 cell migration following 
treatment with N-WASP inhibitor using ECIS. M igration was significantly decreased 
in MDA^-H N-WASP inhibitor, MDAcl5exp+  N-W ASP inhibitor and M DACL5rib2+ N- 
WASP inhibitor when compared to untreated cells (p<0.001, p=0.006 and p=0.018 
respectively, n=3).
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Figure 5.11: Effect o f  Claudin-5 on MDA-MB-231 cell m igration following 
treatment with Arp2/3 inhibitor using ECIS. M igration was significantly decreased in 
MDAwt+Arp2/3 inhibitor and M DAc,5exp+Arp2/3 inhibitor (p<0.001 respectively). 
MDACL5nb2+Arp2/3 inhibitor did not show significant differences when compared to 
untreated cells (p=0.06, n=3).
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Figure 5.12: Effect o f  Claudin-5 on M DA-M B-231 cell m igration following 
treatment with ROCK inhibitor using ECIS. M igration was significantly decreased in 
M D A ^  ROCK inhibitor (p<0.001). M DAc,5exp+ ROCK inhibitor and M DACL5rib2+ 
ROCK inhibitor did not show significant differences when com pared to untreated 
cells (p=0.403 and p=0.072 respectively, n=3).
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Migration
rate
HGF N-W ASPinhibitor
Arp2/3
inhibitor ROCK inhibitor
vs. untreated vs. untreated vs. untreated vs. untreated
M D A '"
Increased
PO.OOl
Reduced
PO.OOl
Reduced
PO.OOl
Reduced
PO.OOl
MDACL5“ P
Increased
PO.OOl
Reduced
P=0.006
Reduced
PO.OOl
No effect 
P=0.403
MDACL5rib2
Increased
P=0.003
Reduced
P=0.018
N o effect 
P=0.06
No effect 
P=0.072
Table 5.1: Data summarising ECIS results o f  transfected and control MDA-MB-231 
cells after treatments.
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Figure 5.13: (A) Expression of N-W ASP and RO CK 1 in transfected and control 
cells. (B) Co-immunoprecipitation of Claudin-5 with N-W ASP and RO CK  1. (C) 
Co-immunoprecipitation of N-W ASP with Claudin-5. (D) Co-im m unoprecipitation 
of ROCK 1 with Claudin-5.
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Figure 5.14: Effect o f  Claudin-5 on in vivo  tum our developm ent. There w ere no 
significant differences between M D A cl5expand M D A ^  using Tw o-W ay A N O V A  
test (p=0.29), indicating that C laudin-5 has no direct effect on tum our developm ent.
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5.4 Discussion
The disruption o f the T ight Junction  (T J) s tructure is a com m on feature of 
m any hum an cancer cells. D ow nregulation o f d iffe ren t TJ pro teins has been linked 
w ith stag ing  and m etastatic po tential in various cancers includ ing  breast (H oover et 
al., 1998). In addition, in vivo  and in vitro  data has revealed  that over-expression  of 
TJ pro teins in cancer cells, such as C laud in -4 , leads to a decrease in invasiveness and 
m etastases in anim al m odels (M ichl e t al., 2003). S im ilar conclusions w ere found 
w hen cells breast cancer cells overexp ressing  C laud in -16 , show ed a decrease in 
invasiveness and m otility (M artin et al., 2008a). T hese stud ies have provided  
p rom ising  evidence that TJ proteins m ight serve as usefu l m olecu lar targets in the 
p rognosis o f cancer. In this study, w e used ce lls transfected  w ith C laudin-5  
expression  sequence and ribozym e transgenes to assess the im pact o f reducing  the 
expression  o f our protein of interest as w ell as enhancing  it in order to evaluate 
changes in the aggressive nature o f M D A -M B -231  cells. T he o ther purpose o f the 
study w as to establish a possible link  betw een C laudin-5  and m otility  o f  the cells. 
T his w as done as the initial results suggested  that C laudin-5  m ight p lay  a role in cell 
m otility , not ju s t functioning as a sim ple sea ling  pro tein  in the TJ structure.
In itially , we questioned the role o f C laudin-5  w hen transepithelia l electric 
resistance (TER ) was m easured. T ran sep ith e lia l e lec tric  resistance (TER ) is the 
easiest and m ost sensitive m easure  o f  barrier strength . M D A CL5nb2 show ed the 
h ighest resistance, w hereas the resistance  o f M D A cl5exp and the control w ere low er 
and follow ed the sam e trend, a lthough M D A cl5exp w as sign ifican tly  h igher than 
control cells. These pre lim inary  resu lts revealed that C laudin-5  w as not p lay ing  a real
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role in keeping the cell barrier tight. In fact, the com pensation of the lack of Claudin- 
5 could be balanced with one of the other 23 m em bers of the Claudin family which 
m ight alter the barrier strength, therefore explaining why the knockdown cells 
displayed higher transepithelial resistance. The sam e explanation could be applied to 
forced-expression and the very sim ilar trends that it shared with the control cells.
The involvement of Claudin-5 in cell growth was tested, although there 
appeared not to be an involvement of Claudin-5 in cell growth. Cell adhesion to 
extracellular matrix is fundamental in the organization of the epithelium  as a 
continuous layer but also in the regulation of m any cellular processes such as 
m otility (Chlenski et al., 1999). M D A CL5nb2 dem onstrated a decrease in adhesion 
whereas M D A cl5exp appeared to increase adhesion when compared to the control cells, 
although these results did not reach significance. Integrins are described as being the 
“eyes’'’ o f  cancer cells in identifying their surrounding extracellular matrix (ECM ), 
and they participate in the m aintenance o f positional stability in normal epithelia; in 
breast cancer however, different studies have linked integrins with metastasis 
(Felding-H aberm ann et al., 2001). The question therefore arises as to whether the 
absence o f Claudin-5 in a cell alters levels o f integrins and other adhesion-related 
proteins, thus changing the adhesion o f the cancer cell when compared to the control. 
The results obtained when the ability to adhere to a gold electrode trough ECIS 
technology was measured in real tim e agreed with the in vitro function assay. Once 
again, Claudin-5 knockdown appears to have the lowest adherence (as in the 
M atrigel experiments) to .the gold electrode. The invasiveness of the cells through the 
ECM  did not show any relevant differences between cells over-expressing or
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knocking-down levels of Claudin-5. This result agrees with the data obtained in the 
in vivo experiments, where the M DAcl5exp cells were analysed for their ability to 
grow and develop in nude mice. Over a period of one month, no differences were 
found between the two groups of anim als, the control (injected with M DApef6) and 
those injected with M DAcl5exp.
Taking these results together, we began to speculate whether Claudin-5 might 
be involved in cell motility. We perform ed a further set of experim ents to assess the 
level of involvement of Claudin-5 in breast cancer motility. As breast cancer cells 
acquire a motile phenotype, this is translated into changes in highly dynamic 
structures like actin filaments and cytoplasm ic m icrotubular complex (Insall and 
Jones, 2006). W e decided to investigate the effects on m otility of over-expression or 
knockdown of Claudin-5. To achieve this, an in vitro m otility assay and a traditional 
wound healing assay was carried out, both revealing that M D A CL5nb2 showed a 
reduction in motility. Moreover, ECIS was used in order to m easure in real time how 
fast cells migrate after wounding. Sim ilar results were obtained; M D A CL5nb2 was 
indeed slower when compared to the control. However, M D A cl5exp cells were the 
fastest in each of the assays m entioned above and their capability to adhere to the 
electrode was increased, agreeing with the prelim inary results obtained when the in 
vitro  adhesion assay was performed.
Until now, we have shown that knockdown of Claudin-5 expression in a 
breast cancer cell line resulted in a less adhesive and less motile cell phenotype when 
compared to controls. The opposite was seen when Claudin-5 expression was forced, 
resulting in a more adhesive and more motile phenotype but with no differences in
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invasiveness in vivo and in vitro. W e m ight tentatively conclude from this that 
Claudin-5 might be a motility regulator, or at least have a role in the motility of these 
human breast cancer cells.
The M etastasis and Angiogenesis Research Group has carried out a 
significant body of work on the role and effect of HG F in epithelial cancer cells.
HGF is a powerful motogen able to prom ote proliferation, invasion, and migration of 
epithelial cells by binding to its tyrosine kinase receptor c-m et (Jiang et a l ,  2005) as 
well as m odulating expression and function o f TJ m olecules in human breast cancer 
cell lines and decreasing trans-epithelial resistance (M artin et al., 2004a). Cells 
displaying enhanced or suppressed expression o f Claudin-5 respond in keeping with 
the well established effect after treatm ent with HGF, showing reduced epithelial 
resistance and increased motility. ECIS experim ents corroborated these results.
To address the possibility that Claudin-5 m ight play a role in regulating cell 
m otility, different m otility-regulators were studied in order to search for any possible 
links between Claudin-5 and a range of m otility-related proteins. Cell motility was 
analysed using ECIS after being treated with different m otility inhibitors. In 
particular the N-W ASP inhibitor (W iskostatin), the Arp2/3 inhibitor (CK-0944636) 
and the ROCK inhibitor (Y-27632) responded in an unexpected way in our 
transfected cells. Neuronal W iskott - A ldrich syndrom e protein, N-W ASP, is 
ubiquitously expressed in m am m alian tissues and it is responsible for connecting 
several signalling pathways to the initiation o f actin assem bly via the Arp2/3 
complex. N-W ASP has been reported to exist in a self-folded auto-inhibited 
conformation. W hen activated, conform ational changes occur facilitating the
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interaction with the Arp2/3 complex and subsequent nucleation. In other words, the 
Arp2/3 complex acts as a pattern for the elongation of the actin microfilaments 
(Dovas and Cox, 2010). The Rho-associated serine-threonine protein kinase, ROCK, 
is ubiquitously expressed in m am malian tissues and it is directly linked, after 
activation, with numerous processes related to actin-m yosin, such as actin 
cytoskeletal reorganisation and the form ation of focal adhesions. It also has an 
im portant role in cell migration by prom oting the contraction of the cell body and is 
required for tail retraction in cancer cells (Lane et al., 2008). The transfected and 
control cells were treated with the N -W A SP inhibitor, responsible for stabilising the 
auto-inhibited conformation of the N -W A SP protein (Guerriero and W eisz, 2007), 
and their rate of speed was measured using ECIS after wounding. Results showed an 
inhibition in their motility, however, this inhibition was m arginally reduced in 
knockdown cells. The Arp2/3 inhibitor, responsible for blocking the active 
conform ation of the complex (Nolen et al., 2009), was able to inhibit cell motility in 
the control cells and in cells over-expressing Claudin-5. However, to our surprise, 
Arp2/3 was no longer able to inhibit m otility in the knockdown cells. The effect of 
the RO CK inhibitor (Y-27632) was also studied in our cells. The inhibitor specificity 
is, however, questioned as in vitro studies revealed that it not only exerts an 
inhibitory effect on ROCK proteins but on other kinases also (Grise et al., 2009). 
Nevertheless, the control cells responded to its inhibition showing a lower rate of 
m igration; conversely both transfected cells did not respond to its inhibitory effects. 
Thus far we have shown that the absence o f Claudin-5 clearly caused an alteration in 
cell motility as the Arp2/3 and RO CK  inhibitors were no longer inhibiting cell 
motility in M DACL5nb2. Additionally, in the case of M DACL5nb2 cells treated with N-
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W ASP inhibitor, we observed some inhibition, but at a considerably reduced manner 
compared to N-W ASP inhibitor in control and M D A G15exp cells.
The next question to be addressed follow ing the ECIS results, was to 
investigate any possible protein-protein interaction between Claudin-5 and N-W ASP 
or Claudin-5 and ROCK 1 as well as whether any direct effect was occurring at the 
protein level of these molecules in the control and transfected cells. Co- 
imm unoprecipitation with Claudin-5, followed by im m unoblotting with either N- 
W ASP or ROCK 1 demonstrated an interaction betw een Claduin-5 and N-W ASP as 
well as with ROCK 1. To confirm these interactions, a co-im m unoprecipitation with 
either N-W ASP or ROCK 1 followed by im m unoblotting with Claudin-5 was carried 
out confirm ing the interactions between these protein pairs. Previously, studies have 
already linked TJ with N-W ASP and the A rp2/3 complex. The intestinal epithelial 
cells, T84, when treated with N -W ASP inhibitor showed an inhibition in the 
form ation o f TJ (Ivanov et al., 2005). A  m ore recent study using Sertoli cells linked 
the inhibition of N-W ASP, and therefore the inhibition of Arp2/3, in the nucleation 
process with barrier disruption in the blood-testis barrier causing a failure of 
sperm atic transit (Lie et al., 2010). N -W A SP protein in M DA-M B-231 cells has been 
reported to be expressed at a very low level (M artin et al., 2008b). The results 
obtained in the current study agree. The levels of RO CK 1 did not show any real 
differences among transfected and control cells, this possibly could be due to the 
high level of this protein found in M DA-M B-231 wild type cells as already reported 
(Lane et al., 2008).
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This study suggests that Claudin-5 m ight be involved in cancer cell motility; 
in particular, it appears to be involved in the signal pathway of N-W ASP and ROCK. 
However, understanding cell m otility requires detailed knowledge not only of the 
signalling networks, but also about their dynam ics. Unfortunately, some of the 
signalling pathways are only just starting to be analysed and we clearly still have a 
great deal to learn about cell m otility, particular in cancer cells. This possible new 
role of Claudin-5 in breast cancer cell m otility opens the door to future studies in 
which Claudin-5 and therefore TJ m ight switch from  static structures to very 
dynam ic ones, and offers an exciting glim pse into how m odulation of transmembrane 
TJ proteins could be targeted in cancer m etastasis.
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Chapter 6
Effect of Claudin-5 expression on HECV 
human endothelial cells
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6.1 Introduction
Epithelial and endothelial cell m onolayers form barriers that seal the 
intercellular space between neighbouring cells and transform  the layer of individual 
cells into an effective permeability barrier. T ight Junctions (TJs) are highly regulated 
areas o f adhesion between epithelial and endothelial cells. A  key step in metastasis is 
the interaction and penetration of the vascular endothelium  by dissociated cancer 
cells. Tum our cells have to invade the surrounding tissues, reach the endothelial 
barrier and penetrate the barrier to escape and enter the bloodstream. Therefore, TJ, 
as the first barrier that cancer cells m ust overcom e in order to m etastasise, have 
emerged as an essential structure in the prevention of cancer metastasis.
C laudins are members of the netw ork of proteins that constitute the TJ 
structure. The primary role of Claudins is in the regulation of paracellular selectively 
to small ions through the pores that they them selves are capable o f form ing (Tsukita 
and Furuse, 2000). However, recent results have challenged the idea that Claudins 
function only as sealing proteins. C laudins have now been shown to be involved in 
cellular growth and in epithelial-m esenchym al transition (EM T) (Ohkubo and Ozawa, 
2004). These results suggest that C laudins play m ultiple roles beyond acting as a 
“doorm an” in the paracellular barrier opening a new avenue o f  research.
The present study used the H ECV endothelial cell line and, following forced 
expression and knockdown of C laudin-5, examined the cellular biological functions 
in response to Hepatocyte Growth Factor (HGF) in order to clarify the role of
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Claudin-5 and to investigate a possible link with m otility-related proteins in 
endothelial cells.
6.2 M aterials and methods 
6.2.1 Cell line
The HECV endothelial cell line was used in this study to investigate the 
effect of Claudin-5 in transfected cell lines H E C V cl5exp and H ECV GL5nb2, including 
H ECV wt and HECVpef6. Cells were continuously m aintained in DM EM -F12 media as 
described in section 2 .2 .
6.2.2 In vitro cell growth assay
The cells were seeded into four 96 well plates and incubated for a broad 
range of hours as described in section 2.6.1. A bsorbance was m easured in order to 
determ ine cell number.
6.2.3 In vitro cell M atrigel adhesion assay
The cells were seeded into a 96 well plate containing a layer o f M atrigel as 
described in section 2.6.3. The num ber o f cells adhered to the artificial basem ent 
m em brane was counted.
6.2.4 In vitro tubule form ation assay and the effect o f pro- and anti-m otility  
agents
The cells were seeded into a 96 well plate containing a layer o f Matrigel.
After incubation another layer of M atrigel was added on top as described in section
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2.6.7. The tubule perimeter was m easured. The sam e protocol was followed when 
cells were treated with HGF and m otility-related inhibitors.
6.2.5 In vitro cell motility assay using C ytodex-2 beads and the effect o f HGF
The cells were incubated with Cytodex-2 beads as described in section 2.6.4. 
The number of cells that were carried by the beads and moved from  the beads to the 
base of the well was counted. The sam e protocol was followed w hen cells were 
treated with HGF.
6.2.6 In vitro cell m igration (wound healing) assay
The m igration of HECV cells across a wounded surface o f a confluent 
m onolayer form ed by the same cell line was exam ined as described in section 2.6.5.
6.2.7 Transendothelial resistance and the effect o f H GF
The cells were seeded into transparent inserts and the resistance across the 
layer was m easured as described in section 2.7.1. The sam e protocol was followed 
when cells were treated with HGF.
6.2.8 ECIS
The cells were seeded into electrical arrays allow ing the cells to adhere to the 
gold electrodes within the array as described in section 2.7.2 causing a change in 
resistance followed by electrical w ounding of the formed monolayer. The same 
protocol was followed when cells w ere treated with HGF and m otility-related 
inhibitors.
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6.2.9 Analysis o f protein levels o f N -W A SP and R O C K  1 using W estern blotting. 
Claudin-5 co-im m unoprecipitation for N -W A SP and R O CK  1
W estern Blotting was used to see levels o f expression of N-W ASP and 
ROCK 1 as described in section 2.5. Claudin-5 co-im m unoprecipitation was carried 
out using cell lysates of HECV wt and H E C V cl5exp and probed with antibodies against 
N-W ASP and ROCK 1 as described in section 2.5.1.6. N-W ASP and ROCK 1 co- 
imm unoprecipitation was carried out as described above and probed with antibodies 
against Claudin-5.
6.2.9 In  vivo tum our growth and developm ent
The impact of Claudin-5 on tum our growth was assessed in an in vivo system 
as described in section 2 .6 .8 ., where a broad num ber o f factors may influence the 
effects of over-expression of Claudin-5 in this particular developm ent model. In this 
model, breast cancer cells were co-injected with endothelial cells that had a different 
Claudin-5 expression profile, in order to assess the contribution of claudin-5 in 
endothelial cell to the growth of breast tum ours.
6.3 Results
6.3.1 Effect o f altering C laudin-5 expression on H ECV cell growth
The effect of suppressing and over-expressing Claudin-5 expression on the 
growth o f the H ECV endothelial cell line was examined following 1,3 and 4 day 
incubation periods using an in vitro  cell growth assay (Figure 6.1). No significant
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differences in cell growth rate between H EC V wt, H ECV pef6 and HECVcl5expor 
HECVCL5nb2 were seen in any of the incubation periods. However, the growth rate of 
HECVCISexp was reduced in each of the m easurem ents when compared to H ECVwt 
and H ECV pef6; day 1 HECVwt(52% ±38.15), H ECV pef6 (57.01% ±8.96) and 
HECVcl5exp (26.65%±21.30), ( p=0.29 and p=0.069 respectively); day 3 HECVwt 
(497.19% ±68.86), HECV pef6 (487 .41% ±31.35) and H ECV cl5exp (459.90% ±84.77),
( p=0.52 and p=0.06 respectively); day 4 H E C V wt (705.85% ±96.32), 
HECV pefA(735.95% ±57.84) and H ECV cl5exp (702.72% ± 142.90), ( p=0.97 and p=0.69 
respectively). The opposite effect was observed in the incubation period day 3 and 
day 4 o f HECV CL5nb2 where the cell growth w as increased when com pared to the 
controls; day 3 HECVwt (497.19% ±68.86), H EC V pef6 (487 .41% ±31.35) and 
HECV CL5rib2 (567.52% ±36.55), (p=0.12 and p=0.44 respectively); day 4 HECVwt 
(705.85% ±96.32), HECVpef6 (735.95% ±57.84) and HECV CL5rib2 (736.62.72% ±36.92), 
(p=0.68 and p=0.98 respectively).
6.3.2 Effect o f Claudin-5 on H E C V  cell adhesion
The adhesive capacity of H E C V cl5exp and H ECV GL5nb2 cells to adhere to 
matrix was analysed in an in vitro M atrigel adhesion assay (Figure 6.2). There was a 
significant difference between the adherence o f H EC V cl5exp and H ECV wt and 
H ECV pefA with H ECV cl5exp cells being less adherent to m atrix (HECVwt (87.68±7.09), 
H ECV pef6(80.2± 15.99) and H EC V cl5exp (19.66±3.33), (p<0.001 for both controls). In 
the case o f H ECV GL5nb2, no significant differences were found when compared to the 
controls (HECVwt (87.68±7.09), H ECV pef6 (80.2±15.99) and HECV CL5rib2 
(88.94± 13.50), (p=0.743 and p=0.087 respectively).
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6.3.3 Effect of Claudin-5 on HECV cell tubule formation
The angiogenic potential of the untreated cells H ECV wt, HECV pef6 
HECVcl5exp and HECVGL5nb2 alongside cells treated with the pro-m otility and 
angiogenic factor HGF and m otility inhibitors (against N-W ASP, RO CK and Arp 
2/3) and a combination of both agents was assessed using an in vitro  M atrigel tubule 
formation assay. Untreated HECV cells form ed tubule structures (Figure 6.3); 
however significant differences were found in the transfected cells when compared 
with controls. HECV CI5exp dem onstrated a significant decrease in tubules when 
compared to H ECV wt and HECV pef6 (H EC V wt (4050.03±220.67), H ECV pef6 
(4102.978±585.82) and HECVcl5exp (654±686.13), (p<0.001 for both controls). The 
opposite effect was observed in H E C V CL5nb2 where a significant increase in tubules 
was seen when compared to H ECV wt and H E C V pef6 (H ECV wt (4050.03±220.67), 
H ECV pef6 (4102.978±585.82) and H E C V CL5rib2 (5749.93±873.24), p<0.001 for both 
controls).
Treatm ent with HGF (50ng/m l) positively affected the capability of these cell 
lines to form tubules (Figure 6.4). Follow ing quantification of tubule perim eter, a 
significant increase in tubules was observed in com parison to untreated control. 
Control cells displayed a significant increase in tubules when compared to untreated 
cells, H EC V wt+HGF (H EC V wt (3 9 1 1.60±457,09) and HECV wt+HGF 
(6252.46±373.39), HECV pef6+H G F (H EC V pef6 (4224.74±375.06) and 
HECV pef6+HGF (5616.23±990.80) (p<0.001 for both controls). H ECV cl5exp 
dem onstrated a significant increase in tubules when compared to H ECV cl5exp+HGF 
(H ECV cl5exp (344±751.07) and H EC V cl5exp+HGF (664.26±240.58), (p<0.005). A
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sim ilar response to HG F was observed in H E C V CL5nb2, where significant differences 
were found when compared to H E C V CL5rib2+H G F (H EC V CL5rib2 (5690.70±383.33) 
and H E C V CL5rib2+HGF (7556±244.09), (p<0.001).
Follow ing treatm ent with m otility inhibitors, diverse responses were observed 
in these cells. W hen cells were treated w ith the N -W A SP inhibitor (50pM ) (Figure
6.5), control cells displayed a significant decrease in tubules when compared to 
untreated cells, H EC V w,+N-W ASP (H EC V wt (3911 .60±457.09) and HECVwt+N- 
W ASP (3034.54±197.42), H ECV pef6+N -W A SP (H EC V pef6 (4224.74±375.06) and 
H ECV p"f6+N -W A SP (3 140.45±69.58) (p<0.001 for both controls). H EC V cl5exp had 
significantly decreased levels of tubule form ation com pared with untreated cells 
(H ECV cl5exp (344.93±383.33) and H E C V cl5exp+N -W A SP (155.03±69.58), p=0.045). 
However, although H ECV GL5nb2 dem onstrated a reduced num ber o f tubules 
com pared to untreated cells, the data w as not statistically significantly different 
(H ECV CL5rib (5690.70±383.32) and H EC V CLJ5rib+N -W A SP (5347.18±307.06), 
p=0.052). Treatm ent o f these cells w ith A rp2/3 inhibitor (lOnM ) adversely affected 
the capability to form tubule structures in the control cells, H ECV wt+ Arp2/3 
(H EC V wt (391 1.60±457.09) and H E C V wt+ A rp2/3 (3108.92±212.12), H ECV pef6+ 
Arp2/3 (H EC V pef6 (4224.74±375.06) and H EC V pef6+ Arp2/3 (3222.42±193.95) 
(p<0.001 for both controls), and transfected cells H ECV cl5exp and H ECV CL5nb (Figure
6 .6 ). H ow ever, from the transfected cells only H EC V GI5exp displayed significant 
differences when com pared to untreated cells (H EC V cl5exp (344.93± 251.07) and 
H EC V cl5exp+Arp2/3 (9 5 .1 12± 51.4 l), p<0.001). Conversely, HECVCL5nb did not 
show significant d ifferences when com pared to treated cells (H ECV CL5r,b 
(5690.70±383.32) and H E C V CL5rib+A rp2/3 (5396.65±288.53), p=0.084). ROCK
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inhibitor (50nM ) was also capable o f altering the ability of these cells to form tubules 
(Figure 6.7). Sim ilar to the effect o f the above m entioned inhibitors, control cells and 
H ECV cl5exp had significantly decreased tubule form ation when compared with 
untreated cells, HECVwt+ ROCK (H EC V wt (3911.60±457.09) and HECVwt+ ROCK 
(2754.10±394.93), HECVpef6+ RO CK  (H EC V pef6 (4224.74±375.06) and HECVpef6+ 
ROCK (3134.94.42± 142.27) (p<0.001 for both controls), H ECV cl5exp 
(344 .93±251.07) and HECVcl5exp+RO CK  (126.62±82.93), p<0.05). In the case o f 
H ECV CL5rib2 however, although there was a slight reduction in the number of tubules 
form ed, the data was not found to be significant (H EC V CL5nb (5690.70±383.32) and 
H ECV CL5rib+ROCK (5412.67±289.08), p=0.133).
H aving established the im pact of the m otility inhibitors and HG F on these 
cell lines, we exam ined the com bination o f these agents with HGF. Cells treated with 
a com bination o f HGF/N-W ASP inhibitor showed differences in the num ber of 
tubules form ed. The control cells treated with HG F/N -W A SP inhibitor revealed a 
decrease in the num ber of tubules form ed w hen com pared with untreated and HGF 
treated cells (H EC V wt(3911.60±457.09), H EC V wt+HGF (6252.46±323.35) and 
H ECV wt+HG F/N -W A SP (3909.50±329.10), (H EC V wt vs. HECV wt+HGF/N-W ASP 
p=0.68, and H ECV wt+HGF vs. H E C V w,+H G F/N -W A SP p<0.001); 
(H EC V pefb(4224.74±375.06), H EC V pef6+HGF (5612.23±410.80) and 
H EC V pef6+HG F/N -W A SP (3839.36±247.41), (H EC V pef6 vs. HECV pef6+HGF/N- 
W ASP p=0.02, and H ECV pef6+H G F vs. H EC V pef6+HGF/N-W ASP p<0.001). 
H ECV cl5exp cells treated with H G F/N -W A SP inhibitor also revealed a decrease in the 
num ber of tubules form ed com pared with untreated and HG F treated cells 
(H ECV cl5exp (344 .93±251.07), H ECV cl5exp+HGF (664.26±240.58) and
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H E C V cl5exp+HGF/N-W ASP (247.10±93.03), (H EC V cl5exp vs. HECV cl5exp+HGF/N- 
W ASP p=0.28, and HECVcl5exp+HG F vs. H E C V cl5exp+HGF/N-W ASP p<0.001). 
H EC V c L5nb cells treated with H G F/N -W A SP inhibitor showed a small reduction in 
the num ber of tubules formed compared with H G F treated cells, however no 
significant differences were seen. Significant differences were found when 
com paring untreated HECVcl^ rib with H E C V CL5rib +HG F/N -W A SP (HECVCL5rib 
(5690.703±383.32), HECVclJrib +HGF (7556.08±244.09) and H EC V CL5rib +HGF/N- 
W ASP (7282 .16±312.05), (HECVCL5rib vs. H E C V CL5rib +HGF/N-W ASP p<0.001, 
and H E C V CL5rib +HGF vs. HECVCLJ5nb +H G F/N -W A SP p=0.054). Control cells, 
H ECV wt and H ECV pef6, show sim ilar behaviour w hen treated with HGF+N-W ASP. 
In both cell lines a significant decrease in the num ber of tubules formed was seen 
(p<0.001) (Figure 6 .8 ).
Treatm ent of HECV with a com bination o f HGF/Arp2/3 inhibitor again 
revealed differences in the num ber o f tubules form ed in the transfected and control 
cells. The control cells treated with H G F/A rp2/3 inhibitor revealed a decrease in the 
num ber o f tubules formed when com pared untreated and H G F treated cells(H ECVwt 
(3911.60±457.09), HECVwt+HG F (6252,46±323.35) and H ECV wt+HGF/Arp2/3 
(3387.59±174.18), (HECVwt vs. H E C V wt+H G F/ Arp2/3 p=0.005, and 
H E C V wt+H G F vs. H ECVwt+H G F/ A rp2/3 p<0.001); (HECV pef6 (4224.74±375.06), 
H EC V pef6+HGF (5612.23±410.80) and H ECV pef6+HGF/ Arp2/3 (3589.01±278.02), 
(H EC V pef6 vs. H ECV pef6+HG F/ A rp2/3 p<0.001, and HECV pef6+HGF vs. 
H EC V pef6+HGF/ Arp2/3 p<0.001).
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H ECV cl5exp cells treated with H G F/A rp2/3 inhibitor displayed a decrease in 
the num ber of tubules formed compared with untreated and HG F treated cells 
(H EC V cl5exp (344.93±251.07), HECVcl5exp+H G F (664.26±240.58) and 
H EC V cl5exp+HGF/Arp2/3 (164.03±33.49), (H EC V cl5exp vs. H ECV cl5exp+HGF/Arp2/3 
p=0.04, and H ECV c,5exp+HGF vs. H E C V c,5exp+HG F/A rp2/3 p<0.001). HECVCL5rib 
cells treated with HGF/Arp2/3 inhibitor showed a small reduction in the number of 
tubules form ed compared with H G F treated cells, however, no significant differences 
were seen. Nevertheless, significant differences were found when com paring 
untreated H EC V CLSrib with H ECV CL5rib +H G F/A rp2/3 (H EC V CL5rib 
(5690.703±383.32), HECVCL5rib +HGF (7556.08±244.09) and H ECV clJ5rib 
+HG F/A rp2/3 (7344.40±307.32), (H EC V CL5rib vs. H EC V CL5rib +HGF/Arp2/3 
inhibitor p<0.001, and H ECV CL5rib +H G F vs. H E C V clJ5rib +HGF/Arp2/3 p=0.12). 
Control cells (H EC V wt and H ECV pef6) exhibited sim ilar behaviour when treated with 
HG F+Arp2/3. In both cell lines, a significant decrease in the num ber of tubules 
formed was seen (p<0.001) (Figure 6.9).
The impact of com bining H G F/R O C K  inhibitor was examined in the 
transfected as well as control cells. The control cells treated with HGF/ROCK 
inhibitor revealed a decrease in the num ber o f tubules form ed when compared 
untreated and H G F treated cells (H EC V wt (3 9 1 1.60±457.09), H EC V wt+HGF 
(6252.46±323.35) and H ECV wt+H G F/R O C K  (3505.72±256.78), (H ECV wt vs. 
H ECV wt+HG F/ RO CK p=0.03, and H E C V wt+HG F vs. H ECV wt+HGF/ ROCK 
p<0.001); (H EC V pef6 (4224.74±375.06), H ECV pef6+HGF (5612.23±410.80) and 
H ECV pef6+HG F/ ROCK (3287.79±73.06), (H EC V pef6 vs. H ECV pef6+HGF/ ROCK 
p<0.001, and H ECV pef6+H G F vs. H E C V pef6+HG F/ ROCK p<0.001). HECV cl5exp
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cells treated with HGF/ROCK inhibitor data displayed a decrease in the number of 
tubules formed compared with untreated and H G F treated cells (HECVcl5exp 
(344 .93±251.07), HECVcl5exp+HGF (664.26±240.58) and HECVcl5exp+HGF/ROCK 
(218.24±60.21), (HECVcl5exp vs. H ECV cl5exp+H G F/ROCK p=0.16, and 
H ECV cl5exp+HGF vs. HECVcl5exp+HG F/RO CK  p<0.001). HECV CL5rib cells treated 
with H G F/RO C K  inhibitor showed a small increase in the number of tubules formed 
com pared with HGF treated cells, however, no significant differences were seen. 
Nevertheless, significant differences were found when comparing untreated 
HECVCL5rib with HECVCL5rib +HG F/ROCK (H EC V CL5rib (5690.703±383.32), 
H ECV c:L5rib +HGF (7556.08±244.09) and H ECV CL5rib +HGF/ROCK 
(7621.91 ±266.025), (HECVCL5rib vs. H ECV CL5rib +HG F/ROCK p<0.001, and 
H ECV CL5rib +HGF vs. HECVCL5rib +H G F/R O C K  p=0.59). Control cells, HECV wt and 
H EC V pef6, revealed similar behaviour when treated with HG F+RO CK inhibitor. In 
both cell lines a significant decrease in the num ber of tubules formed was seen 
(p<0.001) (Figure 6.10).
A ll the results are sum m arized in Table 6.1.
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Figure 6.1: Effect o f  Claudin-5 on in vitro  cell growth o f  HECV cells using the in 
vitro  cell growth assay. The cell growth o f  HECV0565* and HECV^ 5"52 did not show 
any significant difference when compared to HECV"* and HECV1*®5 (mean ±SD, 
n=3).
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Figure 6.2: Effect o f  Claudin-5 on in vitro  cell adhesion o f  HECV cells using the in 
vitro M atrigel adhesion assay. The data presented is representative is the mean o f  at 
least 3 independent repeats and the error bars represent the standard error o f  the 
mean. The adhesive capacity o f  H ECV cl5exp was significantly decreased in 
comparison with the controls HECV"* and HECV 1*16 (** represents p<0.001 for both 
controls).
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Figure 6.3: (A) Effect o f  Claudin-5 on in vitro tubule formation o f  HECV cells using 
the in vitro Matrigel tubule formation assay. The data presented is representative is 
the mean o f  at least 3 independent repeats and the error bars represent the standard 
error o f  the mean. The ability to form tubules o f  HECV0 5 ®*13 was significantly 
decreased in comparison with the controls HECV3* and HECV13®16 (** represents 
p<0.001 for both controls). In contrast, the capacity o f  HECV01'5"52 to form tubules 
was significantly increased when com pared to the controls HECV'* and HECV13®55 
(**p<0.001 for both controls). (B) Representative pictures o f  tubule formation in 
HECV cells.
HECVC L 5nb2
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Figure 6.4: Effect o f  HGF treatment on in vitro tubule formation o f  HECV 
transfected and control cells using the in vitro M atrigel tubule formation assay. The 
data presented is representative is the mean o f  at least 3 independent repeats and the 
error bars represent the standard error o f  the mean. The ability o f  HECV015®5*1’ and 
HECV0 ^ " 152 to form tubules after treatm ent with HGF was significantly increased in 
comparison with the untreated cells (*represents p<0.05 and ** p<0.001).
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Figure 6.5: Effect o f  N-W ASP inhibitor on in vitro tubule formation o f  HECV 
transfected and control cells using the in vitro M atrigel tubule formation assay. The 
data presented is representative is the mean o f  at least 3 independent repeats and the 
error bars represent the standard error o f  the mean. The ability o f  HECV015**1’ and 
HECVOL5nb2to form tubules after treatm ent with N -W A SP inhibitor was reduced in 
com parison with the untreated cells, however, only HECVcl5exp shows significant 
differences (*represents p<0.05).
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Figure 6 .6 : Effect o f  Arp2/3 inhibitor on in vitro  tubule formation o f  HECV 
transfected and control cells using the in vitro  M atrigel tubule formation assay. The 
data presented is representative is the mean o f  at least 3 independent repeats and the 
error bars represent the standard error o f  the mean. The ability o f  HECV°15exp and 
HECVCL5nb2 to form tubules after treatm ent with Arp2/3 inhibitor was reduced in 
comparison with the untreated cells, however, only H ECV °l5exp shows significant 
differences (*represents pO .O O l).
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Figure 6.7: Effect o f ROCK inhibitor on in vitro  tubule formation o f  HECV 
transfected and control cells using the in vitro M atrigel tubule formation assay. The 
data presented is representative is the mean o f  at least 3 independent repeats and the 
error bars represent the standard error o f  the mean. The capability o f  HECVc,5exp and 
HEC to form tubules after treatm ent with ROCK inhibitor was reduced in
comparison with the untreated cells, however, only H ECV°l5exp shows significant 
differences (*represents p<0.05).
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Figure 6 .8 : Effect o f  a combination o f  HG F/N-W A SP inhibitor on in vitro tubule 
form ation o f  HECV transfected and control cells using the in vitro Matrigel tubule 
form ation assay. The data presented is representative is the mean o f  at least 3 
independent repeats and the error bars represent the standard error o f  the mean. 
F ffiC V ^ ^ + H G F /N -W A S P  data revealed a significant decrease in the number o f  
tubules form ed compared to HGF treated cells, however no significant differences 
were found compared to untreated cells (HECVcl5exp vs. HECVcl5exp+HGF/N-W ASP 
p=0.28, and HECVcl5exp+HG F vs. HECVcl5exp+HGF/N-W ASP p<0.001). No 
significant differences w ere found betw een FIECVCL5nb2+HGF and 
FlECVCL5nb2+H G F/N -W A SP p=0.054. Untreated UECVCL5nb2 showed significantly 
less tubules com pared to HECVCL5rib2+HG F/N -W A SP p<0.001.
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Figure 6.9: Effect o f  a combination o f  HGF/Arp2/3 inhibitor on in vitro tubule 
form ation o f  HECV transfected and control cells using the in vitro Matrigel tubule 
formation assay. The data presented is representative is the mean o f  at least 3 
independent repeats and the error bars represent the standard error o f  the mean. 
HECVcl5exp+HGF/Arp2/3 data revealed a significant decrease in the number o f  
tubules formed compared with untreated and HGF treated cells (HECVcl5exp vs. 
HECVc,5exp+HGF/Arp2/3 p=0.04, and H E C V ^ p + H G F  vs.
HECVc,5exp+HGF/Arp2/3 p<0.001). No significant differences where found between 
HECVCL5rib2+HGF and HECVCL5rib2+HGF/Arp2/3 p=0.12 Untreated HECVCL5nb2 
formed significantly less tubules com pared to HECV€L5nb2+HGF/Arp2/3 p<0.001.
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Figure 6.10: Effect o f  a combination o f  HGF/ROCK inhibitor on in vitro tubule 
form ation o f  HECV transfected and control cells using the in vitro Matrigel tubule 
form ation assay. The data presented is representative is the mean o f  at least 3 
independent repeats and the error bars represent the standard error o f  the mean. 
HECVcl5exp+HGF/ROCK data revealed a significant decrease in the number o f 
tubules form ed compared with HGF treated cells, however no significant differences 
were observed in untreated cells (HECVcl5exp vs. HECVcl5exp+HGF/ROCK p=0.16, 
and HECVC5^exp+HGF vs. H E C V ^ ^ + R O C K  p<0.001). No significant differences 
were found between HECVCL5rib2+HGF and HECVCL5rib2+HGF/ROCK p=0.59. 
Untreated HECV€L5nb2 form ed significantly less tubules compared to
H E C V CL5rib2+ H G F / R O C K  p < 0  o o i .
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Table 6.1: Data summarising the results o f tubule formation assay o f transfected and control HECV cells after treatments.
Mean tubule 
perimeter field 
(pm)
HGF N-WASPinhibitor
Arp2/3
inhibitor
HGFN-
WASP
inhibitor
HGF/Arp2/3
inhibitor
HGFROC K 
tub ftiitor
HGF/N
WASP
inhibitor
HGF/Arp2/3
inhibitor
HGF/ROCK
m h tbit o i
\s.
untreated
vs. vs. 
untreated untreated
VS,
untreated
vs. | vs.' „ . vs. 
unnreatfd i untreated j untreated
vs.
HGF
vs.
HGF
vs.
HGF
HECV1"1
Increase
P<0.001
Decrease
P<0.001
Decrease
P<0.001
Decrease
P<0.001
Decrease
P=0.68
Decrease
PC0.001
Decrease
P=0.03
Decrease
P<0.001
Decrease
P<0.001
Decrease
P<0.001
HECYP*
Increase
P<0.001
Decrease
P<0.001
Decrease
P<0.001
Decrease
P<0.001
Decrease
P=0.02
Decrease
P<0.001
Decrease
P<0.001
Decrease
P<0.001
Decrease
P<0.001
Decrease
P<0.001
HECVa5o»
Increase
P=0.015
Decrease
P=0.045
Decrease
P<0.001
Decrease
P=0.045
Decrease
P=0.28
Decrease
P=0.047
Decrease
P=0.16
Decrease
P<0.001
Decrease
P<0.001
Decrease
P<0.001
HECVCLSrib2
Increase
P<0.001
Decrease
P=0.052
Decrease
P=0.084
Decrease
P=0.133
Increase
P<0.001
Increase
P<0.001
Increase
P<0.001
Decrease
P=0.054
Decrease
P=0.12
Increase
P=0.59
6.3.4 Effect o f Claudin-5 on H ECV cell m otility and the effect o f HGF
A Cytodex-2 bead motility assay was used to examine a possible role of 
Claudin-5 in cell motility. Transfected and control cells, either untreated or treated 
with HGF, were evaluated. HECV cl5exp cells did not show significant differences 
when com pare to the controls (HECVwt (7.44±2.63), H ECV pef6 (6.5±3.34) and 
H EC V cl5exp (6.82±2.77), (p=0.43 and p=0.74 respectively). In contrast, HECV CIJ5rib2 
cells dem onstrated significantly increased cell m otility compared to the controls 
(H EC V W| (7.44±2.63), HECVpef6 (6.5±3.34) and HECV CLJ5rib2 (18.7±3.49), p<0.001 
for both controls) (Figure 6.11 A).
The cells were additionally evaluated after treatm ent with HGF. This pro­
m otility agent increases cell m otility in H E C V GI5exp and control cells, HECV wt and 
H ECV pef6, when compared to untreated cells (H EC V wt+H G F(18.26±5.62), 
H ECV pef6+H G F (22.31±6.60) and H ECV cl5exp+HG F (18.18±4.75), p<0.001). 
H ow ever, in the case of HECVCL5nb2, although a slight increase in the num ber of 
m otile cells was observed, the data was not found to be significant 
(H EC V CL5rib2+HGF (19.44±4.93), p=0.64) (Figure 6.11 B).
6.3.5 Effect o f Claudin-5 on H EC V  cell m igration
The effect of Claudin-5 on cellular m igration was examined using an in vitro 
cellular migration assay. H E C V GL5nb2 showed a significantly increased cellular 
m igration when compared to the controls 60 minutes after wounding (H ECV wt 
(1 3 .5 1± 14.80), HECVpef6 (22 .57±1.34) and HECVCL5rib2 (56.75±21.38), p<0.05 for 
both controls). A decreased cell m igration was seen in HECV G15exp after 60 minutes
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when com pared to controls (HECVwt(13.51±14.80), H ECV pef6 (22.57±1.34) and 
H E C V cl5exp (7.02±1.42), p=0.49 and p<0.05respectively). A lthough the effect is only 
statistically significant when com paring to H E C V pef6, the trend remains marked 
(Figure 6.12).
6.3.6 Effect o f  Claudin-5 on H EC V  T ransendothelial resistance and their 
response to H G F
Transendothelial resistance (TER) w as used to assess the effect of over­
expressing or knocking-down of Claudin-5 on Tight Junction functionality in HECV 
cells. H E C V cl5exp showed increased TER  over a period o f 4 hours in comparison 
with the control H ECV wt (change in TER after 30 m inutes H ECVwt(-98.66±1.3) vs. 
H E C V cl5exp (-65.66±1.6); 60 m inutes H E C V wt(-142 .66 i0 .77) vs. HECV cl5exp (- 
128.33±4.3); 2 hours HECVwt (-167 .66 i2 .18 ) vs. H ECV cl5exp (-156. 33±2.8); 4 hours 
H EC V wt (-194 .33 i2 .42 ) vs. H ECV cl5exp (-175 i2 .15 ), p<0.01). Changes in TER were 
more evident in H ECV CL5nb2 when com pare to the control (change in TER after 30 
m inutes H E C V wt(-9 8 .6 6 il.3 )  vs. H EC V clJ5rib2 (-69 .66 i6 .77); 60 m inutes HECVwt(- 
142 .66i0 .77) vs. HECVCLJ5rib2 (-118 i3 .2 ) ;  2 hours HECVwt(-167.66i2 .18) vs. 
H ECV CL5rib2 ( -1 2 4 .3 3 il.8 1 ); 4 hours H ECV wt (-194 .33i2 .42) vs. H ECV CL5rib2 (- 
89 .33 i2 .1 ), p<0.001) (Figure 6.13).
Treatm ent of cells w ith H G F (50ng/m l) resulted in a significant reduction of 
TER in transfected and control cells when com pared to untreated cells over a period 
of 4 hours (change in TER  after 30 m inutes H ECV wt+ H G F (-1 2 5 il.2 ), 
H ECV cl5exp+H G F (-109 .66 i2 .3 ), H EC V CL5rib2+HGF ( -9 5 il.6 ) ;  60 m inutes 
H ECV wt+ H G F (-160 .66 i4 .24 ), H ECV cl5exp+HG F (-1 9 0 il.6 4 ), H ECV CL25rib2+HGF (-
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160±1.89); 2 hours HECVwt+H G F(-199.66±1.7), H ECV cl5exp+HGF (-210±4.3), 
H ECV CL5rib2+HGF (-189±5.6); 4 hours H ECV wt+H G F(-245.66±1.3), 
H ECV cl5exp+HGF (-240±2.4), HECVclJ5rib2+H G F (-180.66±2. 8), p<0.001) (Figure 
6.14).
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Figure 6.11: (A) Effect o f  Claudin-5 on in vitro  cell m otility o f  HECV cells. The 
m otility o f  HECV €L5nb2 was significantly increased in comparison to the controls 
(p<0.001for both controls). (B) Effect on motility after treatm ent with HGF. 
Transfected and control cells showed an increase in motility, however, only the 
controls and FLECV0156^  results were significant (p<0.001). The data presented is 
representative is the mean o f  at least 3 independent repeats and the error bars 
represent the standard error o f  the mean.
231
70
60
50
40
30
+•»
20
10 *
0
30min 45min 60minnn
-10
Time (minutes)
HECV WT 
HECV pEF6 
HECV CL5exp 
HECV CL5rib2
Figure 6.12: Effect o f  Claudin-5 on in vitro  cell m igration o f  HECV cells. 
H E C V ^ ^ ^ c e lls  showed an increase in m igration when compared to the controls 60 
m inutes after wounding (p<0.05). The m igration o f  HECVcl5exp was reduced in 
com parison to the controls at 60 m inutes. However, only significant differences were 
found when compared to HECVpefis (p<0.05) (mean ±SD, n=3).
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Figure 6.13: (A) Effect o f  Claudin-5 on transendothelial resistance on HECV cells. 
Significant changes were seen on HECV0156*** and HECV01 5^"52 over a period o f  4 
hours when compared to the control (p<0.01 and p<0.001 respectivley). (B) A 
polynomial model was used to visualise the trend o f  the presented data. R 2 indicates 
that the regression line clearly fits the data (mean ±SD, n=3).
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Figure 6.14: Effect o f  Claudin-5 on transendothelial resistance on HECV cells after 
treatm ent w ith HGF. Significant changes were seen in transfected and control cells 
over a period o f  4 hours when compared to the untreated cells (p<0.001) (mean ±SD, 
n=3).
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6.3.7 Effect of Claudin-5 on H ECV cell attachm ent to and m igration across an 
electrode
Electric Cell Impedance Sensing (ECIS) was used to analyse differences in 
attachm ent and spreading following w ounding in real-tim e between transfected and 
control cells. The process requires a m onolayer o f cells being grown on small gold 
electrodes, applying AC current and m onitoring resistance changes caused by the 
adhesion or migration after wounding of cells onto the electrode. The greater the 
resistance to the AC current, the more cells are attached on the electrode. The cells 
were analysed for their adhesive capacity and m igration to a gold electrode in real­
time m easurem ents using a Two-W ay A N O V A  test. This test was used as it permits 
the com parison of two groups, transfected cells vs. control, on two variables, time vs. 
treatment.
The HECVcl5exp and H ECV CL5nb2 cells dem onstrated a significantly 
decreased adhesive capacity compared to the control H ECV wt (p=0.003 and p=0.002 
respectively) (Figure 6.15 A).
In recovering from electrical w ounding (5V AC for 30 seconds), the 
transfected cells showed differences in their rates of m igration. The H E C V GL5nb2 cells 
were significantly more motile com pared to the control as the resistance in the 
electrode increased as the cells begin to spread over the electrode (p=0.047). 
However, the HECVGI5exp cells showed a m arkedly reduced migration (p<0.001) 
(Figure 6.15 B).
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Figure 6 .15: (A) Effect o f  Claudin-5 on the cell adhesion o f  HECV cells using ECIS. 
Significant differences were seen in transfected cells when compared to the control. 
HECV056^  and HECVCL5nb2showed a significantly reduced adhesive capacity 
(p=0.003 and p=0.002 respectively). (B) Significant differences were revealed after 
wounding. HECVCL5nb2 showed significant increased migration (p=0.04) whereas 
H e c v 015^  showed a decreased migration rate (p<0.001).The data presented is 
representative o f  at least 3 independent repeats.
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6.3.8 Effect o f Claudin-5 on H EC V  cell m igration over an electrode and the 
effect o f pro- and anti-motility agents
ECIS was also used to study the effect o f HGF, N -W A SP inhibitor 
(W iskostatin), Arp2/3 inhibitor (CK-0944636) and RO CK  inhibitor (Y-27632) on 
cell m igration of the transfected HECV cells. The cells were analysed after wounding 
for their m igration speed, across the electrode, in real time. Tw o-W ay A N O V A  test 
was the statistical test chosen for the study.
Follow ing electrical wounding and treatm ent with HG F and m otility 
inhibitors differences in cell capability to m igrate were seen. The transfected and 
control cells treated with HGF (50ng/m l), revealed an increase in m otility when 
com pared to the untreated cells (pcO.OOl, p=0.012 and p<0.001 respectively) (Figure 
6.16).
W hen cells were treated with N -W A SP inhibitor (50pM ), the m igration speed 
of H EC V W1+N-W ASP and H ECV cl5exp+N -W A SP was m arkedly reduced after 5 
hours o f treatm ent when compared to untreated cells (p=0.023 and p=0.001 
respectively). In contrast, H EC V CL5nb2+N -W A SP showed no significant differences 
when com pared to the untreated cells (p=0.173) (Figure 6.17).
Arp2/3 inhibitor (lOnM ) adversely inhibited the m igration o f H EC V wt + 
Arp2/3 and H ECV cl5exp+ Arp2/3, w hen com pared to untreated cells after wounding 
(p<0.001for both cell lines). Surprisingly, the migration of H ECV GL5nb2+ Arp2/3 was 
no longer inhibited, in contrast, it w as enhanced when compared to untreated cells 
(p=0.015) (Figure 6.18).
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Treatm ent of cells with RO CK  inhibitor reduced their m igration of HECV wt + 
RO CK  and H ECV cl5exp+ ROCK, when com pared to untreated cells after wounding 
(p=0.013 and pcO.OOl). However, in H EC V CL5nb2+ RO CK  the m igration of the cells 
was reduced although significant differences w ere not seen when compared to the 
untreated cells (p=0.087) (Figure 6.19).
All the results are summarized in Table 6.2.
6.3.9 Effect o f Claudin-5 on protein level o f  N -W A SP and ROCK1 and their 
interaction
H E C V wt, HECVG15exp and H ECV clJ5rib2 W estern blotting showed very low 
levels o f N-W A SP at protein levels. Protein levels of R O C K  1 revealed sim ilar high 
levels in the transfected and control cells (Figure 6.20 A).
Im m unoprecipitation of Claudin-5 follow ed by im m unoblotting with N- 
W A SP and RO CK  showed a protein-protein interaction between Claudin-5 and these 
m otility-related proteins in HECV wt and H E C V cl5exp (Figure 6.20 B). To further 
confirm  this, imm unoprecipitation results w ith either N -W ASP (Figure 6.20 C) or 
RO CK  1 (Figure 6.20 D) followed by im m unoblotting with Claudin-5 confirmed the 
interaction of the proteins.
6.3.10 Effect o f  Claudin-5 on H E C V  cell tum our growth in vivo
To assess the im pact o f altering Claudin-5 expression in HECV cells on 
tum our developm ent in vivo, H E C V cl5exp cells co-injected alongside with M DApef6, 
were com pared to H E C V pef6 co-injected with M DApef6. Tum our developm ent over 33 
days was m onitored. H E C V cl5exp did not seem to alter tumour developm ent in this
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model and no significant differences were seen betw een control M D A pef6 and 
H ECV pef6 tumours and M DApef6and H EC V cl5exp tum our (p = 0.25) (Figure 6.21).
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Figure 6.16: Effect o f  Claudin-5 on H ECV cell migration follow ing treatm ent with 
HGF using ECIS. M igration was significantly increased in H E C V ^+ H G F, 
H ECV °l5exp+HGF and H ECV€L5nb2+HGF when compared to untreated cells 
(p<0.001, p=0.012 and p<0.001 respectively). The data presented is representative o f  
at least 3 independent repeats.
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Figure 6.17: Effect o f  C laudin-5 on H ECV cell m igration following treatment with 
N -W A SP inhibitor using ECIS. M igration was significantly decreased in HECVwt+ 
N -W A SP inhibitor and H ECV05®*1’*  N -W A SP inhibitor when compared to untreated 
cells (p=0.023 and p=0.001). H ECV€L5nb2+  N-W ASP inhibitor did not show any 
difference in cell m igration (p=0.173). The data presented is representative o f  at least 
3 independent repeats.
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Figure 6.18: Effect o f  Claudin-5 on HECV cell migration following treatment with 
Arp2/3 inhibitor using ECIS. M igration was significantly decreased in 
HECVwt+Arp2/3 inhibitor and H ECVcl5exp+Arp2/3 inhibitor (p<0.001 vs. respective 
untreated controls). HECVCL5nb2+Arp2/3 inhibitor showed an increase in migration 
when com pared to untreated cells (p=0.015).The data presented is representative o f  
at least 3 independent repeats.
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Figure 6.19: Effect o f  Claudin-5 on H ECV cell m igration when cells were treated 
with RO CK inhibitor using ECIS. M igration was significantly decreased in 
HECVwt+ RO CK inhibitor and HECVcl5exp+ ROCK inhibitor (p=0.013 and p<0.001 
vs. respective untreated controls). HECVCL5nb2+ ROCK inhibitor showed a decrease 
in m igration when com pared to untreated cells (p=0.087). The data presented is 
representative o f  at least 3 independent repeats.
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M igration
rate
HGF
N -W A SP
inhibitor
Arp2/3
inhibitor
ROCK
inhibitor
vs. untreated vs. untreated vs. untreated vs. untreated
H E C V ^
Increased
PO.OOl
Reduced
P=0.023
Reduced
P<0.001
Reduced
P=0.013
HECVCL5exp
Increased
P=0.012
Reduced
P=0.001
Reduced
P<0.001
Reduced
P<0.001
HECVCL5rib2
Increased
P<0.001
N o effect 
P=0.173
Increased
P=0.015
N o effect 
P=0.087
Table 6.2: D ata sum m arizing ECIS results o f  transfected and control HECV cells 
after treatm ents.
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Figure 6.20: (A ) Expression o f N -W A S P  and R O C K  1 in transfected  and control 
cells. (B ) C o-im m unoprecip ita tion  o f C laud in -5  w ith N -W A S P  and R O C K  1. (C) 
C o-im m unoprecip ita tion  o f N -W A S P  w ith  C laudin-5 . (D ) C o-im m unoprecip itation  
o f R O C K  1 w ith C laudin-5.
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Figure 6.21: Effect o f  Claudin-5 on in vivo  tum our developm ent. No significant 
differences w ere found between H ECV cl5exp & M D A 1)616 and the control HECV*5616 
& M D A 1)616 using Tw o-W ay A N O V A  test (p=0.25).
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6.4 Discussion
In this work we have investigated the effects o f knockdown and forced 
expression of Claudin-5 in HECV cells, a hum an endothelial cell line, and 
established a possible link between Claudin-5 and m otility of the cells. Early studies 
reported high levels of Claudin-5 in the TJ o f endothelial cells of the blood vessels 
(Morita et al., 1999c). TJ in endothelial cells function as a barrier through which 
molecules and inflam m atory cells can pass. In the m etastatic process, it is 
fundamental for cancer cells to interact with endothelial cells followed by penetration 
of the vascular endothelium  and entry into the blood stream.
The results obtained from m easuring Transendothelial electric resistance 
(TER), the easiest and m ost sensitive m ethod to assess the resistance formed by the 
cellular sheets, revealed that H ECV CL5nb2 cells showed the highest resistance, 
whereas the resistance of H ECV cl5exp and the control were lower, although 
HECVcl5exp cells displayed a significantly higher resistance than the control cells. 
These prelim inary results were an indication of a possible new role of Claudin-5 as it 
appears not to be involved in keeping the cell barrier tight. One possible explanation 
might be that the absence of Claudin-5 could be balanced by one of the other 23 
m em bers of the Claudin fam ily which m ight alter the overall barrier strength. A 
sim ilar explanation could be applied for the forced expression cells and their similar 
trend shared with the control cells. Thus, interactions and feedback loops between 
Claudin family m em bers, dependent on expression within a tissue, might be key in 
regulating TJ stability.
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The involvem ent of Claudin-5 in cell growth was assessed; however, results 
showed that Claudin-5 had no role in the grow th o f endothelial cells. Cell adhesion 
to the extracellular matrix is fundam ental for living tissue since there are many 
activities in m am m alian cells in vivo, such as m itosis, m orphogenesis, cell 
orientation and cell m otility which depend on it (M itchison and Cramer, 1996). 
Adhesion is o f critical im portance for endothelial cells in the context of angiogenesis 
and wound healing. H E C V cl5exp cells dem onstrated a decrease in cell adhesion 
whereas no significant differences w ere observed betw een H EC V GL5nb2 and control 
cells. As explained in section 5.4, integrins, am ong other adhesive m olecules, have 
been proved to be essential in cell adhesion o f epithelial and endothelial cells as they 
give the cell critical signals about the nature o f its surroundings (Short et al., 1998). 
The question therefore arises as to w hether the over-expression o f Claudin-5 might 
alter levels o f integrins and other adhesion-related proteins, thus, changing the 
normal adhesive feature of the endothelial cell. To com plem ent these results, the 
ability o f the cells to adhere to a gold electrode through ECIS technology was 
measured in real time. The results agreed w ith the in vitro  cell M atrigel adhesion 
assay used. Once again, forced expression o f Claudin-5 resulted in cells displaying 
the lowest adherence, as in the M atrigel experim ents.
Considering the results from  TER experim ents, which revealed that the 
absence o f Claudin-5 increases the barrier strength therefore excluding Claudin-5 
from a sealing protein role, we studied a possible link between Claudin-5 and cell 
motility. To achieve this, a set o f experim ents were carried out in order to assess the 
grade o f involvem ent o f C laudin-5 in cell m otility. The in vitro  cell m otility assay 
alongside a traditional w ound healing assay w as performed. The results revealed a
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significant increase in m otility in the knockdow n cells when com pared to the control 
cells. In agreem ent with this, ECIS was used in order to m easure motility in real time 
after the m onolayer of cells was w ounded. The sam e results were obtained, i.e. 
HECVCL5rib2 cells appeared to be faster than the control cells. In the case of 
HECVcl5exp however, the effect o f forced expression o f Claudin-5 seem s to be 
opposite and reduced the m igration capacity o f the cells after wounding, as shown in 
both the wound healing assay and ECIS, revealing a significant reduction when 
compared to the control.
Until now, we have shown that knocking down the expression of Claudin-5 in 
endothelial cells resulted in a m ore m otile cell phenotype, although no differences in 
adhesion were seen when com pared to the control. The opposite was observed when 
Claudin-5 expression was forced, resulting in less adhesive and less m otile cells. 
Taking all these results together, we can conclude that Claudin-5 m ight be involved 
in m otility or indeed, be a m otility regulator itself.
It has been dem onstrated that endothelial cells rapidly form  capillary-like or 
tubule structures in vitro when seeded w ithin a sandw ich of reconstituted 
extracellular m atrix (ECM ) such as M atrigel. The form ation o f tubules is a process 
that involves several steps including cell adhesion, cell m igration, alignm ent and 
protease secretion am ong others (A rnaoutova et al., 2009). Because the form ation of 
these tubules is quantifiable, we used this assay to assess a possible im pact on 
angiogenic effect when the levels o f expression o f Claudin-5 are altered in the cells. 
This provides another technique to assess a possible effect of Claudin-5 in the motile 
nature o f endothelial cells. The results show ed that the capacity o f H E C V CL5nb2 cells
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to form tubules was significantly increased w hen com pared to the controls, agreeing 
with results obtained when m otility was assessed, whereas for H E C V cl5exp was 
significantly decreased.
As explained in section 5.4., H G F is routinely used in our laboratories, 
mostly as a positive control, it is a very pow erful angiogenic and m otility factor as 
well as a factor that regulates Tight Tunctions (Jiang et al., 2005). Cells displaying 
enhanced and reduced expression levels of Claudin-5 respond positively to the 
effects o f HGF. The transfected and control cells showed a reduction in endothelial 
resistance, an increase in cell m otility and an increase in the num ber o f tubules 
formed. ECIS experiments corroborated these results.
Based on the results obtained in Chapter 5, where M D A -M B-231 cells were 
treated with a number of m otility-regulators in order to search for any possible links 
between Claudin-5 and a range of m otility-related proteins, we treated the cells 
transfected with Claudin-5 expression sequence and ribozym e transgenes w ith N- 
W ASP inhibitor, Arp2/3 inhibitor and RO CK  inhibitor (see details in section 5.6) to 
assess the impact on the cell m otility using ECIS and the in vitro  tubule form ation 
assay. The ECIS results revealed that forced expression and control cells respond as 
expected to all the inhibitors, show ing a decrease in the m otility. H ow ever, the 
knockdown cells did not follow the sam e inhibition trend. In fact, the three inhibitors 
were no longer able to inhibit the m otility o f the cells where C laudin-5 w as absent, 
suggesting a possible link between Claudin-5 and the signal pathw ay of N -W A SP 
and ROCK. Other studies have already shown the effect o f N -W A SP inhibitor in 
endothelial cells, where the addition of the inhibitor led to alm ost com plete
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disappearance of podosomes, which are actin structures responsible am ongst others 
for cell motility (Osiak et a l ,  2005). A nother study has reported that the addition of 
ROCK inhibitor in endothelial cells prevented transendothelial m igration o f lung 
carcinom a cells and changes in the TJ structure in the blood brain-barrier preventing 
m etastasis (Li et a l ,  2006).
Surprisingly, when Arp2/3 inhibitor was added to the knockdow n cells, an 
increase in m otility was observed. An explanation for this unexpected observation 
could be the complex regulation of F-actin form ation and degradation. Actin 
polymerisation is regulated by a signal transduction pathw ay that show s m any 
intrinsic positive as well as negative feedback loops. Exam ples are the positive 
feedback between PI3K and Rac (Dawes and Edelstein-K eshet, 2007; W einer et a l ,  
2007) and the negative feedback between Rho and Cdc42 (Dawes and Edelstein- 
Keshet, 2007). All these molecules are well characterised m em bers of the 
RhoGTPase family and are key regulators o f cytoskeletal dynam ics in cells, 
including those of endothelial origin. A  theoretical study has also addressed the 
activity of Arp2/3 and showed that it operates with an auto-catalytic like m echanism . 
The activation of Arp2/3 will am plify the level o f PI (4,5) P2, a phospholipid 
component enriched at the plasm a m em brane where it is a substrate for a num ber of 
important signalling proteins, at the leading edge o f the cell which again will 
increase the activity of Arp2/3 (Dawes and Edelstein-K eshet, 2007).
W hen tubule formation was tested follow ing treatm ent w ith the inhibitors, 
both forced expression and control cells were seen to have a significant reduction in 
tubule structures formed compared to the untreated cells. H ow ever, although
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knockdown cells resulted in a decrease in tubule structures form ed; differences were 
no longer significant. These results are linked to the m otile nature o f endothelial cells, 
and reveal a possible new role for Claudin-5 related to the N -W ASP and RO CK  
signal pathways. Additional experim ents were carried out to study the effect o f a 
combination of HG F and each individual inhibitor. The addition of a com bination of 
HGF/N-W ASP inhibitor, HGF/Arp2/3 inhibitor and H G F/RO C K  inhibitor 
significantly negated the effect o f H G F in the forced-expression and control cells, 
however, in the knockdown cells the differences between H G F treatm ent alone and a 
mixture of HGF and the inhibitors were not significant. These results agree with our 
suggestion of a new role for Claudin-5, linked to the N -W A SP and R O C K  signalling 
pathways, as the absence of Claudin-5 resulted in cells that did not respond to the 
inhibitors, and the HGF effect is no longer negated by the inhibitors w hen combined.
At this point of the study, the next two questions to be addressed were, could 
there be possible protein-protein interaction betw een Claudin-5 and N -W A SP or 
Claudin-5 and ROCK, and were there any direct effects that m ight occur at the 
protein level o f these m olecules w hen the level o f expression o f Claudin-5 is altered. 
Co-immunoprecipitation with Claudin-5 follow ed by im m unoblotting with either N- 
W ASP or ROCK 1 demonstrated an interaction betw een Claduin-5 and N -W ASP as 
well as with ROCK 1. To confirm  these interactions, a co-im m unoprecipitation with 
either N-W ASP or ROCK 1 followed by im m unoblotting w ith Claudin-5 w as carried 
out confirming the interactions betw een these protein pairs. The protein level o f N- 
W ASP appeared to be very low in the transfected and control cells. In agreem ent 
with these results, very low transcript levels of N -W A SP in som e cells was 
previously reported. It has been suggested that very high or very low levels o f N-
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W ASP can have the same effect (M artin et al., 2008b). N -W A SP and R O C K  1 
protein expression did not show any real differences am ong transfected and control 
cells in non co-precipitated samples. Together this suggests that Claudin-5 m ight 
interact with N-W ASP and ROCK 1 in some m anner but does not appear to have any 
direct effect on their expression in HECV  cells.
In vivo experiments did not reveal any significant differences in tum our 
developm ent when HECV cells with forced expression o f Claudin-5 w ere co-injected 
alongside control MDA-MB-231 breast cancer cells. U nfortunately, at the tim e of 
the in vivo study the Claudin-5 knockdown cells were unavailable and could not be 
included, however it would be interesting to see w hat effect suppressing Claudin-5 in 
endothelial cells could have on tumour developm ent in this in vivo  model.
Cell motility is orchestrated by a variety o f com plicated signal pathw ays, 
with most of them just starting to be unravelled. How ever, understanding cell 
motility not only requires knowledge o f the signal pathw ays regulating actin 
polymerization, but also how the com ponents involved in cell m otility w ork  together 
as a dynamic and integrated system. In this study w e have investigated the role o f 
Claudin-5 in endothelial cells. Our results have revealed that Claudin-5 is not ju st a 
sealing protein in charge of the passage of sm all ions; in fact, C laudin-5 appears to 
be involved in cell motility. This proposed new  role for Claudin-5 should instigate an 
interesting avenue for further research into cell m otility.
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Chapter 7 
General discussion
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7.1 Breast cancer and metastasis
Breast cancer is the most com m on cancer diagnosed in wom en, with 
over one million of new cases reported each year worldw ide. It is w idely recognised 
that the high incidence of breast cancer in the m ore affluent world areas is due to the 
presence of screening programs that help to detect early stages o f invasive cancers. 
Every year about half a million new cased o f breast cancer are reported in Europe, 
with 45.000 new cases in the UK.
Breast cancer is characterized by having unusually long latency. It is capable 
of spreading to a variety of secondary sites that include vital organs such as bone, 
liver and lungs. The chances of survival from  m etastatic breast cancer are less than 
5%. Therefore, the major focus o f research in breast cancer is the prevention and 
treatment of metastasis. A key factor that determ ines the m etastatic nature o f cancer 
cells is their motility. A defining characteristic o f cancer cells is the acquirem ent o f a 
motile phenotype due to changes in their cytoskeletal architecture. A  great deal of 
evidences exists suggesting that Tight Junctions represent a critical barrier which the 
motile cancer cells must overcome in order to penetrate and initiate the m etastatic 
cascade. Nevertheless, different studies have show n dysregulation in TJ structure of 
several cancers including breast. Until the early nineties, TJ were m ainly seen as 
structure with an exclusive task o f sealing the gap betw een two cells, how ever, recent 
studies have shown how TJ are involved in the regulation o f cell proliferation, gene 
transcription and cellular differentiation. A m ong other com ponents o f the TJ 
structure, Claudin family appear to regulate the paracellular barrier o f the cells to 
small ions. However, the role of Claudin proteins in carcinogenesis and progression
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to metastasis needs to be unmasked. Therefore, it is not surprising that the role o f 
Claudins has become an active area o f research as a result o f altered levels of 
expression observed in different cancers including breast.
7.2 Aim s o f this thesis
The first aim of this thesis was to exam ine the role o f Claudin-5 in hum an 
breast cancer by examining the level of expression and distribution in breast tum our 
and normal breast tissues and analysing the levels o f transcripts against clinical 
parameters in order to investigate a possible connection betw een C laudin-5 and the 
clinical outcome of patients.
This thesis was also aimed to exam ine the effect o f knockdow n and forced 
expression of Claudin-5 in the M DA-M B-231 aggressive breast cancer cell line and 
in the HECV human endothelial cell line as well as to assess the effect o f C laudin-5 
forced expression on in vivo developm ent o f m am m ary tum ours. W e also aim ed to 
examine whether the invasive nature o f the breast cancer cells, their adherence to 
matrix, the integrity of the paracellular barrier, their possible role in cell grow th and 
their motility might be comprom ised in the absence o f C laudin-5 as w ell as w hen 
Claudin-5 is overexpressed in the cancer cell. Sim ilarly, w e studied the effect o f 
altering Claudin-5 expression in hum an endothelial cells and the effect caused on 
their adherence, in the paracellular barrier, in growth, in m otility and in their 
capability to form tubules of the endothelial cells. F inally, the effect on cell m otility
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after inhibition of N-W ASP, RO CK  and A rp2/3 com plex  w as assessed in both cell 
lines.
7.3 M ain conclusions from results / sign ificance o f  this thesis 
7.3.1 C laudin-5 and human breast cancer
This thesis has shown for first tim e that C laudin-5  is aberrantly expressed in 
hum an breast cancer and has a link to the clinical outcom e o f the patient. Patients 
w ho died from breast cancer had higher levels o f C laudin-5 com pared with patients 
w ho rem ained disease-free. Furtherm ore, patients w hose tum ours expressed high 
levels o f Claudin-5 had significantly shorter survival than those with low levels of 
expression o f Claudin-5. Thus, it can be seen from  this w ork carried out on human 
breast tissue sam ples that Claudin-5 m ay be a useful prognostic tool in the 
assessm ent o f patient outcome in breast cancer.
7.3.2 C laudin-5 in M DA-M B-231 breast cancer cells
The results of the TER experim ents carried out on M DA-M B-231 breast 
cancer cells revealed interesting differences betw een control, over expression and 
knock down cells. This showed that the role o f C laudin-5 was not prim arily in 
keeping the cell barrier tight. In fact, the lack o f C laudin-5 might be com pensated by 
one o f the other 23 m em bers o f the C laudin fam ily.
The results obtained from  the in vitro  tum our cell (M atrigel) adhesion assays 
agreed with the results.from  the ECIS attachm ent experim ents; where knockdown
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cells w ere significantly less adhesive than the control cells. How ever, in real time 
m easurem ents using ECIS, the forced expression o f Claudin-5 gave the cells a 
significantly  enhanced adhesive capacity agreeing with the trend (although not 
reaching significance) seen in the in vitro  adhesion assays. Further to this, alteration 
o f C laudin-5 levels o f expression did not affect the invasive nature of the M DA-M B- 
231 breast cancer cells. Our results also showed that alteration o f Claudin-5 levels 
appeared to have no effect on the growth o f M DA -M B-231 cells in vitro  or on 
tum our grow th in vivo.
7.3.3 C laudin-5 in H EC V  hum an endothelial cells
The m easurem ent o f TER  in H E C V  hum an endothelial cells produced similar 
results to those dem onstrated in M D A -M B -231 breast cancer cells; w ith differences 
shown betw een control, over-expression and knockdow n cells. These observations 
speculate that the absence o f Claudin-5 m ight be balanced by another m em ber o f the 
C laudin fam ily; as previous studies have reported differential expression of Claudin 
fam ily m em bers in different tissues.
The result o f this thesis show s that alteration o f Claudin-5 levels in HECV  
cells w as not capable o f prom oting cell grow th in vitro.
M anipulation o f H E C V  cells by forced expression of Claudin-5 caused these 
cells to significantly  decrease their adhesive properties both in in vitro  adhesion 
assay experim ents and using EC IS technology. Interestingly, real time m easurem ents 
using ECIS revealed significant reduction in adherence in the knockdow n cells when 
com pared to the controls w hich w as not seen in the in vitro adhesion assays.
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The natural ability o f endothelial cells to rapidly form  capillary-like 
structures was altered when Claudin-5 w as over-expressed, showing a significant 
decrease in the num ber o f tubules form ed. H ow ever, the effect was reversed in the 
absence o f Claudin-5 displaying a significantly larger num ber o f tubules formed 
w hen com pared to the controls. These results clearly indicate that Claudin-5 plays an 
im portant role in angiogenesis.
A dditionally , the in vivo experim ents w ere carried out in order to identify 
w hether forced expression o f Claudin-5 in H ECV  cells, w hen co-injected with 
M D A -M B -231 breast cancer cells resulted in any changes in tum our developm ent. 
No significant differences were found in this experim ent. Unfortunately, there were 
som e problem s in grow ing the knockdow n cells and hence we were unable to assess 
the effect o f C laudin-5 knockdown on in vivo  tum our cell developm ent.
7.3.4 C laudin-5 and its role in cell m otility
One hallm ark o f breast cancer cells is their ability to acquire a m otile 
phenotype. The results o f a panel o f m otility assays in M DA-M B-231 revealed that 
knockdow n o f Claudin-5 resulted in a significant decrease in cell m otility as shown 
by EC IS and cytodex-2 bead m otility  assays. The same trend was seen in the 
w ounding  assay but did not reach a level o f significance. The opposite effect was 
seen in cells over-expressing C laudin-5, how ever, only ECIS results reached 
significance.
Three different cell m otility signalling pathw ays were investigated in relation 
to altered levels o f C laudin-5, nam ely H G F, N -W ASP and ROCK. Results disclosed
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that both transfected cells, as well as controls responded in the same way to the 
addition o f HGF. That is, all cells showed reduced TER and increased m otility in 
response to H G F, indicating that C laudin-5 is not linked to the HG F motility 
signalling  pathw ay.
Control cells treated with either N -W A SP inhibitor (W iskostatin), ROCK 
inhibitor (Y 27632) or A rp2/3 inhibitor (C K -0944636) displayed a decrease in cell 
m otility  as show n by ECIS. The transfected cells responded in different ways. 
T reatm ent w ith N -W A SP inhibitor caused a highly significant decrease in cell 
m otility  in forced expression cells and a less significant effect in the knockdown cells. 
The A rp2/3  inhibitor showed a sim ilar effect to the N -W A SP inhibitor on m otility 
with a h ighly significant decrease in m otility in forced expression cells but no 
significant change in m otility in knockdow n cells. These findings are of interest 
because the A rp2/3 com plex acts dow nstream  of N -W A SP and this study shows that 
w hen C laudin-5  is decreased in the cells the A rp2/3 inhibitor was no longer able to 
inhibit m otility , agreeing with the trend seen w hen cells were treated with the N- 
W A SP inhibitor, as the knockdown cells show ed a reduced response to the inhibitor. 
R O C K  inhib itor did not change the m otility o f either type of transfected cells 
ind icating  a possible connection betw een the level o f expression o f Claudin-5 in the 
cells and the R O C K  signalling pathw ay.
This study is the first to reveal a link betw een Claudin-5 and cell m otility in 
breast cancer cells. This possible link  w as also dem onstrated when interactions 
betw een C laudin-5 and N -W A SP, and Claudin-5 and RO CK  were investigated in
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breast cancer cells by co-im m unoprecipitation o f Claudin-5 as well as N -W ASP and 
RO CK .
The sam e panel o f experim ents was used to analyse the effect of altering 
levels o f expression o f Claudin-5 on m otility o f H ECV  hum an endothelial cells. The 
opposite  results were observed in these cells com pared with the breast cancer cells. A  
significant increase in cell m otility w as seen in all assays including ECIS when 
C laudin-5  w as knocked down. These results agree with the findings o f the tubule 
form ation assays as the form ation o f tubules is a process that involves cell migration.
A s w ith M D A -M B-231 breast cancer cells, the addition o f the powerful 
m otogen H G F  to the H ECV  cells increased cell m otility, tubule form ation and 
decreased T E R  across all cell types. These results also indicate that the HG F 
pathw ay is not connected to C laudin-5.
The H E C V  cells w ere exam ined after treatm ent with the same inhibitors used 
for the M D A -M B -231 breast cancer cells. W hen cells were treated with N -W ASP 
inhib itor a decrease in cell m otility w as observed in control and forced expression 
cells, how ever, no effect was seen in the cells displaying a reduction in Claudin-5 
levels. T hese results are in agreem ent w ith those from the tubule form ation assays 
w here addition o f N -W A SP inhibitor decreased the ability of both transfected cells to 
form  tubules although only reaching significance in the forced expression cells.
These results clearly indicate a link betw een the N-W A SP pathw ay and Claudin-5 as 
w hen C laudin-5 levels are reduced the inhibitor’s effect was m arginal.
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W hen cells were treated with the A rp2/3 inhibitor sim ilar results were 
obtained as w hen the N -W A SP inhibitor w as used. This is not surprising as Arp2/3 
com plex is seen dow nstream  of N-W ASP.
A lthough R O C K  is involved in a different cell m otility pathway, the cells 
responded to the R O C K  inhibitor in a parallel way to N -W A SP and Arp2/3 complex 
inhibitors; again show ing that the knockdow n of Claudin-5 in these cells masked 
their response to these inhibitors.
Furtherm ore, with the use o f the com bination of H G F with each of the 
inhibitors during  tubule form ation assays, we saw a negation in the effect o f HG F in 
both control and forced-expression cells. H ow ever, the reduction o f Claudin-5 levels 
in H E C V  cells restored the effects o f H G F as the inhibitors were less effective on 
these cells.
This study is the first to reveal a link betw een Claudin-5 and cell m otility in 
endothelial cells (Figure 7.1). This possible link was further dem onstrated when 
in teractions betw een Claudin-5 and N -W A SP, and Claudin-5 and R O C K  1 were 
investigated  in H E C V  hum an endothelial cells by co-im m unoprecipitation of 
C laudin-5 as w ell as N -W A SP and R O C K  1.
This study has revealed the different effects o f altering Claudin-5 expression 
in two different cell types, the hum an breast cancer cell line M DA -M B-231 and the 
hum an endothelial cell line H ECV . This study portrays a very new and interesting 
role for C laudin-5 in cell m otility. It is clear from the data presented in m y thesis that 
expression o f C laudin-5 in d ifferent cell types have different im pact on cells
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functions: nam ely Claudin-5 forced expression increases the aggressiveness o f breast 
cancer, but reduces the angiogenic effect on endothelial cells. These two 
observations have contrasting im pact on cancer progression. It is clear that the 
clinical data o f the present study totally support the conclusion from the cellular data 
on breast cancer cells. A lthough the angiogenic im pacts observed with endothelial 
cells contrad ict those seen with breast cancer and breast cancer cells, the following 
possib ilities exist and should be explored in future: 1.Claudin-5 expression in the 
body. C laudin-5  has been indicated to be m ainly expressed in endothelial cells in the 
central nervous system . It is therefore plausible that the relatively low levels in 
endothelial cells in m am m ary gland m ay only have a m inor effect on breast cancer; 2 . 
The level o f expression in endothelial cells in breast cancer. In the present study, we 
have not been able to specifically com pare the levels o f Claudin-5 in endothelial cells 
from norm al m am m ary tissues and breast cancer tissues, an im portant topic to 
fo llow ing  in future studies. It is possible that Claudin-5 in these two types o f tissues 
(norm al vs tum our) do not vary. Together, I believe that the angiogenic effect 
observed w ith C laudin-5 m ay be an im portant biological observation and its link to 
d isease progression  in cancer, particularly  in breast cancer, is an exciting topic for 
future research.
A lthough Claudin-5 is expressed naturally in both cell lines the effect of 
altering its expression is different. These results are not contradictory as cancer cells 
are not norm al and do not behave in the sam e w ay as normal, healthy cells 
explain ing w hy the sam e m olecule has different effects when its levels are altered. 
H ow ever, in both parallel studies this thesis proves a link between Claudin-5 and
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m otility. M any questions still need to be answ ered but this study has shed light on a 
possib le role for C laudin-5 in the m etastasis and progression of hum an breast cancer.
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Figure 7.1: Cell motility pathways. The complexity o f cell motility is illustrated. The question marks indicate the missing gap 
between Caludin-5 and N-WASP, and Claudin-5 and ROCK signalling pathway (Figure modified from Ingenuity Systems, Inc.).
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7.4 Future work
The results from the work presented in this thesis dem onstrate an exciting 
glim pse into how Claudin-5 functions in both hum an breast cancer and endothelial 
cells. C ontrary  to popular thought, we have shown that Claudin-5 has little function 
in the TJ o f these cells, but appears to be directly involved in the regulation of their 
m otility. This is o f extrem e interest, as there has been an enorm ous push in recent 
years to find w ays o f inhibiting m etastasis in hum an breast cancer as motility is a key 
aspect o f cancer cells during the m etastatic cascade, this w ork has great relevance in 
this field.
The intriguing results we have shown, also raise a num ber of questions that 
would be vital for future w ork on both breast cancer and TJ function as a whole, 
particularly  in endothelial cells. O bviously, tim e did not allow for further 
investigation o f som e of the questions raised, but which require further investigation:
1. The interaction betw een the A R P2/3 and Claudin-5 should be proved 
beyond doubt. This w ould be carried out using co-im m unoprecipitation. M oreover, it 
would be in teresting to see if the overall levels of the ARP2/3 com plex are altered in 
cells that have had Claudin-5 over-expressed or knocked-dow n. In addition, any 
changes in location o f the com plex could be assessed using im m unofluorescence.
2. The initial results from  our in vivo  study investigated the effect of Claudin- 
5 over-expression. Subsequently, we also created the knockdown subline. If time and 
funds had allow ed, we w ould have liked to have carried out an in vivo tumour model 
study using this, especially  in light o f our w ork showing the increased tubule
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form ation obtained from the Claudin-5 knockdow n cells. This shows that Claudin-5 
has the potential to be a target in anti-angiogenesis therapy, and would provide an 
avenue o f research that w ould constitute another thesis in itself.
3. From  our w ork, we have shown that Claudin-5 is involved in the signalling 
pathw ay related to the N -W A SP fam ily for m otility and cytoskeletal rearrangements. 
W e did not have sufficient time to investigate this fully; the pathw ay is com plex, 
w ith m any m em bers. Future w ork should look at which other m em bers Claudin-5 
could have possib le interactions with, how it prevents the effect o f the N-W ASP, 
A rp2/3 and R O C K  inhibitors. M oreover, this is also true for the m otility pathw ay 
regulated in part by the GEFs, and in our study, the effect that Claudin-5 has on 
R O C K  function. There appears to be som e link betw een both these m otility 
regulators, as show n in Figure 7.1. The question m arks indicate our gap in current 
know ledge, and certainly beg for further research.
4. Both N -W A SP and R O C K  are activated by GTPase. W e w ould have liked 
to investigate how this m ight be turned o ff by Claudin-5; is the physical interaction 
betw een the m olecules enough to prevent activation? Or does Claudin-5 have some 
other effect on these proteins? The phosphorylation status o f R O C K  and N -W A SP in 
cells w ith /w ithout Claudin-5 could be assessed.
5. W e know  from  our research show n here, that Claudin-5 did not interrupt 
the signalling  pathw ay for m otility  as initiated using HGF. It w ould be interesting to 
see if there is a sim ilar response if  we used other growth factors, e.g. VEGF, FGF, 
IGF, EG F, PD G F and other angiogenic factors.
267
6 . A lthough not shown in this thesis, we also discovered that Claudin-5 
directly  precipitates w ith |3-catenin. A lthough we did not have time in the current 
study to investigate this more thoroughly, it suggests that Claudin-5 might also be 
involved in the construction o f adherens junctions, in addition to being present in TJ 
(as expected). It m ight be that there is a dynam ic interaction betw een the Adherens 
and T ight junctions, as m ore evidence has shed light on the proteins that although 
once thought to be specific to a particular junction type, have now been shown to be 
found in both (M artin TA , personal com m unication).
The w ork presented in this thesis has revealed a hitherto unknown role for 
C laudin-5 in both breast cancer and endothelial cells and has opened an avenue for 
future w ork  that could be o f great interest to the field.
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